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ABSTRACT
This thesis describes studies to investigate the regulation of guanylate cyclases 
pathways in blood vessels. Endogenous iS-nitrosothiols have been implicated in the 
regulation of soluble guanylate cyclase (sGC), by modulating nitric oxide (NO) 
bioactivity. To determine whether the biotransformation of S-nitrosothiols by isolated rat 
aorta is enzyme-dependent, stereoisomers of S-nitrosoglutathione (GSNO), 
S-nitrosocysteine (CYSNO) and S-nitroso-N-acety 1-penicillamine (SNAP) were 
synthesised and their decomposition and relaxant effects characterised. Decomposition 
of these S-nitrosothiol stereoisomers by Cu(I), Cu(II), Cu/Zn superoxide dismutase 
(Cu/Zn SOD) or rat aorta was equivalent (P>0.05). Similarly, the vasorelaxant activity 
of iS-nitrosothiol stereoisomers was equipotent (P>0.05). The selective Cu(I) chelator, 
bathocuproine disulfonic acid (BCS), blocked the decomposition of 5'-nitrosothiol 
stereoisomers by Cu(I), Cu(II), Cu/Zn SOD and rat aorta (P<0.05) and significantly 
inhibited their relaxant effects (P<0.05). These studies suggest that in rat aorta, there 
are no stereospecific vasorelaxant effects of S-nitrosothiols, consistent with non- 
enzymatic release of NO. Biotransformation of iS-nitrosothiols is, in part, dependent on 
Cu(I) ions.
The sensitivity of sGC to NO and particulate guanylate cyclase (pGC) to atrial 
natriuretic peptide (ANP) regulates vasodilatation in response to these mediators. To 
determine the role of endogenous NO as a feedback regulator of sGC and pGC, rat 
aorta was incubated in vitro with bacterial lipopolysaccharide (LPS) to mimic many 
aspects of sepsis. LPS produced “high output” NO from inducible nitric oxide 
synthase (iNOS) and reduced the potency of the direct (SPER-NONOate, sodium 
nitroprusside, GSNO and BAY 58-2667) and indirect (acetylcholine and histamine) 
sGC activators. iNOS (1400W) but not cyclooxygenase (indomethacin) inhibition, 
preserved acetylcholine- and SPER-NONOate-dependent relaxations in LPS-treated 
vessels (P<0.05). LPS reduced the potency of 8-bromo-cyclic guanosine-3’,5’- 
monophosphate (P<0.05), but not forskolin (adenylate cyclase activator) or 8-bromo- 
cyclic adenosine-3’,5’-monophosphate (P>0.05). LPS also reduced the potency of the 
pGC activators C-type natriuretic peptide and ANP. 1400W, the sGC inhibitor 1H- 
[l,2,4]Oxadiazolo[4,3-a]quinoxalin-l-one (ODQ) or both, preserved relaxations to 
ANP in LPS-treated vessels. 1400W and/or ODQ also reversed established 
desensitisation to ANP within minutes (all P<0.05 versus LPS alone). These results
3
indicate that sGC and pGC signalling are desensitised following exposure to LPS, 
consistent with a compensatory mechanism offsetting high-output NO production by 
iNOS. This effect is specific to cGMP-dependent pathways since the cAMP pathway 
was unaltered. The mechanism of desensitisation is likely to involve a reversible 
biochemical change, since the responsiveness was restored immediately following 
removal of excess NO (by 1400W) or cGMP (by ODQ). These observations suggest that 
inflammatory cardiovascular disorders associated with excessive NO production (i.e. 
septic shock) are characterised by specific impairment of GC-cGMP-mediated 
vasorelaxation that is mediated, at least in part by cGMP, and readily reversible.
To investigate the mechanism(s) of iNOS-derived NO-mediated 
desensitisation of sGC and pGC, pharmacological inhibition of phosphodiesterases 
(type 5 (sildenafil), 1A1 (vinpocetine), and 3 (milrinone)), protein phosphatase 2A 
(okadaic acid and cantharidic acid), superoxide anion (SOD) and myeloperoxidase 
(4-aminobenzoic hydrazide) were used to probe the role of these enzymes. 
Desensitisation of ANP- and NO-mediated dilatation by iNOS-derived NO was 
unaffected by inhibition of these enzymes (all P>0.05 versus LPS alone). However, 
activation of protein kinase C by phorbol 12-myristate 13-acetate and thymeleatoxin 
caused desensitisation of both guanylate and adenylate cyclases. If PKC activation 
causes LPS-induced desensitisation of sGC and pGC, then other mechanisms must 
preserved cAMP-mediated relaxation.
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EDHF Endothelium-derived hyperpolarizing factor
EDRF Endothelial derived relaxing factor
EDTA Ethylenediamine-tetraacetic Acid
EGTA Ethylene glycol-bis-(2-aminoethyl)-N,N,N', N'-tetraacetic acid
eNOS Endothelial nitric oxide synthase
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FAD Flavin adenine dinucleotide
FMN Flavin mononucleotide
GC Guanylate cyclase
GCD Guanylate cyclase catalytic domain
GSH Glutathione
GSNO S-nitrosoglutathione
GSSG Thiol disulfide
GTN Glyceryl trinitrate
GTP Guanosine-5'-triphosphate
HO-1 Haem-oxygenase-1
ICAM-1 Intercellular adhesion molecule-1
IL-lp Interleukin-lp
IM Indomethacin
iNOS Inducible nitric oxide synthase
IP3R Inositol triphosphate receptor
IRAG Inositol triphosphate associated G-kinase
IRAK Interleukin-1 receptor-associated kinase
KC1 Potassium chloride
KHD Kinase-homologous regulatory domain
LBP LPS-binding protein
LDL Low density lipoprotein
L-NAME N°-nitro-L-arginine methyl ester
L-NMMA N°-monomethyl-L-arginine
LPS Lipopolysaccharide
MPO Myeloperoxidase
NADPH Nicotinamide adenine dinucleotide phosphate
NED N-(l-napthyl) ethylendiamine dihydrocloride
NF-kB Nuclear factor-kappaP
nNOS Neuronal nitric oxide synthase
NO Nitric oxide
NPR Natriuretic peptide receptor
NPs Natriuretic peptides
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o 2~ Superoxide anion
ODQ 1 H-[ 1,2,4]Oxadiazolo[4,3-a]quinoxalin-1 -one
ONOO- Peroxynitrite
PBS Phosphate buffered saline
PDE Phosphodiesterases
PDI Protein disulfide isomerase
PE Phenylephrine
pGC Particulate guanylate cyclase
PKC Protein kinase C
PKG Protein kinase G
PMA Phorbol 12-myristate 13-acetate
PP2A Protein phosphatase 2A
ROS Reactive oxygen species
RSNO S-nitrosothiols
SA Sulphanilamide
SDMA Symmetric dimethylarginine
SDS Sodium dodecyl sulphate
SEM Standard error of the mean
sGC Soluble guanylate cyclase
SNAP S-nitroso-N-acetyl-penicillamine
SNOAlb S'-nitrosoalbumin
SNOHb S'-nitrosohaemoglobin
SNP Sodium nitroprusside
SPER-NO Spermine-NONOate
TEMED T etramethy lethy lenediamine
TLR4 Toll-like receptor 4
t-PA Tissue-type plasminogen activator
TRAF6 TNF receptor-associated factor-6
TW-ANOVA Two-way analysis of variance
U46619 9,11-Dideoxy-l la ,9 a  epoxymethano-prostaglandin
VCAM-1 Vascular cell adhesion molecule-1
VSMC Vascular smooth muscle cell
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1. INTRODUCTION
Guanylate cyclases (GC) synthesise cyclic guanosine-3’,5’-monophosphate 
(cGMP) in response to nitric oxide (NO) and natriuretic peptides (NPs). Two 
isoforms of GC are expressed in mammalian cells. Soluble guanylate cyclase (sGC), 
which is activated principally by NO, and a family of particulate guanylate cyclases 
(pGC) that act as receptors for the natriuretic peptide family (Lucas et al., 2000). 
Upon production of intracellular cGMP, physiological effects via a variety of 
mechanisms. These include activation of protein kinases, opening of ion channels, 
and altering intracellular cyclic nucleotide concentrations through regulation of 
phosphodiesterases (PDEs) (Hobbs, 1997; Lucas et al., 2000). Activation of these 
cellular targets contributes to the regulation of vascular tone, platelet function and 
cellular proliferation and trafficking (Vallance & Chan 2001 and Ahluwalia et al, 
2004a). In contrast, abnormalities of the GC-cGMP pathways occur in diseases such 
as hypertension, atherosclerosis, heart failure, diabetes and sepsis (MacAllister & 
Vallance, 1994; Vallance & Chan, 2001 and Han & Hasin, 2003), and contribute to 
the vascular phenotype of these conditions. Thus, regulation of GC-cGMP bioactivity 
is a fundamental physiological process, and a deeper understanding of this pathway is 
likely to lead to the development of novel therapeutics. This chapter describes current 
understanding of the molecular, biological, physiological and pathophysiological 
roles of the two GC-cGMP systems in the cardiovascular system. In section 1.1, the 
NO:sGC:cGMP is discussed, followed by section 1.2 describing the NP:pGC:cGMP. 
Later sections will focus on the specific research questions that were the focus of my 
experimental work.
1.1 Nitric oxide
Originally thought to act merely as an inert layer lining the luminal surface of 
blood vessels, it is now apparent that endothelial cells play important roles in the 
physiology and pathophysiology of the cardiovascular system (Vallance & Chan,
2001). Under normal physiological conditions, the vascular endothelium regulates 
vascular homeostasis through effects on vascular tone, circulating cell function, 
coagulation and cellular proliferation. It performs these functions through the release 
of endothelium-derived regulating factors such as endothelium-derived relaxing
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factor (EDRF) (Furchgott & Zawadzki, 1980), prostacyclin and endothelium-derived 
hyperpolarising factors (Busse et al., 2002; Chauhan et al., 2003a). Aberrant function 
of these mediators can contribute to various cardiovascular diseases.
EDRF1 was discovered by Furchgott and Zawadzki in 1980 where they 
demonstrated the ability of the endothelium to release a potent, labile vasorelaxant 
factor (Furchgott & Zawadzki, 1980). Subsequently, Palmer et al demonstrated that 
cultured endothelial cells from porcine aorta release NO, at a concentration sufficient 
to induce vasodilatation, thus demonstrating that EDRF was NO (Ignarro et al., 1987; 
Palmer et al., 1987). NO is synthesised by means of nitric oxide synthase (NOS). 
Three isoforms of NOS have been identified; constitutive, neuronal NOS (nNOS) 
(Knowles et al., 1989) endothelial NOS (eNOS) (Palmer et al., 1988), and inducible 
nitric oxide synthase (iNOS) (Busse & Mulsch, 1990).
1.1.1 Neuronal nitric oxide synthase
The gene encoding neuronal NOS (nNOS or NOS1; 160 kDa) is localised to 
chromosome 12 (Marsden et al., 1993). nNOS is expressed in a variety of neuronal 
cells (Bredt & Snyder 1994) and other cells types such as the adventitia of blood 
vessels (Nozaki et al. 1993), skeletal myocytes (Kobzik et al, 1994) and cardiac 
myocytes (Xu et al., 1999). nNOS exists as a soluble and membrane bound isoform
2 “b(Hecker et al., 1994). It is regulated acutely through Ca -calmodulin (CaM) binding 
(Abu-Soud et al., 1994).
1.1.2 Endothelial nitric oxide synthase
The gene encoding endothelial NOS (eNOS or NOS3; 134 kDa) is localised to 
chromosome 7 and consists of 26 exons (Marsden et al., 1993). eNOS is the major 
NOS isoform expressed in the cardiovascular system. Although eNOS expression 
occurs primarily in the vascular endothelium, this isoform is also expressed in a wide 
variety of other cell types such as cardiomyocytes, leukocytes, and neurons (Li et al.,
2002). The majority of eNOS is located in the membrane fraction of cells, with only a 
small fraction localised in the cytosol (Forstermann et al., 1991). eNOS is directed to 
the plasma membrane by myristoylation (Pollock et al., 1992), a co-translational
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modification catalysed by A-myristoyltransferase in which an A-terminal glycine 
residue is modified by the formation of a fatty acyl amide bond (Boutin, 1997). This 
process helps to direct and anchor eNOS to the plasma membrane. eNOS is localised 
in the caveolae where it is bound and inhibited by caveolin (Michel et al., 1997). 
Similar to nNOS, eNOS is largely dependent on the intracellular Ca concentration 
and stimuli that increase intracellular Ca2+ (such as acetylcholine, histamine, 
thrombin, serotonin, adenosine diphosphate (ADP), bradykinin, norepinephrine, 
substance P, and isoproterenol) cause the formation of Ca -CaM complexes, 
resulting in the binding to eNOS and consequently the dissociation of caveolin 
(Michel et al., 1997). eNOS remains activated until intracellular Ca2+ levels drop. 
Activation of eNOS also occurs following phosphorylation of serine-1179 by protein 
kinase B (Fulton et al., 1999).
Although eNOS is often considered to be a constitutive enzyme, there are 
numerous factors that have been shown to increase the basal expression and activity 
of the enzyme including shear stress (Uematsu et al., 1995), hypoxia (Le Cras et al., 
1996), oxidised low-density lipoproteins (Ramasamy et al., 1998) and hormones, 
such as oestrogen (Ruehlmann & Mann, 2000). Like nNOS, eNOS produces NO at 
nanomolar concentrations to exert its physiological effects.
1.1.3 Inducible nitric oxide synthase
Inducible nitric oxide synthase (iNOS orNOS2; 130 kDa) is expressed and 
activated in many types of cells, including vascular endothelial cells (Gross et al., 
1991), smooth muscle cells (Koide et al., 1993) and macrophages (Xie et al., 1993) 
following exposure to the cell wall components of gram negative bacteria, 
lipopolysaccharide (LPS) and the proinflammatory cytokines interleukin-lp (IL-ip), 
IL-2, IL-6 , tumour necrosis factor (TNF) and interferon-y (Kirkeboen & Strand,
1999). The gene encoding iNOS is localised to chromosome 17. An important 
distinctive feature of iNOS is that the enzyme is regulated in a Ca2+-independent 
manner, as binding of calmodulin to iNOS is tight even at low Ca2+ (Busse & Mulsch, 
1990). iNOS produces micromolar concentrations of NO; it is generally associated 
with the cytotoxic effects of NO and promoting cardiovascular pathophysiology 
(Shah, 2000).
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LPS can trigger the expression of iNOS through interaction with a LPS- 
binding protein (LBP), which delivers LPS to CD 14, a high-affinity LPS receptor on 
the cell membrane (Wright et al., 1990; Choi & Lee, 2004). Toll-like receptor 4 
(TLR4) in conjunction with the small extracellular protein named MD-2 interacts with 
the CD14-LPS complex, and then activates an intracellular signalling cascade, 
including interleukin (IL)-l receptor-associated kinase (IRAK) and myeloid 
differentiation protein (MyD8 8 ). These in turn activate downstream molecules 
including TNF receptor-associated factor- 6  (TRAF6 ) (Zhang et al., 1999). Activation 
of nuclear factor-kappaP (NF-kB) is crucial for induction of iNOS in vascular smooth 
muscle cells (VSMC) (Schini-Kerth et al., 1997). NF-kB is present in the cytosol as 
an inactive heterotrimer, which upon phosphorylation, dissociation and proteolytic 
degradation of its inhibitory IicBa subunit, is activated and translocates to the nucleus 
where the p65/p50 heterodimer binds to the corresponding response element in the 
promoter of the iNOS gene (Xie et al., 1994; Gomez et al., 2005). Recent studies 
demonstrate a role for eNOS in the expression of iNOS via NF-kB (Vo et a l , 2005, 
Connelly et al., 2005). iNOS induction is associated with ‘high output’ production of 
NO (Thiemermann, 1997).
1.1.4 Structure of NOS
Although there are some structural differences between NOS isoforms, they 
share common structural features. NOS consists of two monomers (Figure 1.1), each 
monomer having two functionally distinct domains. The N-terminal oxygenase 
domain contains the catalytic site, a haem prosthetic group and binding sites for L- 
arginine and the redox cofactor, tetrahydrobiopterin (BH4) (Ghosh & Stuehr, 1995). 
Two important residues for L-arginine binding have been located at amino acids 
residues Glu-371 and Asp-376 (these numbers refer to the location of the amino acid 
in the sequence in the enzyme) in iNOS (Gachhui et al., 1997) and the analogous 
Glu-361 in eNOS (Chen et al., 1997). BH4 is bound to Cys-99 in eNOS (Chen et al.,
1995) and Gly-450 and Ala-453 in iNOS (Cho et al., 1995). The C-terminal reductase 
domain has binding sites for nicotinamide adenine dinucleotide phosphate (NADPH), 
the flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and CaM, 
which are required for electron transfer (Stuehr et al., 1991). The reductase domain 
architecture is similar to that of cytochrome P450BM3 (Narhi & Fulco, 1987). All
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NOS isoforms are only fully functional when dimeric. Dimerisation of eNOS occurs 
by the binding of haem, without which, NOS exists only as a monomer (Klatt et al.,
1996). Crystal structures of the NOS haem domain of all three isoforms (Fischmann 
et al., 1999) show a tightly associated homodimer with the BH4  binding sites 
sandwiched at the dimer interface. Stabilisation of the dimer requires Zn binding to 
two cysteine residues from each subunit (Hemmens et al., 2000).
Reductase Oxygenase
NADPH
^ ^  C a My
Haem
COOH
Haem
NADPH
Oxygenase Reductase
COOH
Figure 1.1 Schematic representation o f a NOS dimer
1.1.5 Synthesis of NO
All three isoforms catalyse the oxidation of L-arginine to produce L-citrulline 
and NO (Figure 1.2). The reaction starts by hydroxylation of L-arginine to form 
A^-hydroxy-L-arginine (L-OHArg) (Leone et al., 1991). The reductase domain of one 
subunit catalyses the transfer of electrons from NADPH via FAD and FMN to CaM.
CaM is essential for the transdomain transfer of electrons to the haem group in the 
oxygenase domain of the second subunit (Abu-Soud & Stuehr, 1993). Binding of 0 2 
to the oxygenase domain catalyses oxidative cleavage of L-OHArg leading to the 
formation of citrulline and NO (Marin & Rodriguez-Martinez, 1997). Once
29
synthesised, the NO diffuses across the endothelial cell membrane and enters the 
VSMC where it activates its main cellular target, sGC, leading to an increase in 
intracellular cGMP.
CitrullineNADPH NADPH
L-OHArgL-arginine
Figure 1.2 Biosynthesis o f NO from L-arginine.
1.1.6 Soluble guanylate cyclase (NO receptor)
Although NO can react with other molecules (section 1.4.5), soluble guanylate 
cyclase (sGC) is considered as the principal physiological target for the freely 
diffusible intercellular messenger. Through sGC, the NO signals are coded into 
cytosolic cGMP accumulation. In turn, cGMP targets several classes of downstream 
effectors, principally cGMP-dependent kinase G, cyclic nucleotide-gated ion channels 
and cGMP-stimulated and-inhibited phosphodiesterases (a further description is 
found in section 1.2.2) (Hobbs, 1997).
1.1.6.1 Structure of sGC
Soluble guanylate cyclase is widely expressed in the cardiovascular system 
and other cell types. Originally, sGC was purified from bovine and rat lung and 
shown to exist as a heterodimer. Several isoforms of sGC have been cloned and 
characterised. In the rat, sGC consists of 82 kDa (a l)  and 70 kDa (p i) subunits
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(Kamisaki et al., 1986). Further subunits have also been identified from human foetal 
brain; an 82 kDa subunit designated a2 and a 76 kDa subunit designated p2 
(Harteneck et al., 1991; Yuen et al., 1990). Each subunit consists of at least three 
domains: (i) Haem-binding domain, (ii) catalytic domain and (iii) dimerisation 
domain (Figure-1.3). The haem-binding domain is located at the N-terminus of each 
subunit. The presence of the haem prosthetic group is required for activation of sGC 
by NO (Ignarro et al., 1982). Haem is a five-membered nitrogen-containing ring with 
four nitrogen atoms coordinated with a central iron that can be either Fe2+ (ferrous or 
the reduced form) or Fe3+ (ferric or the oxidised form). The fifth member of the ring 
in sGC is an imidazole axial ligand coordinated by the pi subunit at His-105 (Stone 
& Marietta, 1994). Mutation of this histidine located near the N-terminus of the pi 
subunit, results in the inability of sGC to bind haem and produces an enzyme that is 
unresponsive to NO (Ignarro et al., 1982).
Catalytic domains are present in the C-terminus of both a  and p subunits. The 
C-terminal of each subunit exhibits high homology not only among these subunits but 
also between the C-terminal domains of pGC and adenylate cyclase (AC) (Hobbs,
1997). Although both a  and p subunits contain their own catalytic domains, sGC 
activity is dependent upon co-expression of both subunits. For example, expression of 
either the a l  or the pi subunit in L cell fibroblasts does not result in any measurable 
sGC activity (Buechler, et al., 1991). The catalytic conversion of guanosine-5'- 
triphosphate (GTP) to cGMP by the catalytic domain relies on the presence of the
2 T 2 +divalent cations Mn and Mg as cofactors (Ohlstein et al., 1982). The availability 
of the latter two cations can modulate enzyme activity by enhancing activation, as 
well as increasing substrate affinity for sGC (Wolin et al., 1982).
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Amino Terminal
Haem Binding
Dimerisation
Guanylate Cyclase
— Fe
/ \
Carboxyl Terminal
Figure 1.3 Illustration showing different domains o f soluble guanylate cyclase.
1.1.6.2 Mechanisms of activation
Activation of sGC by NO involves the binding of NO to the prosthetic haem 
group, which leads to up to 200-fold activation of the enzyme (Stone & Marietta,
1994). Several models exist to explain the activation of sGC by NO; the simplest is 
thought to occur in two steps: first, NO binds to the sixth coordinated position of the 
haem and results in a six-coordinated NO-Fe2+-histidine-complex. The subsequent 
step is the breakage of the histidine bond leading to the formation of a five-
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coordinated nitrosyl-haem complex (Friebe & Koesling, 2003), the resulting 
conformational changes presumably propagates to the active site of the enzyme, and 
causes an increase in the rate of cGMP synthesis. A more complex model of NO 
activation of sGC has been suggested. In this model transition from the six-coordinate 
to the five-coordinate complex depends on the ambient NO concentration. This 
results in a scheme where NO not only activates the enzyme by binding to the haem 
but also regulates the velocity of activation via binding to a second non-haem binding 
site (Zhao et al., 1999).
1.1.6.3 Activators of sGC
In addition to endogenously generated NO from the endothelium or released 
from S-nitrosothiols, sGC is activated by exogenous NO administrated in the form of 
NO-donors. These agents release NO spontaneously, such as spermine-NONOate 
(SPER-NO) or, require metabolism by tissues to release NO, such as organic nitrates 
(Bennett et al., 1994).
Carbon monoxide (CO) also increases sGC activity in vitro, but is less 
effective (4-fold increase) than NO (200-fold increase; Stone & Marietta, 1994). 
Endogenous CO generation stems primarily from the enzymatic degradation of haem 
by the haem oxygenase enzyme system. Its small effect in vitro may be amplified by 
in vivo factors; exogenous compounds such as YC-1 and BAY-41-2272 have been 
found to enhance the effect of CO in vitro, so that CO activates sGC to the same level 
as NO (Kim et al., 2006). YC-1, a benzylindazol derivative, activates sGC 
independently of NO and CO (Ko et al., 1994; Hobbs, 1997), but also potentiates the 
effect of NO, presumably by stabilisation of the enzyme’s active configuration (Wu et 
al., 1995). Other compounds activating sGC in a haem-dependent manner include 
BAY-41-2272 and BAY 41-8543 (Stasch et al., 2002a). BAY 58-2667 increases the 
activity of sGC in a haem-deficient enzyme and in the presence of ODQ (Stasch et 
al., 2002b; Hobbs, 2002). They are potent vasodilators and inhibitors of platelet 
activity (Hobbs & Moncada, 2003). Further investigations on the mechanism of 
action of this class of compound have shown that there is a regulatory binding site in 
the region of cysteines 238 and 243 in the a  subunit (Stasch et al., 2001).
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1.1.6.4 Inhibitors of sGC
The most widely used inhibitor is ODQ, which is a potent and selective 
inhibitor of sGC in brain slices (Garthwaite et al., 1995). ODQ does not lead to the 
inhibition of pGC or AC or lead to the inactivation of NO (Hobbs, 1997). ODQ has 
no effect on NOS activity at concentrations less than 30pM (Feelisch et al., 1999), 
suggesting that this compound is suitable for differentiating between the cGMP- 
dependent and cGMP-independent effects of NO. sGC can also be inhibited by 
methylene blue and LY-83583, but these compounds are non-selective and interfere 
with NO synthesis by inhibition of NOS (Luo et al., 1995).
1.1.7 Physiology of NO-cGMP signalling
In the vasculature, NO synthesised from endothelial cells plays critical roles in 
the regulation of vascular tone, platelet activity, smooth muscle proliferation and 
endothelial cell apoptosis. This section describes in more details the contribution of 
NO-cGMP pathway in the regulation of vascular homeostasis.
1.1.7.1 Regulation of vascular tone
Several lines of evidence indicate that there is a continuous basal synthesis of 
NO from the vascular endothelium to maintain resting vascular tone in animals and 
humans. In rings of rabbit aorta, inhibition of basal endothelial NO synthesis by 
N -monomethyl-L-arginine (L-NMMA), a specific inhibitor of endothelium-derived 
NO synthesis, causes significant endothelium dependent contraction (Rees et al., 
1989). Intravenous infusion of L-NMMA into experimental animals induces a dose 
dependent increase in blood pressure which is reversed by intravenous administration 
of L-arginine (Rees et al., 1989). Mice with disruption of the eNOS gene are 
hypertensive and isolated blood vessels of these mice do not relax to endothelium- 
dependent vasodilators such as acetylcholine (ACh) (Huang et al., 1995). In the 
human forearm vasculature, infusion of L-NMMA into the brachial artery causes 
substantial dose-dependent vasoconstriction, suggesting that generation of NO is 
crucial in maintaining peripheral vasodilatation in humans (Vallance et al., 1989). 
Pharmacological inhibition of NO synthesis causes dose-dependent increases in blood
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pressure, systemic and pulmonary vascular resistance in healthy human (Stamler et 
al., 1994). Thus NO plays crucial role in the regulation of vascular tone.
1.1.7.2 Regulation of platelet activity
NO released by the endothelial cells towards the vascular lumen is a potent 
inhibitor of platelet aggregation and adhesion to the vascular wall, via activation of 
platelet sGC (Radomski et al., 1987). In vitro studies have shown that stimulation of 
sGC inhibits aggregation of washed human platelets (Furlong et al., 1987). It has 
been suggested that NO from endothelial cells diffuses into platelets and binds to 
sGC, leading to an increase in cGMP and a decrease in intracellular Ca flux. This 
decrease in Ca2+ flux may decrease platelet association with fibrinogen (Mendelsohn 
et al., 1990). In mice lacking eNOS there is a significant decrease in the bleeding 
times suggesting that sGC activation by NO regulates thrombus formation (Freedman 
et al., 1999). These observations suggest that NO is important for regulation of 
platelet activity.
1.1.7.3 Regulation of circulating cells
Endothelium-derived NO plays important roles in the regulation of cellular 
trafficking in blood vessels. Inhibition of NO release enhances leukocyte adherence 
to the coronary endothelium (Lefer & Ma, 1993). Adhesion molecules regulate 
attachment and trans-endothelial migration of leukocytes. NO inhibits IL-lp- 
mediated expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) (Takahashi et al., 1996). NO decreases the 
expression of monocyte chemoattractant protein-1 (MCP-1), and of surface adhesion 
molecules such as CD11/CD18, thereby preventing leukocyte adhesion to vascular 
endothelium and leukocyte migration into the vascular wall (Li & Forstermann,
2000). Recent work has shown that leukocyte recruitment is enhanced in eNOS 
knockout mice and activation of sGC reduces leukocyte rolling and adhesion to levels 
observed in wild type animals by down-regulation of P-selectin expression 
(Ahluwalia et al., 2004b). These findings suggest that NO is important anti-adhesive 
and anti-atherogenic agent.
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1.1.7.4 Regulation of smooth muscle proliferation
Smooth muscle cells are normally quiescent in the vasculature, and their 
proliferation is associated with narrowing of the arterial lumen. Therefore, regulation 
of their growth is highly important. Activation of sGC by NO was shown to inhibit 
the proliferation of VSMC in a cGMP-dependent manner (Garg & Hassid, 1989). 
Mice lacking eNOS showed increased intimal hyperplasia following balloon injury 
compared with normal mice (Moroi et al., 1998). NO can also inhibit smooth muscle 
proliferation in a cGMP-independent manner, by directly inhibiting the activity of 
arginase and ornithine decarboxylase to decreases the formation of polyamines that 
are key to cell proliferation (Ignarro et al., 2002). Thus, by inhibiting the proliferation 
and migration of VSMC, NO may protect against cardiovascular diseases such as 
atherogenesis. This effect of NO in combination with its effects on cellular adhesion, 
platelets and vascular tone give rise to the thesis that endogenous NO is an important 
antiatherogenic, cytoprotective mediator.
1.1.7.5 Regulation of endothelial cell apoptosis
Increased endothelial cell apoptosis is associated with atherosclerosis. 
Activation of sGC by NO protects endothelial cells from apoptosis. Low 
concentrations of NO antagonise the apoptosis-inducing stimuli, such as TNF-a, but 
high concentrations of NO can induce apoptosis (Shen et al., 1998). The protective 
effects of NO against apoptosis of endothelial cells might involve cGMP-dependent 
inhibition of cytochrome c release from mitochondria (Chung et al., 2001). Thus NO 
plays a dual role in the regulation of apoptosis depending on its concentration.
1.1.8 Pathophysiology of NO-cGMP
A number of cardiovascular disorders are associated with endothelial 
dysfunction and/or abnormality in the NO-cGMP pathway such as hypertension 
(MacAllister & Vallance, 1994), diabetes and inflammatory vascular diseases such as 
septic shock and atherosclerosis (Vallance & Chan 2001). This section describes the 
role of NO-cGMP pathway in these diseases.
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1.1.8.1 Hypertension
Physiologically, vascular tone is regulated by a balance between vasodilators 
and vasoconstrictors and any abnormality in this balance is likely to lead to abnormal 
vascular function. Substantial evidence from animal and human studies indicates that 
endothelial function is impaired in hypertension, with reduced NO production or 
bioactivity (Bolad & Delafontaine, 2005). Although many studies report normal 
smooth muscle dilator function, there is evidence that the activity of the downstream 
component of NO-cGMP pathway is reduced. In spontaneously hypertensive rats 
(SHR), the levels of both subunits of sGC are downregulated and the relaxation of 
aortic rings to the sGC activator YC-1 is also attenuated (Ruetten et al., 1999). In 
lead-induced hypertension, relaxation to both ACh and sodium nitroprusside (SNP) is 
reduced, with reduced expression of both a l  and pi subunits of sGC (Marques et al.,
2001). Recent work has shown that the levels of sGC and cGMP were significantly 
lower in 4- and 8 -week SHR compared with age-matched rats (Ndisang & Wang, 
2003). In summary, these data suggest that in hypertension both upstream 
(endothelium) and downstream (smooth muscle) aspects of the NO-cGMP pathway 
are impaired.
1.1.8.2 Diabetes
A hallmark of diabetic vascular disease is endothelial dysfunction. Reduced 
endothelium-mediated vasodilation has been found in studies in arteries from diabetic 
animals and humans. In streptozotocin-induced diabetic rats, endothelium-dependent 
relaxation to ACh is impaired. Acute administration of L-arginine in these animals 
normalises the defective relaxation to ACh (Pieper & Peltier, 1995). Recent work in 
this animal model of diabetes also showed that the impaired endothelium-dependent 
relaxation to ACh is associated with increased levels of endogenous NOS inhibitors 
(asymmetric dimethyl L-arginine (ADMA)) suggesting the possible role of these 
substances in the endothelial dysfunction of type 1 diabetes mellitus (Xiong et al.,
2003).
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In a model of type 2 diabetes mellitus (Goto-Kakizaki rats) relaxation of 
mesenteric arteries to ACh and SNP was blunted consistent with reduced activity 
and/or expression of sGC (Witte et al., 2002). In men with type 2 diabetes mellitus, 
McNeill et al showed that the forearm blood flow responses to the endothelium- 
dependent vasodilator is significantly impaired in diabetic men compared with control 
subjects (McNeill et al., 2000). Moreover, in patients with type 2 diabetes mellitus, 
the forearm blood flow responses to both methacholine chloride and SNP are 
significantly reduced suggesting either reduced sensitivity of smooth muscle sGC or 
increased breakdown of NO (Williams et al., 1996). Taken together, these 
observations indicate that the NO-cGMP pathway is impaired in both types of 
diabetes mellitus.
1.1.8.3 Cardiovascular inflammation
In animals and humans there is evidence that acute inflammation causes 
endothelial dysfunction. This might provide a mechanism to link the association 
between acute systemic inflammation and the transiently elevated risk of 
cardiovascular events (Vallance et al., 1997). Hingorani and co-workers demonstrated 
that systemic inflammation caused by salmonella typhi vaccine in healthy volunteers 
impairs endothelial but not smooth muscle responses in resistance and conduit vessels 
(Hingorani et al., 2000). Similar findings were shown by Kharbanda et al in which 
systemic inflammation causes endothelial dysfunction that was prevented by pre­
treatment with aspirin (possibly through modulation of the cytokine cascade) 
(Kharbanda et al., 2002). In healthy volunteers, induction of acute systemic 
inflammation by low doses of Escherichia coli endotoxin impairs forearm blood flow 
responses to ACh but not glyceryl trinitrate (GTN). The anti-oxidant vitamin C 
counteracted this effect of endotoxin, suggesting that oxidative stress may play an 
important role in the pathogenesis of endothelial dysfunction during inflammation 
(Pleiner et al., 2002). Recent studies by Clapp et al also demonstrated a role for 
oxidative stress in inflammation-induced endothelial dysfunction (Clapp et al., 2004). 
In addition to the role of oxidative stress in causing endothelial dysfunction, 
Mittermayer and others examined the role of the cofactor BH4 and found that forearm 
blood flow responses to ACh are impaired following 3.5 hr infusion of Escherichia 
coli endotoxin that was restored to baseline reactivity by BH4  and vitamin C. The
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authors suggested that vitamin C may exert some of its effects by increasing BH4  
concentrations (Mittermayer et al., 2005). These findings demonstrate that acute 
inflammation in humans is associated with oxidative stress mediated-endothelial 
dysfunction.
1.1.8.4 Atherosclerosis
The NO-cGMP pathway plays a crucial role in the inhibition of smooth 
muscle proliferation, cellular adhesion and platelet aggregation as mentioned above. 
Endothelial dysfunction is likely to be involved in the initiation and development of 
atherosclerotic lesions, and contribute to the pathogenesis of plaque instability and 
thrombosis (Charakida et al., 2006).
Abnormal endothelial function occurs in atherosclerotic animals and humans. 
Studies on arterial segments from hypercholesterolaemic rabbits demonstrated that 
there is accelerated inactivation of NO, probably due to enhanced formation of the 
superoxide anion (O2 ) (Minor et al., 1990). In patients with hypercholesterolemia, 
endothelium-dependent vasodilatation to ACh is impaired in both coronary and 
peripheral vessels before the development of clinical atherosclerosis (Chowienczyk et 
al., 1992). In human atherosclerosis, immunohistochemical measurement of the level 
of eNOS indicates reduced eNOS protein expression in carotid arteries obtained 
during surgery (Oemar et al., 1998). Overproduction of the endogenous inhibitors of 
eNOS, ADMA, has been reported in patient with atherosclerosis, this increased level 
positively correlated with risk factors for atherosclerosis (Miyazaki et al., 1998). 
These studies demonstrate different mechanisms that reduce the bioavailability of NO 
and contribute to atherogenesis.
Although much of the evidence points to endothelial dysfunction, there is also 
evidence of dysfunction in the sGC-cGMP pathway downstream from NO in 
atherosclerosis. Low density lipoprotein (LDL), which plays a key role in the 
development of atherosclerosis, reduces the responsiveness of sGC to 
nitrovasodilators (Schmidt et al., 1992). A recent study has shown that 
hypercholesterolemia induces overexpression of dysfunctional vascular sGC, which 
may contribute to the pathogenesis of atherosclerosis (Laber et al., 2002). In
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summary, atherosclerosis is a multi-factorial vascular disease, in which impairment of 
the NO-cGMP pathway plays an important role in its pathogenesis.
1.1.8.5 Septic shock
Septic shock is a systemic inflammatory state characterised by vascular 
smooth muscle dysfunction, leading to hypotension, inadequate tissue perfusion, and 
multiple organ failure with a high mortality rate (Shah, 2000). It is generally accepted 
that the hyporeactivity to vasoconstrictors associated with septic shock is due to over­
activation of the NO-cGMP pathway as a result of iNOS-derived NO (Shah, 2000). 
This was suggested by studies showing the reversal of endotoxin-induced 
hypotension through pharmacological inhibition of iNOS. In animal models of septic 
shock, administration of the NOS inhibitor (N -nitro-L-arginine methyl ester (L- 
NAME)) reverses endotoxin-induced hypotension suggesting the involvement of NO 
in the reduced blood pressure (Kilboum et al., 1990). Further evidence supporting the 
role of iNOS-derived NO in the reduced blood pressure, came from studies of iNOS 
gene knockout mice. In these animals, the hypotension caused by LPS is markedly 
attenuated (MacMicking et al., 1995). Also, pretreatment of animals with 
dexamethasone inhibits the LPS-induced expression of iNOS and attenuates the 
circulatory failure and hyporeactivity to vasoconstrictor agents, further supporting the 
concept that excess NO production is pathogenic in circulatory failure in septic shock 
(Paya et al., 1993).
In humans, pharmacological inhibition (L-NMMA) of NO synthesis by iNOS 
increases blood pressure in septic shock patients but decreases cardiac output (Petros 
et al., 1994) and has no effect on mortality. It is possible that non-selective inhibitors 
of NOS have adverse effects on outcome through inhibition of eNOS causing 
excessive vasoconstriction in the microcirculation. Selective inhibitors of iNOS could 
represent a useful therapeutic approach for septic shock, whereas non-selective NOS 
inhibitors (although increasing blood pressure initially) may worsen the final 
outcome. Therefore, further experimental work by using a selective inhibitor directed 
only against iNOS is required. The most selective inhibitor of iNOS activity so far is 
1400W (Garvey et al., 1997). Inhibition of iNOS by 1400W has been shown to 
reverse hyporeactivity to vasoconstrictors in mesenteric arteries in experimental
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model of septic shock in rats (O’Brien et al., 2001). Recently, Miyamoto et al 
demonstrated that inhibition of iNOS and sGC by 1400W and ODQ, respectively, 
restores the hyporeactivity to vasoconstrictors in rat aortic rings, further supporting 
the role of NO-cGMP pathway in septic shock (Miyamoto et al., 2004). These 
observations indicate that “high output” iNOS-derived NO is likely to mediate the 
hypotension and hyporeactivity to vasoconstrictors in septic shock.
1.2 Natriuretic peptides
Natriuretic peptides (NPs) are a family of hormones that activate the 
particulate guanylate cyclase (also called natriuretic peptide receptors). These 
vasoactive hormones include atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP), C-type natriuretic peptide (CNP) and urodilatin. NPs play important roles in 
the regulation of cardiovascular and renal physiology (section 1.2.3). The messenger 
RNA transcript for ANP is approximately 1 kb in size and encodes a precursor 
protein (pro-ANP) of 126 amino acids. Human pro-ANP is cleaved into a 98 amino 
acid amino-terminal fragment and a 28 amino acid carboxy-terminal fragment (by a 
serine protease named corin (Yan et al., 2 0 0 0 )), which represents the biologically 
active hormone (Espiner et al., 1995). The atrial myocyte is considered the main site 
of synthesis of ANP (Atlas et al., 1984) and it is released in response to atrial 
distension. In addition, ANP expression is directly stimulated by angiotensin II, 
endothelin-1 or adrenomedullin (McFarlane et al., 2003).
BNP was originally isolated from porcine brain, but in humans it is 
synthesised and secreted from the left ventricle (Yasue et al., 1994). Human BNP is 
produced first as a 108 amino acid precursor (proBNP). Further processing is required 
to release a biologically active hormone, which consists of 32 amino acids (Yasue et 
al., 1994) and an N-terminal fragment (NT-proBNP). CNP is primarily synthesised 
and stored in vascular endothelial cells in response to shear stress (Okahara et al.,
1995), where it is thought to act as an endothelium-derived hyperpolarising factor 
(Chauhan et al., 2003a). CNP is also found in the kidney, and brain, including high 
concentrations in the human hypothalamus and midbrain (Komatsu et al., 1991). CNP 
is produced first as a pro-CNP consisting of 126 amino acid peptide. Pro-CNP is 
further processed to generate 22 and 5 3-amino acid peptides by the serine protease
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furin (Wu et al., 2003). CNP-22 peptide is more widely and abundantly expressed and 
is more potent than CNP-53 peptide (Minamino et al., 1990). Urodilatin or D-type 
natriuretic peptide is the fourth member of the natriuretic peptide system. Urodilatin, 
which binds to the ANP receptor, is synthesised mainly in the kidney and formed 
from the same ANP pro-hormone and consists of 32 amino acids. Urodilatin is a more 
potent natriuretic agent than ANP (Abassi et al., 1992). Urodilatin regulates Na+ and 
H2O handling in the kidney (Drummer et al., 1997). Thus, NPs are a family of 
hormones including ANP, BNP, CNP and urodilatin that, upon generation, require 
further processing to generate the metabolically active hormone.
1.2.1 Natriuretic peptide receptors (particulate guanylate cyclases)
NPs exert their physiological effects by binding to high-affinity receptors on 
the surface of target cells. Three natriuretic peptide receptors (NPRs) subtypes have 
been isolated NPR-A, NPR-B, and NPR-C (Ahluwalia et al., 2004a). Each of the NPs 
interacts with each of the NPR subtypes with differing kinetics. For NPR-A the 
affinity is ANP>BNP»CNP whereas the affinity for NPR-B is CNP»ANP>BNP 
(Koller & Goeddel, 1992). NPR-C interacts with all 3 NPs, although with slightly 
greater affinity for ANP. The non-selective affinity characteristics of NPR-C for all 
three NPs support its role as a clearance receptor to regulate circulating levels of NPs 
(Maack et al., 1987). NPR-A and NPR-B consist of an extracellular ANP-binding 
domain, a single transmembrane sequence, and an intracellular domain consisting of a 
kinase-homologous regulatory domain (KHD) and a guanylate cyclase catalytic 
domain (GCD) (Figure-1.4) (Misono, 2002)
1.2.1.1 Extracellular domain
The ANP binding site at the extracellular domain has been characterised by 
mutagenesis experiments. Mutation at Glu-169 and His-185 caused significant loss of 
ANP binding, suggesting involvement of these residues in hormone interaction 
(Misono, 2002). Mutation at Phe-166, Arg-176 or Asn-180 demonstrated ANP 
binding comparable to the wild-type but significantly reduced cGMP stimulation, 
suggesting that these residues play a role in initiating or transferring the signal of 
hormone binding to activate the guanylate cyclase catalytic domain (Misono, 2002).
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Miyagi et al found at least five potential glycosylation sites in the extracellular 
domain that seem to have no role in hormone binding but may be required for folding 
and transport of the receptor to the cell surface (Miyagi et al., 2000). The binding of 
ANP to its receptor was found to require the presence of chloride in a concentration- 
dependent manner. The chloride-dependent ANP receptor regulation may work as a 
feedback mechanism regulating ANP natriuresis (Misono, 2000).
1.2.1.2 Transmembrane domain
All NPRs have a single transmembrane domain that is required for 
localisation to the membrane, but not for signal transduction. In addition to 
localisation, the transmembrane domains seem to facilitate receptor oligomerisation 
(Lemmon et al., 1994). Beyond the transmembrane domain toward the cytoplasmic 
region, there is a juxtamembrane domain, which is a short region distal to the 
transmembrane domain that undergoes a significant conformational change 
responding to ANP binding and may mediate transmembrane signal transduction 
(Huo et al., 1999). However, full understanding of the precise role of the 
transmembrane and juxtamembrane domain remains to be defined.
1.2.1.3 Intracellular domain
The intracellular domain of the ANP receptor consists of two subdomains, the 
KHD and GCD. Mutagenesis studies have shown that deletion of the KHD causes 
constitutive activation of the GCD, suggesting the KHD regulates the GCD by 
suppressing its activity (Chinkers & Garbers, 1989). Studies on the KHD have 
demonstrated that the binding of adenosine triphosphate (ATP) to the KHD is 
required for the responsiveness to ANP (Chinkers et al., 1991). The KHD is 
phosphorylated at serine and threonine residues, and modulates responsiveness to 
ANP (Potter & Hunter, 1998a). Five residues (Ser-513, Thr-516, Ser-518, Ser-523, 
and Ser-526) within the KHD are phosphorylated when NPR-B is expressed in human 
293 cells. Mutation of any of these residues to alanine reduces NPR-B 
phosphorylation state and guanylate cyclase activity (Potter & Hunter, 1998b).
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Figure 1.4 Illustration showing different domains ofNPRs.
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1.2.2 Mechanisms of pGC activation and cGMP-dependent relaxation
The mechanisms by which the signal is initiated by natriuretic peptide and 
translated into catalytic activation (i.e. cGMP formation), and the termination of that 
signal, have not been completely determined. However, it is generally accepted that, 
in its basal state, the KHD interacts with the GCD domain to suppress its activity. 
Binding of ANP to its receptor relieves this suppressive effect, leading to the 
elevation of the guanylate cyclase catalytic activity (Chinkers & Garbers, 1989). 
Binding of ATP to the KHD augments guanylate cyclase activation by ANP. Recent 
work demonstrated that ATP increases activity primarily by maintaining receptor 
phosphorylation status and also acts by stabilizing the enzyme function (Antos et al., 
2006). However, the entire process mediating this signalling mechanism is not 
completely understood.
Activation of guanylate cyclase stimulates the conversion of GTP into cGMP. 
It is widely accepted that the mechanism of relaxation is triggered by the formation of 
cGMP, which subsequently phosphorylates and activates protein kinase G (PKG) 
(Figure 1.5). PKG is a common final pathway for cGMP-derived from sGC or pGC. 
Stimulation of PKG leads to activation and inhibition of various proteins including 
ion channels, ions pump, receptors and enzymes, with a resultant effect to reduce the
• 2 “b  2 “Fcytosolic Ca level and the sensitivity of contractile apparatus to the Ca (Carvajal
et al., 2000). PKG reduces intracellular calcium by activating membrane and
2+ 2+ sarcolemmal Ca /ATPase pumps to increasing Ca extrusion, and sequestration in
the sarcoplasmic reticulum. PKG-dependent phosphorylation of the regulatory protein
phospholamban, the inositol triphosphate receptor (IP3R) (Komalavilas & Lincoln,
1994) and inositol triphosphate associated G-kinase substrate (IRAG) (Geiselhoringer
et al., 2004) also reduces intracellular Ca2+ concentration. PKG also phosphorylates
and opens Ca24-activated K channels, which hyperpolarise the cell membrane and
2 +  2-t 2+inhibit the influx of Ca through voltage-gated Ca channels. Reduction of Ca 
influx leads to smooth muscle relaxation (Yamakage et al., 1996). PKG inhibits 
voltage-gated Ca2+ channels probably through direct phosphorylation of the channel 
or nearby regulatory protein (Tewari & Simard, 1997). PKG also phosphorylates and 
activate myosin light chain phosphatase (MLCP). Since contraction is dependent on 
the activities of myosin light chain kinase, increased activity of myosin light chain
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phosphatase produces relaxation by decreasing myosin light chain (MLC) 
phosphorylation and decreasing the sensitivity of the contractile apparatus to Ca2+ 
without altering intracellular Ca2+ concentration (Lee et al., 1997).
ANP
(I <7 GTP
GTP cGMP
I], 4. |Ca2*]
— PKG ....... ■ '
Ca /A T P ase  
C ^ pump
MLCP Voltage-gated 
Ca2+ channel
MLC
Ca /ATPase 
pump
CaI+-activated K+
channel
Figure 1.5 The mechanism o f cGMP-mediated relaxation. Conversion o f GTP into 
cGMP stimulates PKG. PKG activates or inhibits a wide range o f cellular targets 
leading to a reduction in the cytosolic Ca2+ concentration and reduction in the 
sensitivity o f the contractile apparatus to Ca2+. Inositol triphosphate (IP3), inositol 
triphosphate receptor (IP3R), phosphatidylinositol biphosphate (PIP2), 
phospholipase C (PLC), myosin light chain (MLC) and myosin light chain 
phosphatase (MLCP). Activation (+) and inhibition (-).
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1.2.3 Physiological functions of natriuretic peptides
1.2.3.1 Regulation of vascular tone and blood pressure
NPs play important roles in the cardiovascular and renal systems, regulating 
their physiological function (Ahluwalia et al., 2004a). ANP and BNP are secreted in 
response to atrial stretch and pressure. Once released into the circulation, NPs reach 
their targets, which include the vasculature, heart, kidneys and adrenal glands 
(McFarlane et al., 2003). Several lines of animal and humans studies have 
demonstrated a major role for NPs in blood pressure control. For example, gene 
knockout studies have shown that disruption of the ANP gene increases sensitivity to 
high-salt diet, resulting in markedly increased blood pressure (John et al., 1995). 
Overexpression of ANP genes resulted in a reduction of systolic blood pressure of 
20-30 mmHg (Steinhelper et al., 1990). In NPR-A gene knockout mice, although the 
sensitivity to high-salt diet is maintained, there is a significant increase in basal blood 
pressure (Lopez et al., 1995). Endothelium-derived hyperpolarizing factor (EDHF) 
plays a fundamental role in the regulation of local blood flow and systemic blood 
pressure. Recent work showed that CNP may be an EDHF (Chauhan et al., 2003a). 
These observations suggest that NPs are endocrine and paracrine agents that regulate 
blood pressure by natriuresis and vasodilatation.
1.2.3.2 Regulation of renal function
NPs regulate renal function; urodilatin is synthesised in the kidneys and can 
modify cardiovascular and renal function by decreasing blood pressure and increasing 
glomerular filtration rate (GFR) (Saxenhofer et al., 1990). ANP regulates renal 
function by different mechanisms. ANP increases fluid and electrolyte excretion and 
opposes the renin-angiotensin-aldosterone system by inhibiting the synthesis and 
release of renin and aldosterone, and by antagonizing the biological effects of 
angiotensin (Tremblay et al., 2002). In contrast, CNP does not seem to play role in 
the renal system, even when injected at high doses in the renal artery, and is therefore 
considered to be more a cardiovascular than renal peptide (Chen & Burnett, 1998).
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1.2.3.3 Effects on coagulation, adhesion and inflammatory cells
Akin to NO, NPs also possess anti-atherogenic properties. ANP and CNP 
inhibit plasminogen activator inhibitor-1 mRNA expression in VSMC through a 
cGMP-dependent pathway (Bouchie et al., 1998). Moreover, in rat cultured aortic 
endothelial cells, BNP and CNP reduce the expression of tissue factor (TF), and the 
expression of plasminogen activator inhibitor-1 (PAI-1) induced by angiotensin II 
(Yoshizumi et al., 1999). Local CNP expression in balloon injured rabbit arteries 
suppresses expression of ICAM-1 and VCAM-1 through enhancement of NO 
production (Qian et al., 2002). CNP inhibits leukocyte recruitment and platelet 
aggregation through suppression of P-selectin expression (Scotland et al., 2005a). 
CNP also has a direct effect on inflammatory cells in vivo; exogenous CNP reduces 
cytokine or histamine-induced leukocyte rolling in mouse mesenteric circulation. This 
anti-adhesion effect is thought to occur through an NPR-C-mediated cGMP- 
independent mechanism (Scotland et al., 2005b).
NPs also have anti-inflammatory properties. Inflammatory mediators such as 
IL-ip, TNF and LPS increase endothelial CNP release. CNP and ANP attenuate the 
induction of the proinflammatory enzyme cyclooxygenase-2 (COX-2). 
Overexpression of CNP by adenoviral gene delivery reduces neointimal hyperplasia 
that develops when veins are grafted to the carotid artery (Scotland et al., 2005b). 
Collectively, these studies show that NPs have substantial anti-atherogenic and anti­
inflammatory properties by inhibiting recruitment and adhesion of inflammatory 
cells, together with inhibition of smooth muscle proliferation. These properties are 
thought to occur by cGMP-dependent and -independent pathways.
1.2.4 Pathophysiological roles of natriuretic peptides
NPs play important roles in a number of cardiovascular diseases. Several lines 
of evidence suggest the importance of NPs in congestive heart failure (CHF) in 
animals (Riegger et al., 1988) and humans (Stoupakis & Klapholz, 2003). In CHF 
there is a significant increase in circulating ANP and BNP, and this correlates with 
the severity of the disease (Luchner et al., 1998). Increased activation of NP pathways 
promote vasodilatation and natriuresis, and in so doing compensate for the effects of
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neurohormonal activation that is a pathogenic in CHF. The plasma level of NPs has 
recently been used as a diagnostic tool and a measure of the response to treatment in 
patients with CHF (Stoupakis & Klapholz, 2003). In addition to their roles in CHF, 
NPs have been suggested to play a protective role in ischemic heart disease such as 
atherosclerosis and restenosis by inhibiting smooth muscle cells migration (Ikeda et 
al., 1997). CNP inhibits growth factor-dependent DNA synthesis in smooth muscle 
cells suggesting that CNP regulates cellular proliferation (Porter et al., 1992). CNP 
was also found in atherosclerotic lesions of different stages suggesting a regulatory 
role of this natriuretic peptide in atherogenesis (Naruko et al., 1996).
In patients with acute myocardial infarction, there are high plasma levels of 
BNP with a positive correlation between plasma concentration and the size of 
infarction (Arakawa et al., 1994). In cardiac hypertrophy, ANP is increased as a result 
of increased ventricular wall stress (McKenzie et al., 1994). Kishimoto at al 
demonstrated that in cardiac myocytes lacking the NPR-A receptor gene, the size of 
the cells is markedly increased and introduction of the NPR-A transgene inhibits 
cardiac ventricular myocyte hypertrophy (Kishimoto et al., 2001). ANP-deficient 
mice exhibit an exaggerated increase in right and left ventricular weight in response 
to volume overload (Mori et al., 2004). In humans with dilated cardiomyopathy, the 
increased levels of plasma ANP and BNP are associated with significant increases in 
ventricular ANP and BNP in both left and right ventricular tissue (Hasegawa et al., 
1993a). Raised levels of plasma BNP have also been found in patients with 
hypertrophic cardiomyopathy (Hasegawa et al., 1993b). These findings suggest that 
NPs may be an important physiological modulator of cardiac hypertrophy. In 
pulmonary hypertension, circulating NPs concentrations are raised that may either 
directly reduce pulmonary arterial pressures or contribute to the vasodilatation 
induced by phosphodiesterase inhibitors (Sebkhi et al., 2003).
NPs have a new emerging role in sepsis and septic shock. Hartemink et al 
found that right and left systolic dysfunction correlated with an increase in plasma 
levels of ANP and its second messenger cGMP during the first 3 days after the 
diagnosis of septic shock (Hartemink et al., 2001). The precursor of ANP, pro-ANP, 
has been studied as a novel hormone marker of cardiac depression caused by sepsis, 
(Mazul-Sunko et al., 2001). CNP has also been implicated in sepsis, with markedly
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elevated serum level of CNP seen in patients with sever infection compared to 
patients with congestive heart failure and hypertension (Hama et al., 1994). These 
studies suggest that NPs might contribute to the hypotension-associated with septic 
patient. Collectively these findings indicate that NPs are involved in various forms of 
cardiovascular pathophysiology.
1.2.5 Therapeutics of natriuretic peptides
The investigation of therapeutic values of NPs has been of great interest since 
NPs are regarded as beneficial in various cardiovascular disorders. For example, in 
patients with CHF, Crozier et al demonstrated that infusion of ANP causes significant 
reductions in mean systemic arterial pressure, mean pulmonary artery pressure, 
pulmonary diastolic pressure, right atrial pressure, and increase of cardiac output 
(Crozier et al., 1986). Though the haemodynamic improvements are significant, the 
effects of ANP infusion are transient so as to limit its practical use. In contrast, 
infusion of BNP, showed a sustained hemodynamic improvement in patients with 
CHF (Marcus et al., 1996). The difference between the effective duration of ANP and 
BNP may be explained by the difference in their plasma half-life. Intravenous 
infusion of nesiritide (a recombinant human BNP) is effective in improving 
haemodynamics of patients with CHF. It decreases systemic vascular resistance, 
pulmonary-capillary wedge and pulmonary artery pressures and elevates cardiac 
index with improvement in CHF symptoms (Colucci et al.,2000). However, recent 
concerns have been raised about the use of nesiritide, with reports of unexpected 
deaths in patients treated with this agent (Sackner-Bemstein et al., 2005). I will revisit 
this and a possible mechanism to explain this phenomenon in section 1.5.3.
Further clinical benefits of NPs come from their diagnostic use. ANP and 
BNP levels are increased in patients with heart failure and in many patients with 
hypertension and chronic renal failure. Because BNP plasma levels correlate more 
closely than ANP levels with left ventricular function, BNP is considered a better 
diagnostic marker of CHF (Stoupakis & Klapholz, 2003). Campbell at al showed that 
the plasma level of NT-proBNP is elevated in subjects with renal failure, myocardial 
infarction and heart failure. They suggested that NT-proBNP is a sensitive indicator 
of cardiac dysfunction and may prove to be a useful tool for the identification and
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management of cardiac dysfunction (Campbell et al., 2000). In a recent study of 1059 
patients with chronic stable angina, Ndrepepa and co-workers showed that the plasma 
levels of NT-proBNP are correlated with mortality. They suggested that the 
circulating levels of NT-proBNP are a prognostic biomarker for patients with chronic 
stable angina (Ndrepepa et al., 2005). Based on the discussion in section 1.2.4 it is 
unclear how increased NP activity is associated with an adverse cardiovascular 
outcome. I will discuss this further in section 1.5.3.
While much of the therapeutic roles for NPs have concentrated on the current 
and potential uses of ANP and BNP, the therapeutic uses of CNP have yet to be 
explored. CNP may hold promise as a cardiovascular drug because recent evidence 
indicates that CNP can regulate coronary blood flow and prevents myocardial 
ischemia/reperfiision injury in rat through an NPR-C-dependent pathway (Hobbs et 
al.,2004). Also CNP can prevent cardiac remodeling following myocardial infarction 
in mice (Soeki et al.,2005).
1.3 Aspects of cGMP-mediated vasodilatation to be addressed in this thesis
I have provided a brief review of the NO and NP systems in the above sections as a 
basis from which to describe the specific research areas that I investigated in this 
thesis. These are two-fold:
1. The role of endogenous adducts of NO, the S-nitrosothiols, as vasodilators 
which is described in section 1.4.
2. The interaction between the sGC and pGC systems, with specific emphasis on 
desensitisation of the guanylate cyclase pathways, described in section 1.5.
1.4 Modulation of NO biology by the formation of £,-nitrosothiols
1.4.1 5-nitrosothiols in biological systems
It has been suggested that NO is stored and carried as S'-nitrosothiol adducts, 
which preserve it from inactivation by several molecules like haemoglobin, molecular
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oxygen or superoxide (Stamler et al., 1992a). S-nitrosothiols have been found 
endogenously in erythrocytes, polymorphonuclear leukocytes, and platelets, as well 
as tissues including brain and lung. The concentrations of S-nitrosothiols in vivo are a 
matter of debate. In the lining of human airways, S'-nitrosothiols (predominantly 
S-nitrosoglutathione (GSNO)) has been detected at concentration of 0.25 pM (Gaston 
et al., 1993). In the cerebellum, GSNO has been detected at concentration of 15.4 
pmol/mg protein (Kluge et al., 1997). Stamler et al found that human plasma contains 
approximately 7pM S-nitrosothiols, 96% was in the form of .S-nitrosoprotein, 82% of 
which was accounted for by S-nitrosoalbumin (SNOAlb) (Stamler et al., 1992a). 
Tyurin et al found that the concentration of S-nitrosothiols was about 9.2 pM (Tyurin 
et al., 2001). However, other studies reported lower plasma concentrations of 
S-nitrosothiols between 20-200 nM (Goldman et al., 1998; Marley et al., 2000). It is 
possible that the difference in the level of S-nitrosothiols observed in these studies is 
due to methodological differences in the analytical techniques.
1.4.2 Formation of £-nitrosothiols
The mechanisms leading to formation of S-nitrosothiols in biological tissues 
are unclear. NO per se does not react directly with sulphydryl-containing compounds 
(RSH) such as glutathione (GSH) to form S-nitrosothiols (RSNO). Several 
mechanisms have been postulated for the formation of S-nitrosothiols in biological 
systems. Gow and colleagues proposed a mechanism for the formation of S- 
nitrosothiols that would proceed at physiologically relevant concentrations of NO. 
They suggested that NO reacts directly with a reduced thiol to produce a radical 
intermediate. In the presence of an electron acceptor, such as oxygen and NAD+ this 
intermediate can be converted to an S-nitrosothiol by the reduction of the acceptor 
(Gow et al., 1997) as follows:
RSH+NO<->RSNOH
r s n o h +o 2^ r s n o +o - 2
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Other studies have suggested alternate routes for the formation of S-nitrosothiols. 
iS-nitrosothiols might be formed by the reaction of an S'-nitrosating agent, such as 
dinitrogen trioxide (N2O3), with thiols as follows:
2N 0+0 2—>2N02
n o 2+ n o ^ n 2o 3
N20 3 +GSH—GSNO+ 2NO~ 2 +H+
In this mechanism, the reaction of NO with oxygen yields nitrogen dioxide. Nitrogen 
dioxide can rapidly react with NO to form N20 3. The latter is a good nitrosating 
agent, which can nitrosate thiols (such as GSH and cysteine) to form S-nitrosothiols 
(Karitonov et al., 1995). Another postulated mechanism includes nitrosyldioxyl 
radical (ONOO) as an intermediary in the formation of S-nitrosothiols within 
biological systems (Gow et al., 1997). In this mechanism NO reacts with oxygen to 
form ONOO. The latter reacts with reduced thiols to form an S-nitrosothiol and 
superoxide according to the following reaction:
N 0+ 0 2^ 0 N 0 0  
ONOO +RSH^RSNO+ 0 ~ 2
However, whether one or more mechanisms are required for the formation of 
S-nitrosothiols in biological systems remains unclear.
1.4.3 Formation of 5-nitrosoproteins
In addition to the low molecular weight S-nitrosothiols, high molecular weight 
S-nitrosothiols have been reported to exist endogenously in the form of 
S'-nitrosoproteins. Formation of S-nitrosoproteins occurs when a specific cysteine 
residue reacts with NO in the presence of an electron acceptor. SNOAlb is the most 
abundant physiological circulating NO carrier regulating NO-dependent biological 
actions in humans (Stamler et al., 1992a). The mechanisms of its formation is thought 
to occur through S-transnitrosation of the sulfhydryl group located at Cys-34 by the 
physiological S-nitroso-compounds, S'-nitrosocysteine (CYSNO) and GSNO (Tsikas 
et al., 2001). Marley et al demonstrated that significant amount of SNOAlb can be
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generated in human plasma under aerobic conditions in a reaction involving two 
molecules of NO and one of O2 (Marley et al., 2001). S-nitrosohaemoglobin 
(SNOHb) is the product of the reaction between NO and haemoglobin, involving S- 
nitrosation of a specific cysteine residue at a position 93 of the P-chain (Jia, et al.,
1996). SNOHb has been proposed to regulate vascular tone under conditions of low 
oxygen tension. Other S-nitrosated proteins that have been described include tissue- 
type plasminogen activator (t-PA; S-nitrosated at Cys-83; Stamler et al., 1992b) 
ornithine decarboxylase (at Cys-360; Bauer et al., 2001), the cell signalling protein, 
p21ra5 (S-nitrosated at Cys-118 leading to activation of downstream signalling 
pathways; Heo & Campbell, 2004).
1.4.4 Biotransformation of 5-nitrosothiols
Several mechanisms have been reported to decompose S-nitrosothiols leading 
to the release of NO including metal ions, thiols, photochemical and enzymatic- 
mediated biotransformation.
1.4.4.1 Role of metal ions
Metal ions decompose S-nitrosothiols to release NO. One of the earliest
• •  ^ 4- • •descriptions of this is the action of mercury (Hg ), which binds to the sulphur atom 
of the S-nitrosothiol, releasing nitrous acid (Saville 1958; Swift & Williams 1997). 
The presence of trace amount of copper ions strongly affects the stability of certain 
S-nitrosothiols (Williams, 1996). Cu(I) catalyses the decomposition of S-nitrosothiols 
probably by homolytic cleavage of the S-N bond resulting in the release of NO (Singh 
et al., 1996). Likewise, the reaction between Cu(II) and S-nitrosothiols leads to the 
release of NO and the production of thiol disulfide. The decomposition of 
S-nitrosothiols by Cu(II) requires the reduction of Cu(II) into the active moiety, Cu(I), 
probably by thiols (Gorren et al., 1996). Copper ions under physiological conditions 
are bound to proteins and enzymes. Dicks and Williams established that protein 
associated-Cu(II) (treated with thiol) catalyses the decomposition of S-nitrosothiols 
through the reduction of Cu(II) to Cu(I) (Dicks & Williams, 1996). This finding is 
important, as it implies that copper-associated enzymes in the body might metabolise 
S-nitrosothiols.
54
Kostka and co-workers reported that CYSNO degradation was enhanced
2 “F 2 “k •several fold by millimolar concentrations of Mg and Ca ions in homogenates 
isolated from porcine aortic smooth muscle (Kostka et al., 1999). Later, this group 
showed that the redox cycling of Fe2+ with the assistance of a protein factor catalyses 
decomposition of the S—NO bond of CYSNO (Sorenson et al., 2000). However, 
other metal ions such as Zn2+, Ni2+, Co2+, Mn2+, Cr3+, or Fe3+ have been shown to 
cause no measurable catalysis of S-nitrosothiols (Williams, 1996).
1.4.4.2 Role of reducing agents
Reducing agents such as ascorbic acid, cysteine and GSH, enhance the 
decomposition of S-nitrosothiols (Kashiba-Iwatsuki et al., 1997). Wong et al showed 
that the reaction of GSH with S-nitrosothiols results in the generation of nitroxyl 
(HNO). The subsequent reaction of HNO with the remaining S’-nitrosothiols and 
thiols results in the generation of NO (Wong et al., 1998). Thiols can cause 
decomposition of S-nitrosothiols by transnitrosation, in which the nitroso group is 
transferred from an S-nitrosothiol to a thiol (Hogg, 1999), although this does not 
release free NO. Thiols can also reduce metal ions which may then cause 
decomposition of S-nitrosothiols (Gorren et al., 1996).
1.4.4.3 Enzymatic decomposition
Certain enzymes have been reported to breakdown S-nitrosothiols. Askew and 
co-workers demonstrated that the enzyme, y-glutamyltranspeptidase, decomposes 
GSNO in vitro leading to the formation of unstable S-nitrosothiol called 
S-nitrosocysteinylglycine, which subsequently decomposes in the presence of metal 
ions leading to the release of NO (Askew et al., 1995). Nikitovic and Holmgren 
showed that GSNO is a substrate for the enzyme thioredoxin reductase, which 
generates stoichiometric amounts of GSH and NO by homolytic cleavage (Nikitovic 
& Holmgren, 1996). Jourd'heuil et al reported that Cu/Zn superoxide dismutase 
(Cu/Zn SOD) causes decomposition of GSNO in a manner that is accelerated by the
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presence of GSH (Jourd'heuil et al., 1999). It is unclear whether this is an enzymatic 
or chemical process, catalysed by exposure of bound copper to GSNO.
Additionally, it has been demonstrated that the intracellular enzyme 
glutathione-dependent formaldehyde dehydrogenase may have a role in the 
metabolism of GSNO (Liu et al., 2001) and that xanthine oxidase might also catalyse 
the decomposition of S-nitrosothiols (Trujillo et al., 1998). Further, recent studies 
have pointed to a possible role of the cell-surface protein disulfide isomerase (PDI) in 
the biotransformation of S-nitrosothiols. For instance, in human erytheroleukaemia 
cells, inhibition of PDI decreases cGMP generation after S-nitrosothiol exposure (Zai 
et al., 1999). Moreover, in platelets, PDI has been shown to catalyse the release of 
NO by denitrosation of GSNO (Root et al., 2004). Importantly, since both xanthine 
oxidase (Roussos & Morrow, 1966) and PDI (Narindrasorasak et al., 2003) are 
copper-binding enzymes, the inhibitory effects of copper chelators on S'-nitrosothiol 
biotransformation should be interpreted with caution.
In the nervous system, Davisson et al demonstrated that intracerebro- 
ventricular injection of the L-CYSNO produces greater hemodynamic changes than 
the D-isomer of CYSNO. They suggested that L-CYSNO may activates a specific 
recognition site on brain neurons (Davisson et al, 1997). In the vasculature, Travis et 
al showed that the L-isomer of S'-nitrosopenicillamine generates more cGMP in 
porcine aortic smooth muscle cells than the D-isomer (Travis et al., 1996). This group 
also suggested that a CYSNO recognition site may exist on the vascular smooth 
muscle of resistance arteries in the rat. They showed that in the conscious rat, 
intravenous injections of the L-CYSNO have greater vasodilator effect on mesenteric 
arteries than the D-isomers (Davisson et al., 1996). However, this role of L-CYSNO 
was not observed by another group; Cavero et al showed that responses to L-and 
D-isomers of CYSNO and S-nitroso-N-acetylpenicillamine (SNAP) were equipotent 
in rat aortic rings but L-GSNO is more potent vasorelaxant than D-GSNO (Cavero et 
al., 2000). These observations suggest that there is no consensus on the relative 
contribution of enzyme-dependent biotransformation of S-nitrosothiols in the 
vasculature and more investigations are required to explore this mechanism.
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1.4.5 Biological roles of 5-nitrosothiols
S-nitrosothiols have been shown to cause NO-dependent regulation of 
vascular tone. In rat aortic rings, CYSNO, SNAP and GSNO cause concentration 
dependent relaxation that is inhibited by the NO scavengers, hydroxocobalamin and 
haemoglobin (Rand & Li 1993) and blocked by ODQ (Feelisch et al., 1999). In rat 
pulmonary vasculature, administration of SNAP, causes vasodilatation. This action of 
SNAP was attributed to its ability to donate NO (Emery, 1995). Stamler et al 
demonstrated that the large molecular weight S-nitrosoprotein, SNOHb, also 
vasodilates in an NO-dependent manner (Stamler et al., 1997). Megson et al reported 
that SNAP analogues cause NO-dependent vasorelaxation in isolated rat femoral 
artery and scavenging NO with haemoglobin, removed the vasodilator effect of 
SNAP (Megson et al., 1999). Sogo and co-workers have also shown that 
S-nitrosothiols cause prolonged, NO-mediated relaxation in human saphenous vein 
and internal mammary artery (Sogo et al., 2000). The vasorelaxation of vascular 
strips exposed to visible light suggest a possible role for endogenous NO store to act 
as photosensitive NO-donor within vascular smooth muscle (Megson et al., 2000a; 
Chauhan et al., 2003b). These studies demonstrate that S-nitrosothiols regulate 
vascular tone through the release of their bound NO.
S-nitrosothiols are also potent inhibitors of platelet aggregation. Mellion at al 
showed that CYSNO and SNAP inhibit platelet aggregation in a concentration- 
dependent manner through elevation of cGMP. The NO scavenger, methemoglobin 
partially reversed this anti-aggregatory effect (Mellion et al, 1983). The ability of 
S-nitrosothiols to inhibit platelet aggregation is reduced in the presence of Cu(I) 
chelators (Gordge et al., 1995). Pawloski et al showed that both cell-free and intra- 
erythrocytic SNOHb inhibit platelet aggregation (Pawloski et al., 1998). Megson et al 
investigated the effect of two S-nitrosothiols, GSNO and RIG200, on platelet activity 
and found that these S-nitrosothiols are potent inhibitors of platelet aggregation. This 
effect was abolished in the presence of NO scavenger (Megson et al., 2000b). 
Recently, Crane at al revealed that S-nitrosothiols inhibit platelet aggregation via 
cGMP-independent effects on Ca signalling (Crane et al., 2005). They showed that 
the iS'-nitrosothiol, S-nitroso-N-valerylpenicillamine (SNVP), displayed NO-mediated 
cGMP-independent inhibition of platelet aggregation in platelet-rich plasma in the
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presence of the sGC inhibitor, ODQ. These studies support the thesis that NO 
synthesised by the endothelium or released from S'-nitrosothiols might play important 
roles in the regulation of vascular homeostasis through their ability to inhibit platelet 
aggregation.
In addition to carrying and releasing NO, S-nitrosothiols might regulate 
cellular activities through S-thiolation and S-nitrosation (table 1 .1 ). S-thiolation is a 
biological process that involves the nucleophillic attack of the sulphur group of 
S-nitrosothiols by a thiolate anion (Hogg, 1999). Protein S-thiolation has long been 
regarded as an intracellular response to oxidative stress. It has recently been shown 
that incubation of enzymes with S-nitrosothiols lead to both S-nitrosation and 
S-thiolation. GSNO thiolates glyceraldehyde-3-phosphate dehydrogenase and inhibits 
enzyme activity (Mohr et al., 1999). Konorev and others reported that GSNO S- 
thiolates creatine kinase, which result in the inhibition of the enzyme (Konorev et al., 
2000). Incubation of papain with GSNO and SNAP, results in thiolation at Cys-25 
with subsequent inhibition of this protein (Xian et al., 2000).
S-nitrosothiols modify enzyme activity by S-nitrosation. Stamler et al found 
that S-nitrosation of t-PA made this protein a potent vasodilator and inhibitor of 
platelet activity (Stamler et al., 1992b). Li and others found that NO reversibly 
inhibits seven members of the caspase family via S-nitrosation (Li et al., 1997). 
SNAP and GSNO inhibit coagulation factor XIII activity in a concentration- 
dependent manner, in both purified enzyme and plasma preparations. The inhibition 
occurred through S’-nitrosation of a highly reactive cysteine residue (Catani et al., 
1998). CYSNO inhibits the transcription factor, NF-kB by S'-nitrosation (Marshall & 
Stamler, 2001). The activity of ornithine decarboxylase, a rate-limiting enzyme in the 
polyamine biosynthetic pathway that is required for cell growth is inhibited by 
S-nitrosation by GSNO (Bauer et al., 2001). Kwiecien et al showed that the catalytic 
activity of rhodanese, which catalyses the detoxification of cyanide, was inhibited on 
exposure to SNAP and GSNO as a result of S-nitrosation (Kwiecien et al., 2003). 
Recent work suggests that S-nitrosothiols may have an effect on fibrinogen that is not 
due to either S-nitrosation or thiolation but rather due to interaction with an allosteric 
site leading to changes in the structure of fibrinogen (Akhter et al., 2002). Thus, these
58
studies indicate that S-nitrosothiols are important biological mediators that modulate 
signalling pathways via activation or inhibition of many enzymes and proteins.
Nonetheless, it is not possible to determine if any of these effects of 
S-nitrosothiols are biologically relevant. So far, there is no specific inhibitor directed 
against S-nitrosothiols to allow investigation of their biology. Until it is possible to 
block specifically the action of S-nitrosothiols, there will be uncertainty about their 
biological roles.
Enzymes
Effect of 
S-nitrosothiols
Effect on 
the enzyme
Reference
Soluble guanylate cyclase NO release Activation
Craven & 
DeRubertis, 1983
Gly ceraldehydes-3 -phosphate 
dehydrogenase
Thiolation Inhibition Mohr et al., 1999
Creatine kinase Thiolation Inhibition Konorev et al., 2000
Papain Thiolation Inhibition Xian et al., 2000
Tissue-type plasminogen 
activator
S-nitrosation Activation Stamler et al., 1992b
Caspase S-nitrosation Inhibition Li etal., 1997
Coagulation factor XIII S-nitrosation Inhibition Catani et al., 1998
Nuclear factor-kappa p S-nitrosation Inhibition
Marshall & Stamler, 
2 0 0 1
Ornithine decarboxylase S-nitrosation Inhibition Bauer et at., 2001
p2lnu S-nitrosation Activation
Heo & Campbell, 
2004
Rhodanese S-nitrosation Inhibition Kwiecien et al., 2003
Table 1.1 Modulation o f enzymes activity by S-nitrosothiols.
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1.4.6 Pathophysiological aspects of £-nitrosothiols
Abnormal levels of iS'-nitrosothiols are found to occur in numerous 
pathophysiological conditions suggesting that abnormal regulation of iS'-nitrosothiols 
may contribute to disease pathogenesis. For instance, GSNO was first described in 
human airways with an approximate concentration of 0.3 pM in normal subjects 
(Gaston et al., 1993), this concentration differs under pathological conditions with 
higher concentration in patients with pneumonia and lower concentration in patients 
with asthma (Gaston et al., 1998). Circulating concentrations of SNOAlb and SNOHb 
increase in endotoxemia (Jourd'heuil et al., 2000), and cirrhosis (Ottesen et al., 2001). 
In humans, increased iS'-nitrosothiols in exhaled breath has been reported in patients 
with chronic obstructive pulmonary disease (Corradi et al., 2001) but decreased in 
children with cystic fibrosis (Grasemann et al., 1999).
Increased plasma concentrations of iS'-nitrosothiols have been found in patients 
with preeclampsia (Tyurin et al., 2001). Interestingly, a recent study demonstrated 
that the abnormal high level of iS'-nitrosothiols in women with preeclampsia may be 
due to deficient release of NO from SNOAlb (Gandley et al., 2005), this suggests that 
the hypertension in preclampsia may be, at least in part, due to deficiency in NO 
release from endogenous iS'-nitrosothiols. High concentrations of iS'-nitrosothiols have 
also been observed in hypercholesterolemia (Moriel et al., 2001) and patients on 
chronic haemodialysis (Massy et al., 2003). Thus, these findings suggest that iS'- 
nitrosothiols are involved in the pathophysiology of various systems in vivo. 
Understanding of the regulation of their formation and biotransformation may be 
pathogenically important.
1.4.7 Therapeutic implications of NO and <S-nitrosothiols
The use of glyceryl trinitrate (GTN) in cardiovascular disease is limited by the 
development of tolerance (Parker & Gori, 2001). The mechanism of nitrate tolerance 
is controversial, and it has been suggested that alternative NO donors might not be 
affected by tolerance to the same degree. In rat and rabbit aorta, the response to 
iS'-nitrosothiols was preserved in GTN-tolerant rings (Kowaluk et al., 1987; Smith et 
al., 1994). Administration of iS'-nitrosothiols to rats with congestive heart failure
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showed reduced development of tolerance in comparison with GTN (Bauer & Fung 
1991). Miller and colleagues found that the novel S-nitrosothiol, RIG200 did not 
cause vascular tolerance in an ex vivo study on rat femoral artery (Miller et al., 2000). 
Sogo and others found that, in studies on human saphenous vein and internal 
mammary artery taken from patients undergoing coronary artery bypass grafting, 
S-nitrosothiols (RIG200 and GSNO) caused vasorelaxation that was sustained 
compared to GTN and SNP. They suggested that pretreatment of these vessels with 
iS'-nitrosothiols might improve their patency in the early post-operative period (Sogo 
et al., 2 0 0 0 ).
Balloon angioplasty is limited by the adhesion of platelets to the vascular 
wall. In rabbit models, in vivo administration of the S'-nitrosothiol, SNVP, caused a 
remarkably prolonged and selective inhibition of platelet adhesion in the area of 
vascular injury with a negligible effect on blood pressure as compared to GTN 
(Miller et al., 2003). An anti-platelet effect of GSNO has been documented in healthy 
volunteers, that is evident at doses with minimal vascular effects. This suggests a 
degree of platelet selectivity that might be useful clinically (De Beider et al., 1994; 
Ramsay et al., 1995).
In ischemia/reperfusion injury, iS’-nitrosothiols suppress endothelin-1 release, 
and subsequently inhibit the damaging effects of endothelin-1  during reperfusion 
(Brunner, 1997). SNOAlb inhibits intimal proliferation and platelet deposition 
following injury in rabbit femoral artery (Marks et al., 1995). Moreover, SNOAlb 
provides significant protection of skeletal muscle from ischemia/reperfusion injury 
(Hallstrom et al., 2002). In patients, intra-coronary infusion of GSNO during 
coronary balloon angioplasty prevents the angioplasty-induced increase in platelet 
expression of P-selectin and of glycoprotein Ilb/IIIa, without altering blood pressure 
(Langford et al., 1994). In humans, intravenous injection of GSNO reduces carotid 
emboli formation following angioplasty, suggesting that S-nitrosothiols may be 
clinically useful in the treatment of thromboembolic disease (Molloy et al., 1998; 
Kaposzta et al., 2001). In summary, iS'-nitrosothiols have wide therapeutic beneficial 
effects. They may not develop tolerance, exhibit a certain degree of platelet 
selectivity and show beneficial effects in the treatment of ischemia/reperfusion injury 
and thromboembolic disease.
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1.4.8 Exploring the mechanisms of £-nitrosothiols biotransformation
Based on the above discussion of the biological, physiological (section 1.4.4 
and 1.4.5), pathophysiological (section 1.4.6) and therapeutic (section 1.4.7) 
significance of iS-nitrosothiols it is important to investigate the mechanisms by which 
these NO-donor are bio-transformed in the biological system. The relative contribution 
of enzymatic and non-enzymatic mechanisms of iS'-nitrosothiols biotransformation in 
vascular tissue and the role of free and enzyme-bound copper ions are explored in 
Chapter Three.
1.5 Desensitisation of GC-cGMP pathway
1.5.1 Evidence for desensitisation of sGC and pGC pathways
The sensitisation and desensitisation of GC can be described as changes in the 
responsiveness of GC-cGMP to a given stimulus. This process may be caused by 
changes in the activity, the amount of the enzyme and/or the factors that regulate the 
enzyme. The ambient concentration of NO has been shown to alter the responsiveness 
of guanylate cyclases. Studies have shown greater sensitivity to NO if endogenous 
synthesis of NO is reduced by NOS inhibitors or endothelial denudation (Moncada et 
al., 1991).Vessels with reduced basal NO, as occurs in mice deficient in eNOS, show 
increased sensitivity to NO and NO donors (Hussain et al., 1999). Desensitisation of 
the sGC-cGMP system also occurs after exposure of the tissues to high concentrations 
of NO (Hussain et al., 1999). Overexpression of eNOS leads to reduced responses to 
endothelium-dependent and independent relaxation which can be attributed to 
reduced activity of sGC (Yamashita et al., 2000). A cross-desensitisation between 
endogenously produced NO and exogenously administered NO donors has also been 
found to occur (Papapetropoulos et al., 1998).
Cross-desensitisation between the sGC-cGMP and the pGC-cGMP systems 
has also been described, such that the changes in the sensitivity of one pathway are 
mirrored by the other cGMP-generating system. For example, murine aortic rings 
exposed to ANP show reduced responsiveness to the NO donor SPER-NO (Hussain 
et al., 2001; Madhani et al., 2003). Aorta from eNOS knockout (KO) mice are more
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sensitive to ANP than tissues from WT animals. Moreover, the potency of ANP in 
aorta from WT animals is increased in the presence of NOS inhibitors (Madhani et 
al, 2003). In contrast, the potency of ANP in aorta from eNOS KO animals is 
reduced following pre-treatment of tissues with high concentrations of the NO-donor, 
GTN.
1.5.2 Mechanisms of desensitisation affecting both GC-cGMP pathways
The mechanisms of sensitisation and desensitisation caused by changes in the 
ambient concentration of NO and ANP are yet to be identified. Some studies have 
suggested a reduction in the activity of sGC (Papapetropoulos et al., 1996). Another 
study has suggested that the level and the activity of cGMP-dependent PKG is 
decreased (Yamashita et al., 2000). The mechanism mediating the cross­
desensitisation of NPR-A appears to involves cGMP, since administration of the sGC 
inhibitor, ODQ, significantly preserves relaxation to ANP (Hussain et al., 2001; 
Madhani et al., 2003). Enzyme systems that have been implicated in the regulation of 
the GC-cGMP pathways affecting the sensitivity of sGC and/or pGC-cGMP pathways 
will be discussed in detail below.
1.5.2.1 Role of phosphodiesterases
In VSMC, cGMP is regulated by cGMP-hydrolysing enzymes known as 
phosphodiesterases (PDEs). 11 different PDE isozymes have been identified; the 
predominant PDEs present in arterial smooth muscle are PDE1, PDE3 and PDE5 
(Rybalkin et al., 2003). PDE5 is considered the most important cGMP-hydrolysing 
PDE in VSMC. However, under conditions where calcium levels are elevated, PDE1 
also plays a role in cGMP metabolism. PDEs degrade cGMP by transforming the 
active cyclic nucleotides into inactive 5’-nucleotide monophosphates (Rybalkin et al.,
2003).
Upregulation or downregulation of these cGMP-hydrolysing enzymes leads to 
a reduction or enhancement of the bioactivity of cGMP, respectively. De Garavilla et 
al demonstrated in rats made tolerant following administration of GTN, that the 
vasorelaxation to GTN was restored following treatment with the phosphodiesterase
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inhibitor zaprinast (De Garavilla et al., 1996). In rats made tolerant by continuous 
infusion of GTN for 3 days, Kim and others demonstrated that the reduced 
responsiveness to further treatment with GTN was associated with upregulation of 
PDE1 Al activity and expression (Kim et al., 2001). Oral administration of milrinone, 
a specific inhibitor of PDE3, suppressed intimal thickening in a mouse model of 
vascular injury (Kondo et al., 1999), suggesting the possible involvement of PDE3 in 
inflammatory vascular diseases. These observations indicate that regulation of cGMP 
levels by PDEs are important factors in the determination of the activity of GC-cGMP 
pathway and have important implication in conditions associated with increased 
levels or activity of PDEs.
1.5.2.2 Role of protein kinase C
Protein kinase C (PKC) is a family of at least 12 isoforms that is expressed in 
various cell types, including VSMC, endothelial cells (Krotova et al., 2003) and 
cardiac myocytes. PKC isoforms are divided into three subfamilies. The 
conventional-PKC isoforms (a, pi, pH and y) are activated by the second messengers 
Ca2+ and diacylglycerol (DAG) in the presence of phosphatidylserine (PS) 
(Salamanca & Khalil, 2005). The novel-PKCs isoforms (s, r|, 0, 5 and p) require PS
*5 -4- • •and DAG for full activation but are insensitive to Ca . Finally, the atypical-PKC 
isoforms (X, v and Q  are not activated by DAG or Ca (Salamanca & Khalil, 2005). 
PKC isoforms that have been reported in VSMC include the conventional-PKC 
isoforms (a and p), the novel-PKC isoforms (e, rj, 0, 5 and p) and the atypical 
(£ and X) (Yano et al., 1999; Itoh et al, 2001; Salamanca & Khalil, 2005).
In VSMC, PKC has been shown to alter the sensitivity of sGC. Morrison and 
coworkers demonstrated that the responsiveness of rat aortic rings to endothelium- 
dependent and -independent vasodilators is reduced in vessels precontracted with 
phorbol 12-myristate 13-acetate (PMA) with reduced cGMP production compared to 
those precontracted with noradrenaline (Morrison & Pollock., 1990). The 
responsiveness of rat aortic rings to ACh, SNP, 8-Bromoguanosine-3’,5’-cyclic 
monophosphate (8 -Br-cGMP) but not the adenylate cyclase activator, forskolin, was 
significantly reduced in vessels precontracted with the PKC activators PMA and
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phorbol 1 2 , 13-dibutyrate compared to vessels precontracted with noradrenaline 
(Murphy et al., 1994). Kamata et al demonstrated in rat mesenteric vessels that 
precontraction with PMA reduces the responsiveness to ACh, SNP and forskolin 
compared to those vessels precontracted with methoxamine (Kamata et al., 1995). 
These studies suggest that PKC desensitises sGC-cGMP pathway in blood vessels, 
but its effects on the AC pathway is controversial. However, they do not show which 
isoforms cause this desensitisation.
Desensitisation of NPRs by PKC has also been reported. In stable 
transfectants of NIH 3T3 fibroblasts with NPR-A, activation of PKC decreased 
cGMP accumulation by NPR-A (Potter & Garbers 1994). Exposure of HEK 293 cells 
to the PKC activator, PMA, results in a selective dephosphorylation of Ser-523 in 
NPR-B and reduces the accumulation of cGMP (Potter & Hunter 2000). Replacement 
of this amino acid with alanine or glutamate abolished the inhibition, suggesting that 
dephosphorylation of this serine residue accounts for desensitisation of NPR-B by 
PKC. These studies clearly demonstrate that PKC desensitise NPRs in cultured cells. 
However, it is not known which isoforms cause this desensitisation as these studies 
used PMA, which non-selectively activates both the conventional and the novel-PKC 
isoforms (Tsao & Wang, 1997; Kim et al., 1997 and Krotova et al., 2003).
1.5.2.3 Desensitisation specific for NO: role of free radicals
In general, relatively low concentrations of reactive oxygen species (ROS) 
such as superoxide anion (O2 ) modulate cell signalling and contribute to other key 
functions, such as regulation of activity of transcription factors and gene expression. 
In contrast, higher levels of ROS contribute to vascular dysfunction (Faraci & Didion,
2004). Reduced responsiveness of sGC to NO may occur indirectly through 
scavenging of NO by free radicals. ROS such as O2 can react rapidly with NO, 
reducing its bioavailability and forming peroxynitrite ONOO- (Bouloumie et al.,
1997). ONOO has cytotoxic effects and may account for endothelial injury 
(Bouloumie et al., 1997). ONOO- can produce DNA strand breakage, initiate 
peroxidation of lipids and oxidise, nitrate or nitrosate a variety of proteins, thus 
modifying their function (Stoclet et al., 1999). Several enzymes are involved in the 
generation of O2- , such as xanthine oxidase, NADH/NADPH oxidase, lipoxygenase
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and NOS (Matsuoka, 2001). The scavenging properties of O2 , would affect both 
exogenously and endogenously applied NO. Therefore, increased production of O2 , 
as occurs in disease states associated with inflammation, may reduce the stimulation 
of sGC. Endogenously, cells are equipped with potent inactivators of O2 (i.e. 
antioxidants), one of the most important being superoxide dismutase (SOD). There 
are 3 isoforms of SOD, and each are products of distinct genes but catalyse the same 
reaction: two isoforms of Cu/Zn SOD, one cytosolic and the other is membrane 
bound, the third isoform is manganese SOD which is present in the mitochondria 
(Faraci & Didion, 2004). SOD plays an important role in the elimination of O2 by 
converting it into hydrogen peroxide (which is then converted to H2O and O2 by 
catalase). Because of the efficiency of the reaction, the local concentration of SOD 
may be a key determinant of bioactivity of NO (Faraci & Didion, 2004). Thus, a 
major function of SOD is to protect NO and NO-mediated signalling.
Myeloperoxidase (MPO) is an abundant haemoprotein synthesised by 
activated leukocytes such as neutrophils and monocytes (Heinecke, 1999). MPO- 
mediated mechanisms for NO consumption have been an area of intense recent 
interest. All members of the mammalian haem peroxidase superfamily, to which 
MPO belongs are capable of catalytically consuming NO under physiologically 
relevant conditions (Abu-Soud & Hazen, 2000). Accumulation of MPO within the 
subendothelium, and co-localisation within the subintima of atherosclerotic lesions, 
support the potential role for MPO in promoting oxidative consumption of NO. 
Evidence of an in vivo role for MPO in NO consumption within the vasculature was 
recently reported. Using an animal model of sepsis, Eiserich et al showed that MPO 
modulates NO responses in aorta from wild type versus MPO knockout mice through 
catalytic consumption of NO by MPO-generated free radicals (Eiserich et al., 2002). 
In summary, NO bioavailability is crucial for vascular function and this 
bioavailability is affected during inflammation by free radicals. It is possible that 
oxidative stress could contribute to the mechanism of desensitisation of NO-sGC 
pathway.
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1.5.2.4 Desensitisation affecting NPRs pathway: role of protein phosphatase 2A
Desensitisation of NPRs can occur as a result of receptor degradation, 
downregulation or changes in the phosphorylation status of the receptor (Potter et al., 
2006). Basally, NPRs exist in a phosphorylated state that is required for the 
acquisition of sensitivity towards NPs (Potter & Hunter, 1998a). In human embryonic
T9kidney cells labelled with [ P] orthophosphate, NPR-A is highly phosphorylated 
when unbound to ligand. Exposure to the ligand results in a time-dependent 
dephosphorylation and desensitisation of the receptor (Potter & Garbers, 1992). 
NPR-A can be dephosphorylated and desensitised by the addition of protein 
phosphatase 2A (PP2A), and blocked by the PP2A inhibitor, okadaic acid (Potter & 
Garbers., 1992). In a similar fashion to NPR-A, in vitro dephosphorylation of crude 
NPR-B membranes with purified PP2A resulted in marked losses in CNP-dependent 
NPR-B activity. The presence of PP2A inhibitor okadaic acid preserved the activity 
of NPR-B (Potter, 1998). To examine the absolute requirement of dephosphorylation- 
mediated desensitisation of NPR-A, Potter and Hunter generated a mutant version of 
NPR-A that is a fully phosphorylated receptor but is resistant to dephosphorylation. 
Although this mutant was less responsive to ANP than the wild type, it was resistant 
to the effects of a PP2A inhibitor (Potter & Hunter, 1999). In addition, Zhou et al 
demonstrated that PKG in vascular smooth muscle can activate PP2A (Zhou et al., 
1996). This suggests that desensitisation of NPRs could occur through a cGMP- 
dependent negative feedback mechanism. These data indicate that dephosphorylation 
is a mechanism of NPR-A and NPR-B desensitisation, with PP2A is strong candidate.
1.5.3 Importance of GC desensitisation
Most cellular signalling pathways possess regulatory feedback mechanisms in 
a positive and negative manner, which permit adaptation to changes in the degree of 
activation. The sGC- and pGC-cGMP systems share common roles in cardiovascular 
homeostasis. Therefore, an interaction between these two pathways to regulate cGMP 
levels might represent an important physiological phenomenon. An increase or 
decrease in one cGMP generating system could be compensated by the other cGMP 
system (Hussain et al., 2001; Madhani et al., 2003). This phenomenon may also have 
important pathophysiological and therapeutic implications. In cardiovascular disease,
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it is possible that such integration provides a mean to compensate for dysfunction of 
either cGMP-dependent pathway. For instance, in cardiovascular diseases associated 
with endothelial dysfunction or deficiencies in NO production as in hypertension and 
atherosclerosis, pGC-cGMP pathways could supplement the reduced activity of the 
NO-cGMP pathway.
In contrast, the interaction may represent a negative-feedback mechanism that 
prevents overactivation of cGMP signalling. In disease states associated with 
excessive activation (such as sepsis) of one cGMP generating system might cause a 
downregulation of the other cGMP generating pathway. CHF is associated with 
increased circulating levels of NPs (Luchner et al., 1998). This could lead to an 
increased generation of cGMP and possibly downregulation of both sGC and pGC- 
cGMP systems, contributing to the increased vasoconstriction seen in heart failure.
Therapeutically, the reciprocal interaction between sGC and pGC might also 
contribute to tachyphylaxis during chronic administration of NPs (Tsutamoto et al., 
1992; Komarek et al., 2004) and organic nitrates (Parker & Gori, 2001). Indeed, 
therapies based on supplementing natriuretic peptides or NO are likely to result in 
reduced biological activity of sGC and pGC-cGMP. Down-regulation of vascular 
NO-sGC pathway activity might, therefore, explain the link between increased NP 
activity and increased cardiovascular risk (Wang et al., 2004). This phenomenon 
might also underlie, at least in part, the increase in mortality rate observed in patients 
with heart failure treated with nesiritide (Sackner-Bemstein et al., 2005); cGMP- 
induced resistance to NO could precipitate adverse cardiovascular events (i.e. stoke, 
myocardial infarction) as its cytoprotective influence on vascular tone, leukocytes and 
platelets is diminished. Therefore, a full understanding of this regulatory mechanism 
may have important therapeutic implications for conditions in which there is 
inappropriate activation of sGC or pGC-cGMP signalling pathways.
1.6 Research questions addressed in this thesis
This thesis has attempted to answer three main questions related to the 
endogenous regulation of NO-sGC and NP-pGC pathways that converge to govern 
cGMP signalling in the vasculature. Firstly, in chapter 3, I investigated the
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mechanisms underlying Cu-mediated bioactivation of S-nitrosothiols (as NO-stores or 
NO-donors) and whether this might be facilitated by an endogenous enzyme/receptor 
-dependent or -independent process. Secondly, in chapter 4, I attempted to elucidate 
the effect of LPS, that mimics many aspects of inflammatory vascular disorders in 
vitro, on the sensitivity of GC-cGMP pathway. Finally, in chapter 5, I examined the 
potential mechanism(s) underlying the desensitisation of GC-cGMP pathway by LPS.
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CHAPTER TWO 
MATERIALS AND METHODS
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2. MATERIALS AND METHODS
2.1 Saville assay for iS'-nitrosothiols
2.1.1 Basic principle
This assay was used for the measurement of the decomposition of 
S-nitrosothiols. The assay was established in 1958 by Saville (Saville, 1958) and 
depends on colourimetric determination of S-nitrosothiol concentration.
S-nitrosothiols are known to undergo hydrolysis in the presence of certain metal ions,
2 1
such as Hg , yielding nitrous acid (HNO2). The nitrous acid is detected by reaction 
with sulphanilamide and N-(l-napthyl)ethylendiamine dihydrochloride. Before this 
hydrolytic process occurs, excess and free nitrous acid that may exist as a 
contaminant is removed from the solution with ammonium sulphamate (AS).
• *7 4-Subsequent addition of Hg results in an immediate liberation of nitrogen and the 
formation of a diazonium salt by reaction with sulphanilamide (SA). The reaction of 
the diazonium salt with N-(l-napthyl) ethylendiamine dihydrocloride (NED) results 
in the production of an intensely coloured (purple) azo dye, which can be read 
spectrophotometrically (Abss4o) Figure 2.1.
Removal of free 
nitrous acid by AS
i
Decomposition of 
iS'-nitrosothiols by Hg2+ 
releases nitrous acid
Reaction of nitrous acid with 
SA produces diazonium salt
Reaction of diazonium salt 
with NED Produces azo dye
Figure 2.1 Diagram showing the steps in the Saville’s assay
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2.1.2 Basic protocol
S-nitrosothiols (50pl) treated with copper ions, Cu/Zn superoxide 
(Cu/Zn-SOD) or incubated with rat aorta, were mixed with 50pl ammonium 
sulphamate (0.1%; dissolved in 0.4N hydrochloric acid) for 5 mins (in a 96-well 
plate) to remove free nitrous acid/nitrite ([HJNO2). In contrast, distilled water (50pl)
was added to the standard (sodium nitrite). Standard and S-nitrosothiol samples were
2+then mixed with a solution (50pl) containing sulphanilamide (3%) and Hg (0.25%; 
both dissolved in 0.4N hydrochloric acid) to catalyse the release of NO. This step was 
immediately followed by addition of 50pl N-(l-napthyl) ethylendiamine 
dihydrochloride (0 .1 %) into both standard and S-nitrosothiol samples to form a stable 
azo dye. After 10 mins incubation, absorbance of the purple colour produced was 
read (SpectraMAX 250, provided by Molecular Devices, USA) at 540nm. 
S-nitrosothiol concentration was calculated using a standard curve constructed with 
0-200pM of sodium nitrite by using SoftMax Pro Software. All the readings of the 
standard curve were made in duplicate. The intensity of the colour (Abss4o) is directly 
proportional to the concentration of S-nitrosothiol.
2.2 Stereoisomers of 5,-nitrosothiols
2.2.1 Basic Principles
Two molecules may have exactly the same atoms arranged in exactly the same 
sequence yet differ with respect to the spatial orientation of a key functional group. 
Such molecules are called stereoisomers (Lamzin et al., 1995). Depending on the 
direction in which the key functional group is orientated with respect to the 
molecules, stereoisomers are called either D-isomers (right-handed) or L-isomers 
(left-handed). These subtle differences in structure are extremely important 
biologically. They ensure enzymes, which interact with such molecules in a 
stereospecific way in chemical reactions, cannot combine with the opposite 
stereoisomer. The enzymes of all cells (human and others) can combine only with 
L-amino acids and D-sugars (Lamzin et al., 1995). This approach is widely
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recognised and was used in this work to examine whether the decomposition of 
S-nitrosothiols might involve enzyme dependent mechanisms.
2.2.2 Synthesis of 5-nitrosothiols
Generally, the reaction between thiol groups and acidified nitrite in the 
presence of water results in the formation of S-nitrosothiols (Hogg, 2000). In this 
thesis, this reaction was used to synthesise the DL- and D-isomers of SNAP 
according to the method of Field et al (1978). Briefly, DL- and 
D-acetylpenicillamine were mixed with a two-fold molar excess of sodium nitrite 
under acidic conditions. The resulting fine, green precipitate was filtered and 
air-dried.
Synthesis of L- and D-isomers of CYSNO was also carried out in a similar 
fashion according to the method of Kowaluk & Fung (1990). Here, equimolar 
(20mM) volumes of L- or D-cysteine and sodium nitrite were added to sealed flasks 
and the pH adjusted to approximately 2 by the addition of 0.1 M HC1. After shaking, 
the reaction mixture was kept at 4°C for 30mins and the pH re-adjusted to ~7.4 by 
addition of 0.1M NaOH. A characteristic red colour formed rapidly following 
acidification, indicative of the formation of CYSNO.
Synthesis of L- and D-GSNO was achieved by reaction of equimolar 
(20mM) concentrations of L- or D-GSH (synthesised by the Medicinal Chemistry 
Department, Wolfson Institute for Biomedical Research, University College London) 
and sodium nitrite in the presence of (IN) HC1, as adapted from the method of Hart 
(1985). After shaking, the reaction mixture was kept at 4°C for 30mins. The 
concentrations of L- and D-GSNO and CYSNO generated from the above reactions 
were measured by reading the absorbance of these solutions spectrophotometrically 
(CECIL, CE 2041, 2000 series, Cambridge, England) at 334nm and calculated by 
using this formula, C= Abs3348 1, where C is the concentration, e is the extinction 
coefficient (800M-lcm-l) (Mathews & Kerr, 1993), and L is the path length (1cm). 
To avoid premature decomposition, all S'-nitrosothiols stock solutions were made 
fresh using deionised water (18 Omega Q) just before use, kept on ice and protected
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from light. To examine the decomposition by Cu/Zn-SOD (20pM) or rat aortic rings, 
all solutions and subsequent dilutions were prepared in Krebs’ solution (composition 
(mM): NaCl 118, KC1 4.7, CaCl2 2.5, KH2P 0 4 1.2, MgS04 1.2, NaHC03 2.5, glucose 
1 1 ) to allow the reaction to occur in physiological media.
2.2.3 Assessment of enzyme-dependent and independent decomposition of 
5-nitrosothiols
Decomposition of L- and D-isomers of S-nitrosothiols was examined in the 
presence of free copper ions (copper(I)-acetonitrile and copper(II)-sulphate) or 
complex structures such as the copper containing enzyme, Cu/Zn-SOD and whole 
tissue (rat aorta). The abbreviations Cu(I) and Cu(II) will be used through the rest of 
the thesis to represent copper(I)-acetonitrile and copper(II)-sulphate, respectively.
2.2.3.1 Non-enzymatic (chemical) decomposition
Due to the insolubility and lack of commercial-availability of Cu(I) salts, most 
of the published works assessing the role of copper ions in S-nitrosothiol 
decomposition has been conducted using Cu(II) salts (in the presence of a reducing 
agent such as a thiol or ascorbate), and confirmed the role of Cu(I) ions only by using 
a specific chelator for Cu(I) (e.g. bathocuproine disulphonic acid (BCS) or 
neocuproine). In this thesis, I had access to a water soluble Cu(I)-acetonitrile complex 
(kind gift of Jon Fukuto, UCLA), that enabled direct determination of the role of 
Cu(I) ions on the decomposition rate of L- and D-isomers of GSNO, SNAP and 
CYSNO, and was also used to indirectly assess the role of endogenously stored 
S'-nitrosothiols by using classical organ bath pharmacology. Confirmation of the role 
of Cu(I) ions in the decomposition of L- and D-isomers of S-nitrosothiols by Cu(I), 
Cu(II), Cu/Zn-SOD and rat aorta was made by using the specific Cu(I) chelator, BCS.
2.2.3.2 Enzymatic decomposition
To asses the role of endogenous (potentially enzymatic) breakdown of 
S-nitrosothiols, the vasorelaxant activity of L- and D- isomers of GSNO, SNAP and 
CYSNO were evaluated by using organ bath pharmacology (described in section 2.3) 
and confirmed by examining the decomposition of L- and D-GSNO by rat aortic rings
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in vitro using the Saville assay (as described in section 2.1). This approach was used 
to show that if there is an enzyme-dependent decomposition of S-nitrosothiols then 
the decomposition rate of L-isomers of S-nitrosothiols by rat aorta will be faster than 
that of D-isomers due to the inability of the D-isomer to react stereospecifically with 
an endogenous enzyme. In the case of Cu/Zn-SOD, this enzyme (20pM) was used as 
an example of a copper-containing enzyme to show that such proteins could play an 
important role in the decomposition of S-nitrosothiols in vivo. The specific protocols 
that were used to examine the relaxant effect of L- and D-isomers of S-nitrosothiols 
on rat aorta and their decomposition by copper ions, Cu/Zn-SOD and rat aorta in the 
presence or absence of BCS are described in Chapter Three.
2.3 Organ bath pharmacology
2.3.1 Rationale
Measuring isometric tension of isolated vessels in an organ bath is a widely 
used technique to assess vascular function (Angus & Wright 2000). This technique 
allows the study of pharmacological interventions in the absence of the influence of 
other haemostatic mechanisms, the autonomic nervous system and physical 
influences, such as changes in shear stress. Tissues are suspended in a physiological 
oxygenated solution to allow preservation of function and can be stimulated with 
known concentrations of agonists and antagonists to explore changes in isometric 
force. As it is possible to treat multiple rings from the same vessel in different baths 
simultaneously, this technique lends itself to exploring the effects of different pre­
treatments. In this work, the technique was used to study the vasorelaxant effect of 
the L- and D- isomers of GSNO, SNAP and CYSNO. This technique was also used to 
study the effects of LPS on the response to soluble and particulate guanylate cyclase- 
dependent vasorelaxants and to explore the mechanisms underlying these effects.
2.3.2 Vessel harvesting
Experiments were carried out using male Sprague-Dawley rats (200-25Og) 
reared by the Central Biological Services Unit (University College London) on 
standard chow with water ad libitum. Male rat were used to avoid any discrepancies 
that might arise from differences in gender. Rats were killed by stunning and cervical
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dislocation. The thoracic aorta was immediately exposed and removed in its entirety 
with minimal trauma to maintain tissue integrity. After removal the aorta was 
transferred to pre-oxygenated Krebs’ solution (composition (mM): NaCl 118, KC14.7, 
CaCh 1.25, KH2PO4 1.2, MgSC>4 1.2, NaHCCb 2.5, glucose 11) and extraneous fat and 
connective tissue were removed. The vessel was then cut into 2-3mm rings before 
suspension in the organ bath.
2.3.3 Basic Protocol
All organ baths were cleaned prior to studies with 10% hydrochloric acid and 
30% ethanol followed by multiple washes with purified water (18 Q). Organ baths 
were then filled with Krebs’ solution that was heated to 37°C and bubbled with 
9 5 %0 2 /5 %C0 2 . Each channel was calibrated with a standard 5g weight prior to 
mounting tissues. Vessel rings were suspended between a fixed stirrup and one 
connected to a force transducer (FT03, Grass Transducer, USA) connected to a 
Rikadenki chart recorder. Rat aorta was pre-tensioned to lg and during a 60 mins 
equilibration period, this tension was adjusted, to maintain this level. The organ bath 
set up is shown in Figure 2.2. Following the equilibration period, vessels were primed 
by contraction with potassium chloride (KC1; 48mM) and vessels that did not generate 
active tension of at least lg were discarded; this was repeated twice to ensure 
consistency of effect. Vessels were washed several times over at least 20 mins to 
restore baseline resting tension.
Endothelial integrity was examined by initially contracting the tissues with the 
alpha-adrenoceptor agonist phenylephrine (PE; 0.3pM), allowing a stable plateau to 
occur and then relaxation with ACh (lpM). In rat aorta, ACh acts by stimulating 
increased production of NO from the endothelium by eNOS following muscarinic 
receptor-mediated calcium influx (Furchgott & Zawadzki, 1980), which then acts in a 
paracrine fashion to decrease intracellular calcium in the vascular smooth muscle. 
Changes in sensitivity to ACh, therefore, act as a marker of changes in endothelial 
function. Relaxation by >50% in response to ACh indicated an intact endothelium; 
other vessels were discarded. Studies on denuded vessels were performed to assess 
the role of endothelial cells in endogenous S-nitrosothiol-mediated vasorelaxation.
76
Denudation of the endothelium was achieved by inserting forceps into the lumen of rat 
aortic rings and gently removing the endothelial cells without damaging VSMC. The 
endothelium was deemed denuded if the responses of precontracted (PE; 0.3pM) rings 
gave less than 5% relaxation to ACh (lpM). Vessels were washed several times and 
allowed to return to baseline over at least 30 minutes prior to the specific protocols 
that are described in the relevant data chapters.
Concentration-response curves to PE and U46619 (thromboxane A2 mimetic)
6 2was achieved by cumulative addition of stock solutions of PE (10' -10' M) and 
U46619 (10'6-10'3M) to achieve half log unit changes in concentration at each step. 
This allowed the addition of 25-50pL at each step to a total volume of 25mL in the 
organ bath chamber- thus not significantly altering the total volume over a standard 
concentration-response curve. In LPS-treated vessels, the induction of iNOS caused 
hyporeactivity of the vessels to PE. However, unlike PE, U46619 caused stable 
contractions in vessels incubated with LPS and was therefore used in all experiments 
to pre-contract tissues (approximate ECso: -0.1 pM in control tissues and -0.3 pM in 
LPS-treated tissues). Concentration-response curves to vasorelaxants were performed 
by pre-contracting the vessels with an ECso of PE or U46619 (where appropriate) and 
allowed to reach a plateau before incremental cumulative addition of stock solutions 
of the vasorelaxant of interest. The effect of the added concentration was allowed to 
reach a plateau before the addition of the subsequent concentration. On completion of 
each protocol, the vessels were removed and organ baths were again cleaned prior to 
further experimentation.
2.4 In vitro animal model of sepsis
In animal models, sepsis has been mimicked by administration of LPS. LPS 
contributes greatly to the structural integrity of the bacteria, and protects them from 
host immune defenses. LPS comprises of three parts: polysaccharide side chains, core 
polysaccharides and lipid A (Wright & Kanegasaki, 1971). Treatment with LPS is a 
widely used protocol to induce iNOS expression in vitro and thereby permit study of 
isolated vascular rings. In this work, LPS (0.3pg/ml) from salmonella typhosa 
(serotype: 0901) was incubated with rat aortic rings in the organ bath for 4 hours. 
Translation of iNOS mRNA and the subsequent assembly of iNOS protein is 
associated with ‘high output’ production of NO (Thiemermann, 1997). The cellular
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mechanism by which LPS stimulates the induction of iNOS is described in details in 
Chapter One, section 1.1.3.
Transducer *
Aortic ring
Hook
Water at 
37 °C
Krebs’
solution
* Hook
Figure 2.2 Illustration showing different parts o f the organ bath chamber. Tissue is 
suspended between two hooks in 25 ml organ baths containing warmed (37°C), 
oxygenated Krebs' solution. The tissues were connected to a transducer for the 
measurement o f isometric force.
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2.5 Pharmacological interventions
One approach to assess the roles of various signalling pathways in 
biological systems is to inhibit or activate certain components in the pathway of 
interest and observe the changes that occur as a result. To explore the mechanisms 
leading to the desensitisation of guanylate cyclases by LPS, various specific 
activators and inhibitors were used to investigate enzymes involved in guanylate 
cyclase/cGMP signalling. The activity of protein kinase C (PKC) was stimulated by 
phorbol 12-myristate 13-acetate (5pM), which non-selectively activates both the 
conventional and the novel-PKC isoforms (Tsao & Wang, 1997; Kim et al., 1997; 
Krotova et al., 2003), or thymeleatoxin (0.5pM; EC50 <100nM) which selectively 
activates the conventional-PKC isoforms a, p and y (Ryves et al., 1991; Armstrong & 
Ganote, 1994; Llosas et al., 1996; Krotova et al., 2003). Details of inhibitors used are 
described in Table 2.1. The selected concentrations of the inhibitors were 
approximately 1 0  times their I C 5 0  (the concentration of an inhibitor that is required 
for 50% inhibition of an enzyme in vitro) to ensure substantial inhibition of enzyme 
activity.
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Inhibitor Target enzyme Concentrationused i c 50
(l-[p-Chlorobenzoyl]-5-methoxy- 2- 
methylindole- 3-acetic acid) 
(Indomethacin)
Cyclooxygenase-2 10pM 970nM (Futaki et al., 1994)
1 H-[ 1,2,4]Oxadiazolo[4,3- 
a]quinoxalin-l-one (ODQ)
Soluble guanylate 
cyclase 5pM
20nM (Garthwaite et al., 1995)
Aminobenzoic hydrazide Myeloperoxidase lOpM 300nM (Kettle et al., 1995)
Cantharidic acid Protein phosphatase 2A 500nM 50nM (Li & Casida,1992)
Milrinone Phosphodiesterase 3 lOpM 300nM (Harrison et al., 1986)
N-(3 -(aminomethy l)benzyl) 
acetamidine (1400W)
Inducible nitric oxide 
synthase lOpM 0.8pM (Garvey et al., 1997)
NG-nitro-L-arginine methyl ester 
(L-NAME)
Endothelial nitric oxide 
synthase 300pM 400nM (Moore et al., 1990)
Okadaic acid Protein phosphatase 2A 300nM InM (Ishihara et al., 1989)
Sildenafil Phosphodiesterase 5 3pM 3.5nM (Ballard et al., 1998)
Vinpocetine Phosphodiesterase 1A1 lOOpM 20pM (Hagiwara et al., 1984)
Table 2.1 Specific inhibitors used to investigate enzymes involved in guanylate cyclase-cGMP signalling pathways
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2.6 Western blotting
2.6.1 Rationale
Western Blotting (immunoblotting) allows the identification and semi­
quantification of proteins within biological samples based on their electrophoretic 
properties. Equal quantities of protein are added under denaturing conditions to a 
polyacrylamide gel matrix and are separated according to their molecular weight as 
they move by one-dimensional electrophoresis towards the anode (Figure 2.3). By 
the use of a (coloured) protein ladder of known molecular weights it is possible to 
identify individual products. Specificity is improved by transferring the samples after 
separation to a nitrocellulose transfer membrane that fixes their relative position. 
This can then be stained with antibodies specific to the protein of interest. This 
process is generally performed in two stages, firstly a specific antibody (primary 
antibody) is used against a protein or enzyme such as iNOS and then a secondary 
antibody, tagged with horseradish peroxidase, is applied against the primary antibody. 
The presence of horseradish peroxidase allows the detection of the antibody by its 
emission of light, which is captured on radiographic film. Although only semi- 
quantitative the relative intensity of bands demonstrated by this technique indicate the 
degree on expression of the protein studied provided that equal quantities of total 
protein have been added to the system and complete and equal transfer has occurred 
for all samples.
2.6.2 Protocols
2.6.2.1 Samples preparation
Western blotting was used to detect iNOS protein following incubation of 
rat aorta with LPS (0.3pg/ml; 4hr) in vitro. Aortic rings were immediately removed 
from the organ bath. To preserve tissue proteins, aortic rings were wrapped in 
aluminium foil, immediately snap frozen by immersion in liquid nitrogen and then 
stored at -80°C before protein extraction. Prior to separation by electrophoresis,
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samples were processed to ensure cellular disruption without degradation of the 
relevant protein.
Protein separation
C«thod
^-F ilter papers 
' —  SDSg.1
i —  Nitrocellulose membrane 
' ^J-Filler papers
) —  Anode
Marker
iNOS (130kd)
Protein identification
Secondly antibody
Primary antibody
iNOS protem 
Nitrocellulose membrane
Figure 2.3 Illustration showing the process o f iNOS detection by western blotting
To extract the proteins, vessels were placed in a metal receptacle (which itself 
had been cooled to -80°C) containing liquid nitrogen and smashed with a hammer 
into powder. The vessels were then removed immediately from the metal receptacle 
with clean forceps and kept in tubes containing (150pl) whole cell homogenisation 
buffer (Tris-HCl (50mM), NaCl (150mM) and Triton XI00 (1%) mixed with 
ethylenediamine-tetraacetic acid (EDTA) and ethylene glycol-bis-(2-aminoethyl)-
Positive control
Film development
82
tetraacetic acid (EGTA) and adjusted to pH 7.4 with NaOH)) mixed with 1 tablet of 
protease inhibitors (complete, EDTA-free mini protease inhibitor cocktail; Roche) 
and incubated for 1 hr. The samples were vortexed every 15 min during this period to 
ensure complete tissue homogenisation. Tubes containing homogenised tissues were 
centrifuged at 13000 rpm for 5 min at 4 °C. The supernatant was collected and kept 
on ice for further analysis while the pellets were discarded (since iNOS is a cytosolic 
protein). Samples were then diluted 1:2 with the sample buffer (consists of Tris-HCl 
(20mM), EDTA (2mM), SDS (sodium dodecyl sulphate; 2%), mercaptoethanol 
(10%), glycerol (20%) and bromophenol blue (0.025%) stored at room temperature) 
by mixing 20pl of the sample with 20pl of the sample buffer. Before separation, 
protein was denatured by boiling at 95 °C for 5 min. Samples were then kept on ice 
for 5 min.
2.6.2.2 Protein separation
Separation of proteins was achieved by one-dimensional SDS-PAGE (sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis). The separating gel (7.5% made 
by mixing separating gel buffer (consists of Tris-Base (1.875mM) and SDS (0.5%) 
and adjusted with concentrated HC1 to pH 6 .8 ) with acrylamide/bis-acrylamide 
(30%), ammonium persulphate (10%) and TEMED (NNNN-tetramethylethylene- 
diamine)) was poured over the rig and overlaid with isopropanol (to prevent the 
formation of air bubbles). When gels had set, the isopropanol was poured off by 
inverting. The stacking gel (4% made by mixing stacking gel buffer (consists of Tris- 
Base (0.625mM) and SDS (0.5%) and adjusted with concentrated HC1 to pH 6 .8 ) with 
acrylamide/bis-acrylamide (30%), ammonium persulphate (10%) and TEMED) was 
poured over the separating gel. Combs (0.75mm in width) were inserted to produce 
the samples wells. After the gels had set, the combs were removed and the wells 
cleaned of excess material. The gels were mounted within the clamping frame and 
electrode assembly and placed in the buffer chamber. The chamber was then filled 
between the gels with running buffer (contains Tris base (50mM), glycine (0.384M) 
and SDS (0.1%)) until half full. The samples (20pl) and the marker (lOpl; Precision
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marker plus kaleidoscope was purchased from bio-Rad) were added to the appropriate 
wells within the stacking gel. In order to separate the proteins, the gel was run at a 
constant voltage of 1 0 0 V until the proteins are completely separated according to 
their molecular weight.
Following separation, the gels were removed from the tanks and sandwiched 
between layers of filter papers and a nitrocellulose membrane to allow transfer of the 
samples. The filter papers and nitrocellulose sheet were prepared according to the size 
of the SDS-Gel. The layers were designed from the bottom to the top as follows: six 
filter papers were soaked in solution-1 (contains Tris-Base (0.3M) at pH 10.4 and 
20% methanol), three filter papers were soaked in solution-2 (contains Tris-Base 
(0.025M) at pH 10.4 and 20% methanol), nitrocellulose paper was soaked in 
solution-2 and finally SDS-gel and nine filter papers were soaked in solution-3 
(contains 6 -Amino-n-Hexanoic Acid (0.04M) at pH 7.6 and 20% methanol). The 
graphic plate (anode and cathode) were moistened with distilled water to allow 
current conductance and a constant current of 0.8mA/cm2 passed across for 1 hr to 
achieve transfer. Transfer was verified by assessing the movement of pre-stained 
molecular weight markers from the gel to the membrane. The nitrocellulose 
membrane was stained with Ponceau S solution (1%) to visualise transferred proteins 
while the gel and filter papers were discarded. The Blot was washed with distilled 
water to remove excess Ponceau S solution. Following transfer, the nitrocellulose 
membranes were transferred to clean baths and immersed in solution of phosphate 
buffered saline (PBS) mixed with Tween (PBST) containing 5% skimmed milk 
(Marvel) and gently agitated for at least 1 hr. This milk solution acts to bind and 
block non-specific proteins and improve resolution of antibody identification. After 
blocking, the blot was washed once every 5 mins for 25 nims in PBST.
2.6.2.3 Protein identification
Primary antibody was diluted 1:1000 by addition lOpl of rabbit anti-iNOS 
antibody (BD Transduction Laboratories) into 10ml of 5% skimmed milk (dissolved 
in PBST). The blot was incubated with the primary antibody overnight at 4°C with
84
constant agitation. On completion of the overnight exposure to primary antibody, the 
blot was washed with 5 changes of PBST each for 5 mins.
The secondary antibody (peroxidase-conjugated goat anti-rabbit 
immunoglobulin; Dako Cytomation) was diluted 1:1000 by addition lOpl of 
secondary antibody into 10ml of 5% skimmed milk (dissolved in PBST) and 
incubated with the blot for 1 hr at room temperature. The secondary antibody was 
discarded and the blot was washed extensively with PBST at least 5 times, each for 5 
mins. Development of the bound secondary antibody was achieved with the enhanced 
chemiluminescence (ECL) that is based on the enzymatic production of an acridinium 
ester, by horseradish peroxidase, which emits light. Each gel was covered with ECL 
for 2 mins. The blot was placed in autoradiography hypercassette and developed 
immediately using an automated developer (Compact X4, X-ograph). Finally, the 
developed films were scanned onto a computer with a flat-bed scanner. Localisation 
and identification of iNOS bands was achieved by comparison to a known iNOS- 
positive control.
2.7 Materials
The following compounds were obtained from Sigma; (l-[p-Chlorobenzoyl]-5- 
methoxy-2-methylindole-3-acetic acid; indomethacin), 9,11-Dideoxy-l la ,9 a  
epoxymethano-prostaglandin (U46619), acetylcholine chloride, N-acetyl-D- 
penicillamine, N-acetyl-DL-penicillamine, 4-aminobenzoic hydrazide, ammonium 
sulphamate, atrial natriuretic peptide (from rat), bathocuproinedisulfonic acid, 
cantharidic acid, cupric sulfate anhydrous, D-cysteine hydrochloride monohydrate, 
L-cysteine hydrochloride anhydrous, histamine dihydrochloride, Krebs ringer solution 
(lOx), lipopolysaccharide {Salmonella typhosa), mercuric chloride, milrinone, N~{\- 
naphthyl)ethylendiamine dihydrochloride, A^-nitro-L-arginine methyl ester 
(L-NAME), phenylephrine hydrochloride, sodium nitrite, sodium nitroprusside, 
spermine-NONOate ([N-(2-Aminoethyl)-N-(2-hydroxy-2-nitrosohydrazone)-1,2 
ethylene-diamine; SPER-NO), sulfanilamide, Cu/Zn superoxide dismutase (bovine)
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and vinpocetine. C-type natriuretic peptide (human and porcine), okadaic acid and 
thymeleatoxin were purchased from Calbiochem. Acetonitrile, hydrochloric acid and 
potassium chloride were obtained from VWR LTD. 8 -bromo- adenosine-3’,5’-cyclic 
monophosphate (8 -Br-cAMP), 8-bromoguanosine-3’,5’-cyclic monophosphate (8 -Br- 
cGMP), N-(3-(aminomethyl)benzyl) acetamidine (1400W), forskolin and phorbol 12- 
myristate 13-acetate were obtained from Alexis Corporation. Glyceryl trinitrate was 
obtained from Faulding Pharmaceuticals pic. BAY 58-2667 was obtained from Bayer 
AG, Germany. l//-[l,2,4]-oxadiazolol-[4,3-a]quinoxalin-l-one (ODQ), L- and D- 
glutathione and sildenafil were synthesised at the Wolfson Institute for Biomedical 
Research, University College London.
2.8 Data analysis
Data was expressed as mean (±standard error of the mean (SEM)) for multiple 
replicates of each experiment. In organ bath studies, active tension was expressed as a 
percentage of that generated by potassium chloride. Relaxation was expressed as a 
percentage reversal of pre-contraction tension.
Concentration-response curves were fitted to all the data by non-linear 
regression using Prism (Graph Pad Software, San Diego, CA, USA) to calculate pECso 
values (-log of the EC50 values). pECso values were used to compare the relaxant 
effects of drugs. All results were compared by two-way analysis of variance (TW- 
ANOVA) for repeated measures and where appropriate (as described in the text) 
adjusted with Bonferroni’s correction (BC), with .P<0.05 was considered statistically 
significant.
It should be noted that in the organ bath experimentation, changes in the 
responsiveness of aortic rings to different agonists/antagonists was assessed by 
measuring changes in pECso. Although variability between experiments was small 
and the magnitude of desensitisation large, there are clear limitations of using this 
index alone that might arise from a small n number in certain experiments as well as 
its inability to detect changes in the maximum response. The small n number of some 
studies reported in this thesis may also limit the value of parametric statistics.
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CHAPTER THREE
BIOTRANSFORMATION OF 
S-NITROSOTHIOLS
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3.1 INTRODUCTION
The biological, physiological (section 1.4.4 and 1.4.5), pathophysiological 
(section 1.4.6) and therapeutic (section 1.4.7) importance of S-nitrosothiols has been 
discussed previously. Exploring their roles in biological systems remains limited by a 
lack of full understanding of the mechanisms whereby they are synthesised or degraded 
in biological systems. Therefore it is important to investigate the mechanisms by 
which these NO-donor are bio-transformed.
Evidence that endogenous S-nitrosothiols require metabolism to release NO 
comes from studies demonstrating that the rate of spontaneous release of NO from 
iS-nitrosothiols correlates poorly with their potency in biological systems (Kowaluk & 
Fung 1990; Mathews & Kerr, 1993). Non-enzymatic catalysis of S-nitrosothiols by 
metal ions, (particularly iron and copper) (Williams, 1996), glutathione and ascorbic 
acid, has been implicated in the decomposition of S'-nitrosothiols (Kashiba-Iwatsuki et 
al., 1997).
One approach to define the possible existence of the enzyme-dependent 
mechanisms is to compare the relative biological potencies of stereoisomers of 
specific substrate by specific cell type or enzyme. Differences in the biological 
potencies suggest the presence of stereoselectivity toward S-nitrosothiols, given that 
stereoisomers decompose equally to NO (at least chemically). Several studies have 
been reported using this approach to examine the relative contribution of enzyme- 
dependent biotransformation of S-nitrosothiols (section 1.4.4.3).
The relative contribution of enzymatic mechanisms of NO release from certain 
S'-nitrosothiols in vascular tissue is controversial (Davisson et al., 1996; Cavero et al., 
2000). The aim of this study was to determine whether the biotransformation of 
S-nitrosothiols by isolated blood vessels is enzymatic or non-enzymatic. To achieve this, 
stereoisomers of endogenous (GSNO and CYSNO) and exogenous (SNAP) 
S-nitrosothiols were synthesised and their decomposition and relaxant effects 
characterised. In particular I chose to examine the effects of free copper in solution (as a 
non-stereospecific control), with the effects of a vascular copper containing enzyme
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(Cu/Zn SOD) and whole aorta on the stability of S-nitrosothiols. In addition I examined 
whether there was evidence for stereospecific functional effects of these S-nitrosothiols.
3.2 EXPERIMENTAL PROTOCOLS AND STATISTICS
3.2.1 Decomposition of 5-nitrosothiols; effects of Cu(I), Cu(II) and copper 
chelation
Stock solutions of Cu(I) (lOpM and ImM), Cu(II) (lOpM and ImM), BCS 
(2mM) and various stereoisomers of S'-nitrosothiols (GSNO, SNAP and CYSNO; 222 
pM each) were made in deionised water. These solutions were kept on ice and 
protected from light. The effect of copper ions (lpM or lOOpM final concentration) 
on S-nitrosothiol concentration (lOOpM final concentration) was determined over 60 
mins at room temperature. This protocol was repeated in the presence of BCS 
(lOOpM-ImM). The Saville assay was used to determine the concentration of L-or D- 
isomers of GSNO, SNAP and CYSNO following these treatments (as described in 
2 . 1.2 ).
3.2.2 Decomposition of L-and D-GSNO and DL-and D-SNAP by Cu/Zn SOD
Cu/Zn SOD (20pM final concentration) was incubated with S-nitrosothiols 
(lOOpM final concentration) for up to 60 min at 37°C. This protocol was repeated in 
the presence of GSH (lOOpM final concentration) and BCS (lOOpM final 
concentration). The Saville assay was used to determine S-nitrosothiol concentration 
following these treatments.
3.2.3 Decomposition of L-and D-GSNO by rat aorta in the presence of BCS
Stock solutions of L-and D-GSNO (ImM) and BCS (lOmM), and subsequent 
dilutions, were prepared in Krebs’ solution as described in section 2.2.2. Thoracic 
aorta was obtained from male Sprague Dawley rats (200-25Og) as described in section 
2.3.2. Aortic rings (2-3mm) were cut into half and incubated with L-or D-GSNO
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(lOOpM final concentration) for up to 60 min at 37°C. To examine the effect of 
endogenous copper ions on the decomposition rate of L-or D-GSNO, the protocol was 
repeated in the presence of BCS (lOOpM). The Saville assay was used to determine the 
concentration of L-and D-GSNO.
3.2.4 Effects of the stereoisomers of 5-nitrosothiols on rat aorta
Organ bath studies were performed on rings of rat thoracic aorta from male 
Sprague Dawley rats (200-250 g) killed by cervical dislocation and prepared as 
mentioned in section 2.3.2. Concentration-response curves to L-and D-GSNO (lnM- 
lpM), DL-and D-SNAP (InM-lOpM) and L-and D-CYSNO (InM-lOpM) were 
constructed in rings precontracted to an approximately ECgo with PE. Studies were 
repeated in the presence of BCS (10-lOOpM; pre-incubated for 30 mins). The effect of 
BCS on the response to ACh (InM-lOpM) and SPER-NO (InM-lOpM) was also 
determined.
3.2.5 Effect Cu(I) ions on the intracellular content of <S-nitrosothiols
Concentration-response curves were constructed to Cu(I) (100nM-300pM) in rat 
aortic rings precontracted to an ECgo with PE in the presence and absence of 
endothelium, the sGC inhibitor ODQ (5pM; preincubated for 30 mins) and NOS 
inhibitor, L-NAME (300pJM; preincubated for 30 mins). Concentration-response curves 
to acetonitrile (100nM-300pM) were also constructed in rat aortic rings precontracted to 
an ECgo with PE as a control.
3.2.6 Calculations and statistics
S-nitrosothiol concentration was calculated using a standard curve constructed 
with 0-200p.M of sodium nitrite by using SoftMax Pro Software. The effect of 
different treatments on the stability S-nitrosothiols was expressed as a percentage of 
initial concentration of S-nitrosothiols, and expressed as mean ± SEM. All the data 
were analysed by TW-ANOVA and where appropriate Bonferroni’s correction (BC) 
was applied. Organ bath studies were expressed as described in section 2.8.
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3.3 RESULTS
3.3.1 Decomposition of S'-nitrosothioIs by copper ions
3.3.1.1 Decomposition of DL-SNAP by copper ions
DL-SNAP was relatively stable in the absence of copper ions. Cu(I) (lpM) 
caused a time-dependent decomposition of DL-SNAP (P<0.05 versus control; n=4; 
Figure 3.1; Table 3.1). At 60 minutes, lpM Cu(I) caused 52.5% decomposition of the 
initial concentration of DL-SNAP. Similarly, 1 pM Cu(II) caused a time-dependent 
decomposition of DL-SNAP (P<0.05 versus control; n=4; Figure 3.1). At 60 mins, 
lpM Cu(II) caused 73% decomposition of the initial concentration of DL-SNAP. The 
Cu(I) chelator BCS (100 pM) completely blocked the decomposition of DL-SNAP by 
both Cu(I) and Cu(II) (P<0.05 versus the presence of Cu(I) or Cu(II) alone; n=4; 
Figure 3.1).
-m -  DL-SNAP 
— DL-SNAP+Cu(I) 
DL-SNAP+Cu(II)
-O - DL-SNAP+Cu(I)+BCS 
DL-SNAP+Cu(II)+BCS
80-
60-
40-
20 -
Time (mins)
Figure 3.1 Time-dependent decomposition o f DL-SNAP in the presence or absence o f 
Cu(I) (IpM), Cu(II) (1 pM) and BCS (100pM) . Each point represents the mean ±  
SEM (n=4).
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3.3.1.2 Decomposition of D-SNAP by copper ions
D-SNAP was relatively stable in the absence of copper ions. However, Cu(I) 
(lpM) caused a time-dependent decomposition of D-SNAP (P<0.05 versus control; 
n=4; Figure 3.2; Table 3.1). At 60 mins, lpM Cu(I) caused approximately 54.7% 
decomposition of the initial concentration of D-SNAP. Similarly, Cu(II) (lpM) also 
caused a time-dependent decomposition of D-SNAP (P<0.05 versus control; «=4; 
Figure 3.2). At 60 mins, Cu(II) (lpM) caused approximately 65.6% decomposition of 
the initial concentration of D-SNAP. The Cu(I) chelator BCS (100 pM) completely 
blocked the decomposition of D-SNAP by both Cu(I) and Cu(II) (P<0.05 versus the 
presence of Cu(I) or Cu(II) alone; w=4; Figure 3.2). DL-SNAP and D-SNAP 
decomposed at an equivalent rate in the presence of copper ions (P>0.05; n=4; Table 
3.1).
D-SNAP
D-SNAP+Cu(I)
D-SNAP+Cu(II)
-O - D-SNAP+Cu(I)+BCS 
D-SNAP+Cu(II)+BCS
o  l O O n
80-
40-
Time (mins)
Figure 3.2 Time-dependent decomposition o f D-SNAP in the presence or absence o f
Cu(l) (lpM), Cu(Il) (lpM) and BCS (lOOpM). Each point represents the 
mean ±SEM (n=4).
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Treatments P  values
DL-SNAP vs. DL-SNAP + Cu(I) ♦p o .os
DL-SNAP vs. DL-SNAP + Cu(II) */><o.05
DL-SNAP + Cu(I) vs. DL-SNAP + Cu(I) + BCS *P< 0.05
DL-SNAP + Cu(II) vs. DL-SNAP + Cu(II) + BCS *P<0.05
D-SNAP vs. D-SNAP + Cu(I) *P< 0.05
D-SNAP vs. D-SNAP + Cu(II) */><0.05
D-SNAP + Cu(I) vs. D-SNAP + Cu(I) + BCS */><o.o5
D-SNAP + Cu(II) vs. D-SNAP + Cu(II) + BCS *P<0.05
DL-SNAP vs. D-SNAP Z^ O.05
DL-SNAP + Cu(I) vs. D-SNAP + Cu(I) P> 0.05
DL-SNAP + Cu(II) vs. D-SNAP + Cu(II) T^O.05
Table 3.1 Comparison o f the decomposition o f DL- and D-SNAP in the 
absence and presence o f copper ions (n=4); TW-ANOVA with BC.
3.3.1.3 Decomposition of L-GSNO by copper ions
L-GSNO was stable in the absence of copper ions. Cu(I) (lpM) had no effect 
on the stability of L-GSNO (P>0.05 versus control; n= 4; Figure 3.3; Table 3.2). 
Similarly, Cu(II) (lpM) had no effect on the stability of L-GSNO (/>>0.05 versus 
control; n=4; Figure 3.3). At lOOpM Cu(I), there was a time-dependent 
decomposition of L-GSNO (^<0.05 versus control; n=6; Figure 3.3; Table 3.2). At 
60 mins, Cu(I) (lOOpM) caused 36.7% decomposition of the initial concentration of 
L-GSNO. Cu(II) (lOOpM) caused a small but significant time-dependent 
decomposition of L-GSNO (/><0.05 versus control; n=6; Figure 3.3). At 60 mins, 
Cu(II) (lOOpM) caused 17.2% decomposition of L-GSNO. The Cu(I) chelator BCS 
(ImM) completely blocked the decomposition of L-GSNO by both Cu(I) and Cu(II) 
(P<0.05 versus the presence of Cu(I) or Cu(II) alone; n=6; Figure 3.3).
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40L
0 10 20 30 40 50 60 70
Time (mins)
L-GSNO 
-O-L-GSNO+Cu(I) lOOpM 
L-GSNO+Cu(II) lOOpM 
- o -  L-GSNO+Cu(I)+BCS 
L-GSNO+Cu(II)+BCS 
-A - L-GSNO+Cu(I) lpM 
L-GSNO+Cu(II) 1 pM
Figure 3.3 Time-dependent decomposition o f L-GSNO in the presence or absence o f 
Cu(I) (1-100/jM), Cu(II) (1-lOOpM) and BCS (ImM) . Each point represents the 
mean ±SEM (n>4).
3.3.1.4 Decomposition of D-GSNO by copper ions
D-GSNO was stable in the absence of copper ions. However, Cu(I) (lOOpM) 
caused a time-dependent decomposition of D-GSNO (/><0.05 versus control; «=6; 
Figure 3.4; Table 3.2). At 60 mins, Cu(I) (lOOpM) and Cu(II) (100pM) caused 
approximately 33.5% and 22.3% decomposition of the initial concentration of 
D-GSNO, respectively. The Cu(I) chelator BCS (ImM) completely blocked the 
decomposition of D-GSNO by both Cu(I) and Cu(II) (.P<0.05 versus the presence of 
Cu(I) or Cu(II) alone; n=6; Figure 3.4). L-GSNO and D-GSNO decomposed at an 
equivalent rate in the presence of copper ions (/>>0.05; «=5; Table 3.2).
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100 D-GSNO
D-GSNO+Cu(I)
D-GSNO+Cu(II)
D-GSNO+Cu(I)+BCS
D-GSNO+Cu(II)+BCS
Time (mins)
Figure 3.4 Time-dependent decomposition o f D-GSNO in the presence or absence o f 
Cu(I) (lOOpM), Cu(II) (lOOpM) and BCS (ImM) . Each point represents the mean ±  
SEM (n=6).
Treatments P  values
L-GSNO vs. L- GSNO + Cu(I) l|uM P>0.05
L-GSNO vs. L- GSNO + Cu(II) l^iM P> 0.05
L-GSNO vs. L- GSNO + Cu(I) 1(%M *P<0.05
L- GSNO vs. L- GSNO + Cu(II) lOO^M *P<0.05
L-GSNO + Cu(I) vs. L-GSNO + Cu(I) lOO^M + BCS *P< 0.05
L-GSNO + Cu(II) vs. L-GSNO + Cu(II) 100|iM + BCS *P< 0.05
D-GSNO vs. D-GSNO + Cu(I) lOO^ iM *P<0.05
D-GSNO vs. D-GSNO + Cu(II) 100nM *P< 0.05
D-GSNO + Cu(I) vs. D-GSNO + Cu(I) + BCS */><0.05
D-GSNO + Cu(II) vs. D-GSNO + Cu(II) + BCS ♦ ^o .o s
L-GSNO vs. D-GSNO P> 0.05
L-GSNO + Cu(I) vs. D-GSNO + Cu(I) P> 0.05
L-GSNO + Cu(II) vs. D-GSNO + Cu(II) P>0.05
Table 3.2 Comparison o f the decomposition o f L- and D- GSNO in the absence
and presence o f copper ions (h=6); TW-ANOVA with BC.
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3.3.1.5 Decomposition of L-CYSNO by copper ions
L-CYSNO was unstable in the absence of added copper ions. After 60 mins 
there was 44% decomposition of L-CYSNO under control condition. BCS protected 
L-CYSNO from spontaneous decomposition (/,<0.05 versus control; n=5; Figure 3.5 
Table 3.3). Cu(I) (lpM) caused a rapid, time-dependent decomposition of L-CYSNO 
(^<0.05 versus control; n=5; Figure 3.5). As early as 10 mins, Cu(I) (lpM) caused 
91.6% decomposition of the initial concentration of L-CYSNO, and at 30 mins, Cu(I) 
(lpM) caused complete decomposition of L-CYSNO. The Cu(I) chelator BCS (100 
pM) completely blocked the decomposition of L-CYSNO by Cu(I) (P<0.05 versus 
the presence of Cu(I) alone; «=5). Similarly, Cu(II) (lpM) caused a time-dependent 
decomposition of L-CYSNO (/^O.OS versus control; n=5; Figure 3.5). At 10 
minutes, Cu(II) (lpM) caused almost complete decomposition of L-CYSNO. BCS 
(100 pM) completely blocked the decomposition of L-CYSNO by Cu(II) (^<0.05 
versus the presence of Cu(II) alone; n=5; Figure 3.5).
o
n ®
100
60
20
0
1 1
L-CYSNO
L-CYSNO+Cu(I)
L-CYSNO+Cu(II)
L-CYSNO+Cu(I)+BCS
L-CYSNO+Cu(II)+BCS
L-CYSNO+BCS
10 20 30 40 50 60 70
Time (mins)
Figure 3.5 Time-dependent decomposition o f L-CYSNO in the presence or absence o f 
Cu(I) (lpM), Cu(II) (lpM) and BCS (lOOpM) . Each point represents the 
mean ±SEM (n=5).
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3.3.1.6 Decomposition of D-CYSNO by copper ions
In a similar fashion, D-CYSNO was unstable over a period of 60 mins under 
control condition. At 60 mins, approximately 43.2% of the initial concentration of D- 
CYSNO was decomposed. BCS (lOOpM) protected D-CYSNO from this 
decomposition (/><0.05 versus control; n=5; Figure 3.6; Table 3.3). Cu(I) (lpM) 
caused a fast, time-dependent decomposition of D-CYSNO (/><0.05 versus control; 
n=5; Figure 3.6). At 10 mins, Cu(I) (lpM) caused approximately 89% decomposition 
of D-CYSNO, and at 30 mins, Cu(I) (lpM) caused complete decomposition of 
D-CYSNO. Chelation of Cu(I) with BCS (100 pM) completely blocked the 
decomposition of D-CYSNO by Cu(I) (P<0.05 versus the presence of Cu(I) alone; 
n=5). Similarly, Cu(II) (lpM) caused a time-dependent decomposition of D-CYSNO 
(P<0.05 versus control; n=5; Figure 3.6). At 10 mins, lpM Cu(II) caused 93.7% 
decomposition of D-CYSNO. BCS (lOOpM) completely blocked the decomposition 
of D-CYSNO by Cu(II) (P<0.05 versus the presence of Cu(II) alone; n=5; Figure 
3.6). L-CYSNO and D-CYSNO decomposed at an equivalent rate in the absence or 
presence of copper ions (/*>0.05; n=5; Table 3.3).
o
N°ON
100
80
60
40
20
0
D-CYSNO
D-CYSNO+Cu(I)
D-CYSNO+Cu(II)
D-CYSNO+Cu(I)+BCS
D-CYSNO+Cu(II)+BCS
D-CYSNO+BCS
0 20 30 40 50 60 70
Time (mins)
Figure 3.6 Time-dependent decomposition o f D-CYSNO in the presence or absence o f 
Cu(I) (ljuM), Cu(II) (lpM) and BCS (lOOpM) . Each point represents the mean ±  
SEM (n=5).
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Treatments P  values
L- CYSNO vs. L- CYSNO + Cu(I) *P<0.05
L- CYSNO vs. L- CYSNO + Cu(II) *P< 0.05
L-CYSNO + Cu(I) vs. L-CYSNO + Cu(I) + BCS ♦pco.os
L-CYSNO + Cu(II) vs. L-CYSNO + Cu(II) + BCS *P< 0.05
D-CYSNO vs. D-CYSNO + Cu(I) *P< 0.05
D-CYSNO vs. D-CYSNO + Cu(II) *p<o.os
D-CYSNO + Cu(I) vs. D-CYSNO + Cu(I) + BCS *^<0.05
D-CYSNO + Cu(II) vs. D-CYSNO + Cu(II) + BCS *P<0.05
L-CYSNO vs. D-CYSNO P>0.05
L-CYSNO + Cu(I) vs. D-CYSNO + Cu(I) P>0.05
L-CYSNO + Cu(II) vs. D-CYSNO + Cu(II) P>0.05
Table 3.3 Comparison o f the decomposition o f L- and D- CYSNO in 
the absence and presence o f copper ions (n=5); TW-ANOVA with BC.
3.3.2 Effect of Cu/Zn SOD on the stability of S'-nitrosothiols
3.3.2.1 Decomposition of L-GSNO by Cu/Zn SOD
Cu/Zn SOD (20pM) alone had no effect on the stability of L-GSNO (P>0.05 
versus control; n=4; Figure 3.7; Table 3.4). GSH (100pM) alone caused a small but 
significant, time-dependent decomposition of L-GSNO (/><0.05 versus control; n=3). 
At 60 mins, GSH (lOOpM) caused 14.6% decomposition of the initial concentration 
of L-GSNO. However, both Cu/Zn SOD (20pM) and GSH (lOOpM) caused greater 
decomposition of L-GSNO (P<0.05 versus control; n=4) than that of GSH or Cu/Zn 
SOD alone. At 60 mins, both Cu/Zn SOD and GSH caused 47.5% decomposition of 
L-GSNO. BCS (lOOpM) significantly blocked the decomposition of L-GSNO by both 
Cu/Zn SOD and GSH (/><0.05 versus the presence of both Cu/Zn SOD with GSH 
alone; n=4; Figure 3.7).
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Figure 3.7 Time-dependent decomposition o f L-GSNO in the presence or absence o f 
Cu/Zn SOD (20pM), GSH (lOOpM), Cu/Zn SOD plus GSH or a combination o f 
Cu/Zn SOD, GSH and BCS (lOOpM). Each point represents the mean ±SEM  (n=4).
3.3.2.2 Decomposition of D-GSNO by Cu/Zn SOD
Cu/Zn SOD (20juM) alone had no effect on the stability of D-GSNO (P>0.05 
versus control; «= 4; Figure 3.8; Table 3.4). GSH (lOOpM) alone caused a significant 
time-dependent decomposition of D-GSNO (P<0.05 versus control; n=3). At 60 
mins, GSH (lOOpM) caused 17.1% decomposition of D-GSNO. However, both 
Cu/Zn SOD (20pM) and GSH (lOOpM) caused greater time-dependent 
decomposition of D-GSNO compared with that of GSH or Cu/Zn SOD alone (P<0.05 
versus GSH alone; n=4). At 60 mins, both Cu/Zn SOD and GSH caused 54.1% 
decomposition of the initial concentration of D-GSNO. BCS (lOOpM) significantly 
blocked the decomposition of D-GSNO by both Cu/Zn SOD and GSH (P<0.05 
versus the presence of both Cu/Zn SOD with GSH alone; n=4; Figure 3.8). Cu/Zn 
SOD (20pM) and GSH (lOOpM) caused similar decomposition of D-GSNO and 
L-GSNO CP>0.05; n=4).
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Figure 3.8 Time-dependent decomposition o f D-GSNO in the presence or absence o f 
Cu/Zn SOD (20pM), GSH (lOOpM), Cu/Zn SOD plus GSH or a combination o f 
Cu/Zn SOD, GSH and BCS (lOOpM). Each point represents the mean ±SEM  (n=4).
Treatments P  values
L-GSNO vs. L-GSNO + SOD P>0.05
L-GSNO vs. L-GSNO + GSH *P<0.05
L-GSNO vs. L-GSNO + SOD + GSH *P<0.05
L-GSNO + GSH vs. L-GSNO + SOD + GSH *P<0.05
L-GSNO + SOD + GSH vs. L-GSNO + SOD + GSH + BCS *P<0.05
L-GSNO + SOD + GSH vs. D-GSNO + SOD + GSH P> 0.05
D-GSNO vs. D-GSNO + SOD P> 0.05
D- GSNO vs. D-GSNO + GSH *P< 0.05
D-GSNO vs. D-GSNO + SOD + GSH *JP<0.05
D-GSNO + GSH vs. D-GSNO + SOD + GSH *P< 0.05
D-GSNO + SOD + GSH vs. D-GSNO + SOD + GSH + BCS ♦p o .os
Table 3.4 Comparison o f the decomposition o f L-and D-GSNO in the absence
and presence o f Cu/Zn SOD, GSH and BCS (n=4); TW-ANOVA with BC.
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3.3.2.3 Decomposition of DL-SNAP by Cu/Zn SOD
Cu/Zn SOD (20pM) had no effect on the stability of DL-SNAP (P>0.05 
versus control; n=6; Figure 3.9; Table 3.5). GSH (lOOpM) also had no effect on the 
stability of DL-SNAP (P>0.05 versus control; n=6). However, the presence of both 
Cu/Zn SOD (20pM) and GSH (lOOpM) caused a significant time-dependent 
decomposition of DL-SNAP (/><0.05 versus control; n=6; Figure 3.9). At 60 mins, 
both Cu/Zn SOD and GSH caused 59.3% decomposition of the initial concentration 
of DL-SNAP. BCS (lOOpM) completely blocked the decomposition of DL-SNAP by 
both Cu/Zn SOD and GSH (P<0.05 versus the presence of Cu/Zn SOD with GSH 
alone; n - 6; Figure 3.9).
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Figure 3.9 Time-dependent decomposition o f DL-SNAP in the presence or absence o f 
Cu/Zn SOD (20pM), GSH (lOOpM), Cu/Zn SOD plus GSH or a combination o f 
Cu/Zn SOD, GSH and BCS (lOOpM). Each point represents the mean ±SEM  (n=6).
3.3.2.4 Decomposition of D-SNAP by Cu/Zn SOD
Cu/Zn SOD (20pM) alone had no effect on the stability of D-SNAP (P>0.05 
versus control; n=6; Figure 3.10; Table 3.5). GSH (lOOpM) alone also had no effect 
on the stability of D-SNAP (P>0.05 versus control; n=6). However, both Cu/Zn SOD 
(20pM) and GSH (lOOpM) caused a significant time-dependent decomposition of 
D-SNAP (P<0.05 versus control; n=6). At 60 mins, both Cu/Zn SOD and GSH
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caused 61% decomposition of the initial concentration of D-SNAP. BCS (lOOpM) 
completely blocked the decomposition of D-SNAP by both Cu/Zn SOD and GSH 
(JP<0.05 versus the presence of Cu/Zn SOD with GSH alone; n=6; Figure 3.10). 
Cu/Zn SOD (20pM) and GSH (100p.M) caused similar decomposition of D-SNAP 
and L-SNAP (P>0.05; «=6).
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Figure 3.10 Time-dependent decomposition o f D-SNAP in the presence or absence o f 
Cu/Zn SOD (20pM), GSH (lOOpM), Cu/Zn SOD plus GSH or a combination o f 
Cu/Zn SOD, GSH and BCS (100pM). Each point represents the mean ±SEM  (n=6).
Treatments P  values
DL-SNAP vs. DL-SNAP + SOD i*>0.05
DL-SNAP vs. DL-SNAP + GSH />>0.05
DL-SNAP vs. DL SNAP + SOD + GSH *P<0.05
DL-SNAP + SOD + GSH vs. DL-SNAP + SOD + GSH + BCS *P<0.05
DL-SNAP + SOD + GSH vs. D-SNAP + SOD + GSH />>0.05
D-SNAP vs. D-SNAP + SOD Z^O.05
D-SNAP vs. D-SNAP + GSH P> 0.05
D-SNAP vs. D-SNAP + SOD + GSH *P<0.05
D-SNAP + SOD + GSH vs. D-SNAP + SOD + GSH + BCS *P< 0.05
Table 3.5 Comparison o f the decomposition o f DL-and D-SNAP in the absence
and presence o f Cu/Zn SOD, GSH and BCS (n=4); TW-ANOVA with BC.
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3.3.3 Decomposition of L-and D-GSNO by rat aorta
Rat aortic tissue caused a time-dependent decomposition of L-GSNO (/,<0.05 
versus control; n=4; Figure 3.11A; Table 3.6). At 60 mins, rat aorta caused 18.5% 
decomposition of the initial concentration of L-GSNO. BCS (lOOpM) completely 
blocked the decomposition of L-GSNO by rat aorta (P<0.05 versus the presence of 
tissue; n=4; Figure 3.11A). In a similar fashion, rat aortic tissue caused a 
time-dependent (P<0.05 versus control; n=4; Figure 3.1 IB) decomposition of 
D-GSNO. At 60 mins, rat aorta caused 20.5% decomposition of the initial 
concentration of D-GSNO. BCS (lOOpM) completely blocked the decomposition of 
D-GSNO by rat aorta (/><0.05 versus the presence of tissue; n= 4; Figure 3.1 IB). 
Thus, the effect of rat aorta on the decomposition of L- and D-GSNO was equivalent 
(P>0.05 versus control; «=4).
Treatments P  values
L-GSNO vs. L-GSNO + Tissue *P< 0.05
L-GSNO+ Tissue vs. L-GSNO + Tissue + BCS *JP<0.05
D-GSNO vs. D-GSNO + Tissue *P<0.05
D-GSNO+ Tissue vs. D-GSNO + Tissue + BCS *P<0.05
L-GSNO+ Tissue vs. D-GSNO+ Tissue />>0.05
Table 3.6 Comparison o f the decomposition o f L- and D- GSNO in 
the absence and presence o f aortic tissue and BCS (n=4); TW-ANOVA 
with BC.
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Figure 3.11 Time-dependent decomposition o f (A) L-GSNO and (B) D-GSNO in the 
absence and presence o f aortic tissue and BCS (lOOpM). Each point represents the 
mean ±SEM (n=4).
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3.3.4 Responses of rat aorta to L-and D-isomers of 5-nitrosothiols
3.3.4.1 Responses of rat aorta to DL-and D-SNAP
DL- and D-isomers of SNAP caused equipotent concentration-dependent 
relaxation of PE-precontracted (ECgo) rat aorta. The pEC5o values for DL-and D-SNAP 
(7.7± 0.17 and 7.6±0.17 respectively; n=9; P>0.05; Figure 3.12) were not significantly 
different. Pre-incubation of rat aortic rings with BCS (10 pM) for 30 mins significantly 
reduced the potency of both DL-SNAP and D-SNAP. The pECso values for DL-and D- 
SNAP in the presence of BCS (6.47±0.18 and 6.39±0.12 respectively; n=9; P<0.05 
versus control; BC; Figure 3.12) were approximately one order of magnitude less as 
compared to control, but were not significantly different from each other («=9; P>0.05). 
Curves were compared by TW-ANOVA.
120-i DL-SNAP
DL-SNAP+BCS
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Figure 3.12 Concentration-response curves to DL-SNAP and D-SNAP (InM-lOpM)
following 30 mins incubation with vehicle or BCS (lOjuM). Relaxation is expressed as 
the percentage reversal o f the PE-induced tone. Each point represents mean ± SEM 
n=9.
3.3.4.2 Responses of rat aorta to L-and D-GSNO
L-and D-isomers o f GSNO also caused equipotent concentration-dependent
relaxation of PE-precontracted (ECgo) rat aorta. The pECso values for L-and D-GSNO
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(7.37±0.15 and 7.12±0.19 respectively; n=5; P>0.05 (T^O.13); Figure 3.13) were 
similar. Incubation of rat aortic rings with BCS (lOpM), for 30 mins significantly 
reduced the potency of both L-and D-GSNO. The pECso values for L-GSNO and 
D-GSNO in the presence of BCS (6.52±0.27 and 6.67±0.21 respectively; n=5; P<0.05 
versus control; BC; Figure 3.13) were significantly less compared to control, but not 
significantly different from each other («=5; P>0.05). Curves were compared by TW-
ANOVA.
L-GSNO
L-GSNO+BCS
D-GSNO
D-GSNO+BCS
Log [L-and D-GSNO] (M)
Figure 3.13 Concentration-response curves to L- and D-GSNO (InM-lpM) following
30 mins incubation with vehicle or BCS (10pM). Relaxation is expressed as the 
percentage reversal o f the PE-induced tone. Each point represents mean ± SEM 
(n=5).
3.3.4.3 Responses of rat aorta to L-and D-CYSNO
L-and D-isomers of CYSNO caused concentration-dependent relaxation of 
PE-precontracted (ECgo) rat aorta. The pECso values for L-and D-CYSNO (7.17±0.21 
and 7.09±0.2 respectively; n= 4; / >>0.05; Figure 3.14A) were not significantly different. 
Incubation of rat aortic rings with BCS (10pM), for 30 mins had no effect on the 
potency of L-and D-CYSNO. The pECso values for L-and D-CYSNO in the presence of 
10pM BCS (7.18±0.12 and 7.41 ±0.12 respectively; n=4; /*>0.05 versus control; Figure 
3.14A) were not significantly different from control. However, incubation of rat aortic
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rings with lOOpM BCS for 30 mins significantly reduced the potency of both L-and D- 
CYSNO (pECso: 6.14+0.15 and 6.33+0.13 respectively; n=5; P<0.05 versus control; 
BC; Figure 3.14B). Curves were compared by TW-ANOVA.
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Figure 3.14 Concentration-response curves to L-and D-CYSNO (InM-lOpM)
following 30 mins incubation with vehicle or BCS (A) lOpM (B) 100/nM. Relaxation is 
expressed as the percentage reversal o f the PE-induced tone. Each point represents 
mean ± SEM (n=4).
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3.3.4.4 Effects of BCS on the responses of rat aorta to SPER-NO
To control for non-specific effects of BCS, the effect of Cu(I) chelation on the 
vasorelaxant activity of SPER-NO was examined. SPER-NO caused concentration- 
dependent relaxation of PE-precontracted rat aorta (ECgo) with a pEC5o value of 
6.57±0.2 in the absence and 6.76±0.14 in the presence of BCS (lOpM for 30 minutes; 
n=5; P>0.05 versus control; TW-ANOVA; Figure 3.15).
■ SPER-NO 
□ SPER-NO+BCS
100 -
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Log[SPER-NO] (M)
Figure 3.15 Concentration-response curves to SPER-NO (InM-lOpM) following 
30 mins incubation with vehicle or BCS (lOpM); Relaxation is expressed as the 
percentage reversal o f the PE-induced tone. Each point represents mean ± SEM 
(n = 5 ).
3.3.5 Effects of BCS and Cu(I) on endogenous NO-mediated responses of rat 
aorta
ACh caused concentration-dependent relaxation of PE-precontracted (ECgo) rat 
aorta that was unaffected by BCS (lOpM; 30 mins). The pEC5o value for ACh in the 
presence and absence of BCS is 7.73±0.19 and 7.81±0.25 respectively n=5; P>0.05; 
TW-ANOVA; Figure 3.16. Addition of Cu(I) (100nM-300pM) caused concentration-
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dependent relaxation of PE-precontracted (ECgo) rat aortic rings that was 
endothelium-dependent (The pECso values is 5.84±0.34; n=3; P<0.05 vessus 
acetonitrile, ODQ, L-NAME or denuded tissue; TW-ANOVA with BC; Figure 3.17). 
In endothelium-intact vessels relaxation to Cu(I) was inhibited by the sGC inhibitor, 
ODQ (5pM; 30 mins) and L-NAME (300pM; 30 mins). Endothelial denudation also 
abolished relaxations to Cu(I)-acetonitrile alone had no effect on the precontracted 
vessels (Figure 3.17).
100
ACh
ACh+BCS
Log [ACh] (M)
Figure 3.16 Concentration-response curves to ACh (InM-lOpM) following 30 mins 
incubation with vehicle or BCS (lOpM); Relaxation is expressed as the percentage 
reversal o f the PE-induced tone. Each point represents mean ± SEM (n=5).
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Figure 3.17 Concentration-response curves to Cu(l)-acetonitrile (l00nM-300pM) 
and acetonitrile (100nM-300pM) in the presence and absence o f endothelium, ODQ 
(5pM; 30 mins) and L-NAME (300pM; 30 mins). Relaxation is expressed as the 
percentage reversal o f the PE-induced tone. Each point represents mean ± SEM 
(n=3).
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3.4 DISCUSSION
In the present study, I investigated the effect of free copper ions, the copper- 
containing enzyme, Cu/Zn SOD, and rat aorta on the stability of stereoisomers of 
S'-nitrosothiols. I also investigated the responsiveness of rat isolated aorta to 
stereoisomers of the endogenous S-nitrosothiols, GSNO and CYSNO, and the 
exogenous S-nitrosothiol, SNAP. These studies demonstrated that biotransformation of 
S-nitrosothiols was in part dependent on the chemical effect of Cu(I) ions. There was no 
evidence of a stereospecific effect of a copper containing enzyme or tissue. In rat 
isolated aorta, there were no stereospecific vasorelaxant effects of S'-nitrosothiols, 
consistent with non-enzymatic Cu (I)-dependent release of NO.
3.4.1 Decomposition of £-nitrosothiols by copper ions
The effect of Cu(I) and Cu(II) on the decomposition of stereoisomers of 
GSNO, CYSNO and SNAP was examined in a protein free system in vitro. Previous 
studies had identified a role for Cu(I) rather than Cu(II) because of the action of the 
Cu(I) chelator, neocuproine. In this chapter I used a novel Cu(I)-releasing complex 
copper (I)-acetonitrile that was soluble in aqueous solution to get a more direct 
insight into the role of this copper species on S'-nitrosothiol breakdown. L-and D- 
isomers of S'-nitrosothiols decomposed on exposure to Cu(I), and as expected there 
was no difference between stereoisomers. The decomposition of S-nitrosothiols by 
Cu(I) and Cu(II) was completely blocked by the specific Cu(I) chelator, BCS, 
suggesting that the effective catalyst in the decomposition is Cu(I) not the oxidised 
form, Cu(II), supporting previous findings (Dicks et al., 1996; Gorren et al., 1996).
There were clear differences in the stability of the different S'-nitrosothiols in 
the presence of copper ions. The presence of as little as lpM Cu(I) has a profound 
effect on CYSNO, which showed complete decomposition within a few minutes. The 
effect of Cu(I) on SNAP is also significant but considerably less than that of CYSNO. 
However, GSNO required comparatively large concentrations of Cu(I) to greatly 
affect its stability. These observations suggest that the rank order of stability in the
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requires other factors. The presence of GSH caused a dramatic acceleration of the 
decomposition rate by Cu/Zn SOD; GSH alone had a minimal direct effect. This 
indicates the requirement of GSH to enhance the decomposition of GSNO and SNAP 
by Cu/Zn SOD. Chelation of Cu(I) by BCS completely blocked the decomposition of 
GSNO and SNAP by Cu/Zn SOD, indicating that decomposition occurs by reaction 
with Cu(I) rather than other components of the enzyme. GSH may act to reduce 
Cu(II) to Cu (I) that is either bound to the enzyme or which has dissociated in 
solution. Alternatively GSH could cause conformational changes in Cu/Zn SOD 
leading to exposure of copper ions to react with GSNO and SNAP. The effect of GSH 
on GSNO, although small, suggests that a transnitrosation reaction might have 
occurred. This effect seems to be specific to GSNO as GSH had no effect on SNAP.
The plasma membrane of many cell types including endothelial and VSMC, 
contains a variety of enzymes that contain copper ions such as, vascular adhesion 
protein 1, lysyl oxidase, benzylamine oxidase, methylamine oxidase (Buffoni & 
Ignesti, 2000; Jalkanen & Salmi, 2001), Cu-ATPase and Cu/Zn SOD (Harris, 2000). 
In the plasma there are also copper-containing proteins such as ceruloplasmin and 
albumin (Harris, 2000). These copper-containing molecules might determine the 
biotransformation of S-nitrosothiols in vivo (Figure 3.18).
3.4.3 Decomposition of stereoisomers of *S-nitrosothiols by rat aorta
Consistent with the results obtained with Cu/Zn SOD, the decomposition of 
L-GSNO by rat aorta was similar to that of D-GSNO. Moreover, decomposition of 
L-and D-GSNO by rat aorta was prevented by Cu(I) chelation. Therefore, whole tissue 
metabolism of GSNO is non-stereospecific and consistent with a direct effect of Cu(I). It 
is not possible to say which of the Cu containing proteins described in section 3.4.2 
might contribute to the metabolism of GSNO by rat aorta.
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3.4.4 Non-stereospecific relaxation of rat aorta by 5-nitrosothiols
The vasorelaxant response of rat aorta to L-and D-isomers of GSNO, SNAP 
and CYSNO were similar with no evidence of a stereospecific effect and consistent 
with non-enzymatic release of NO from these S-nitrosothiols. Cavero et al made 
similar observations with CYSNO and SNAP, but reported L-GSNO to be more potent 
in this vessel than D-GSNO (Cavero et al., 2000). One explanation for the difference 
between the results presented in this chapter and those previously reported, is that both 
stereoisomers of GSH were synthesised in house in order to minimise any differences 
arising from different methods of synthesis (that might, for instance, contain different 
impurities). In addition, in this study spectroscopy was used to ensure that the 
concentrations of L- and D-GSNO in stock solutions were similar. The effect of Cu(I) 
chelation on the stereoisomers was also similar. Stereospecific effects of S-nitrosothiols 
have been reported in animals in vitro and in vivo, so it remains possible that enzymatic 
release of NO might occur in other systems. However, I could find no evidence of this in 
the systems used in this thesis.
Discrepancy between my observations and previous reports that have 
demonstrated stereospecific and/or enzymatic bioactivation of S-nitrosothiols might 
be due to differences in the model (Davisson et al., 1996), type of tissue (Davisson et 
al., 1997; Zai et al., 1999; Root et al., 2004), source of GSH (Cavero et al., 2000) and 
the S-nitrosothiol studied (Travis et al., 1996). As mentioned above, enzymes such as 
xanthine oxidase (Trujillo et al., 1998) and DPI (Zai et al., 1999; Root et al., 2004) 
have also been reported to cause decomposition of S-nitrosothiols. However, in the 
systems that I studied, there was no evidence to support any endogenous enzymatic 
decomposition of S-nitrosothiols; this observation suggests that these enzymes, may 
not contribute to the biological activitry of S-nitrosothiols in vascular tissue. 
Moreover, since xanthine oxidase and DPI have been reported to contain copper ions 
(Roussos & Morrow, 1966; Narindrasorasak et al., 2003), the inhibitory effects of 
copper cheltors on the bioactivation of S'-nitrosothiols should be interpreted with 
caution.
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Figure 3.18 Schematic representation showing the stereoisomers o f S-nitrosothiols bind 
in a non-stereospecific manner to copper-containing enzymes on the cell membrane 
leading to decomposition and release o f NO.
3.4.5 Effect of metal chelation on the response of rat aorta to S-nitrosothiols
Previous reports indicate that the biological activity of S-nitrosothioIs can be 
modulated by Cu(I) in platelets (Askew et al., 1995; Gordge et al., 1995), the rat 
isolated perfused tail artery (Al-Sa’doni et al., 1997) and murine cavemosum 
(Gocmen et al, 2000). Similarly, experiments with neocuproine and cuprizone, 
selective chelators of Cu(I) and Cu(II), respectively, in rat and mouse gastric smooth 
muscle provide evidence that Cu(I), and not Cu(II), modulate the biological activity of 
S-nitrosothiols (De Man et a l , 1999). In keeping with the conclusions from these
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studies (that endogenous Cu(I) plays a role in the generation of NO from S- 
nitrosothiols), I found that chelation of Cu(I) significantly inhibited the relaxations 
induced by S-nitrosothiols, suggesting that the biotransformation of S'-nitrosothiols in rat 
aorta is in part dependent on Cu(I) ions. The relaxations evoked by ACh and SPER-NO 
were not affected by BCS, ruling out a non-specific inhibitory action of specific Cu(I)- 
chelator on smooth muscle reactivity. Moreover, the differential effect of BCS on S- 
nitrosothiol-versus ACh-induced vasorelaxation suggests that an S-nitrosothiol does not 
represent EDRF in the rat aorta, as has been proposed (Myers at al., 1990).
There was evidence of differential sensitivity of S-nitrosothiols to Cu(I), with 
CYSNO being most sensitive to exogenous Cu(l) and most resistant to the protective 
effects of BCS. Presumably the greater sensitivity to Cu(I), results in the requirement 
for higher BCS concentration to inhibit relaxation. Other divalent metal ions such as 
Ca2+ and Mg2+ have been reported to decompose CYSNO but not GSNO (Kostka et 
al., 1999), supporting a heightened sensitivity of CYSNO to metal-catalysed 
breakdown.
3.4.6 Endogenous 5-nitrosothiols
The relaxant effect of Cu(I) was blocked by ODQ and denudation of the 
endothelium indicating that the effect is endothelium-dependent NO relaxation. 
However, the blocking effect of L-NAME indicates that the relaxant effect of Cu(I) is 
eNOS dependent rather than mediated by endogenous S-nitrosothiols. Further studies 
would be required to investigate this further.
3.4.7 Summary and conclusions
This chapter suggests that the biotransformation of S-nitrosothiols by rat aorta 
does not involve stereospecific decomposition, consistent with non-enzymatic release 
of NO. Biotransformation of S-nitrosothiols is in part dependent on Cu(I) ions.
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CHAPTER FOUR
DESENSITISATION OF SOLUBLE AND 
PARTICULATE GUANYLATE CYCLASES 
BY LIPOPOLYSACCHARIDE
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4.1 INTRODUCTION
Previous reports demonstrated that the sGC-cGMP system is influenced by 
the ambient concentration of NO (Hussain et al., 1999). Moreover, through a cGMP- 
dependent process, cross-talk between the sGC-cGMP and the pGC-cGMP systems 
might occur, such that the changes in the sensitivity of one pathway are mirrored by 
the other cGMP-generating system (Hussain et al., 2001; Madhani et al., 2003). 
Further evidence for desensitisation of sGC and pGC pathways by the ambient 
concentration of NO are described in more details in section 1.5.1. These 
observations support the hypothesis that the sGC-cGMP and pGC-cGMP pathways 
play a complementary role in regulating cardiovascular homeostasis. The 
physiological, pathophysiological and therapeutic significance of the interaction 
between sGC-cGMP and pGC-cGMP pathways is described in detail in section 1.5.3.
Inflammatory cardiovascular diseases are commonly associated with iNOS 
expression and ‘high-output’ (i.e. excessive) NO production (Julou-Schaeffer et al., 
1990; Fleming et al., 1991; Shah, 2000). Bacterial sepsis is a systemic inflammatory 
state characterised by vascular smooth muscle dysfunction, leading to hypotension, 
inadequate tissue perfusion, and organ failure. The disease is also associated with 
endothelial dysfunction, predominantly reduced vasodilator influence of eNOS- 
derived NO (Chauhan et al., 2003c). In animal models, sepsis has been mimicked by 
administration of LPS; such a protocol can also be used to induce iNOS expression in 
vitro and thereby permit study of isolated vascular rings. In this chapter, I examined 
whether the endothelial and smooth muscle dysfunction following exposure of 
vascular tissue to LPS alters responsiveness to both sGC and pGC pathways (i.e. NO 
and ANP) and if this dysfunction is specific to cGMP-dependent signalling.
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4.2 EXPERIMENTAL PROTOCOLS AND STATISTICS
4.2.1 Organ bath studies
Organ bath studies were performed on rings from rat (male; Sprague-Dawley; 
200-250 g) thoracic aorta. Vessel harvesting and preparation are as described in Chapter 
Two section 2.3.2.
4.2.1.1 Characterisation of the effect of LPS on contraction
Responses to PE (0.001-10pM; n=6) and U46619 (0.001-1 pM; n=10) were 
examined in vessels incubated with LPS (0.01-lpg/ml), or vehicle (saline) for 4hr. 
Constrictor responses to U46619 (0.001-lpM) were also determined after co­
incubation of vessels with LPS and the iNOS inhibitor, 1400W (lOpM; n=10), or the 
cyclooxygenase inhibitor, indomethacin (lOpM; n=10). Details of the IC5 0  of these 
inhibitors are described in Table 2.1.
4.2.1.2 Effect of LPS on sGC-mediated relaxation
Vessels were incubated with vehicle or LPS (0.3pg/ml) for 4hr and pre­
contracted with U46619 to an approximate ECgo. Concentration-response curves were 
constructed to ACh («=6), histamine («=5), SPER-NO (n= 12), BAY 58-2667 (n=7), 
GSNO (n=l) and SNP («=7). The effect of co-incubation of LPS with 1400W (lOpM; 
4hr; «=7), and indomethacin (lOpM; 4hr; «=5) on the response to ACh and SPER-NO 
was also determined.
4.2.1.3 Effect of LPS on pGC-mediated relaxation
Vessels were incubated with vehicle or LPS (0.3pg/ml) for 4hr and pre­
contracted with U46619 to an approximate ECso. Concentration-response curves were 
constructed to CNP (O.lnM-lpM; n—4) and ANP (O.OlnM-O.lpM; «=10). The effect
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of co-incubation of LPS with 1400W (lOpM; n=6), ODQ (5pM; n=l), or both ODQ 
and 1400W («=5), on the response to ANP was determined.
4.2.1.4 Effect of LPS on the sensitivity of vessels to cGMP
Vessels were incubated with vehicle or LPS (0.3pg/ml) for 4hr and pre­
contracted with U46619 to an approximate ECgo. Concentration-response curves were 
constructed to 8-bromoguanosine-3’,5’-cyclic monophosphate (8-Br-cGMP; 
l-300pM; n=5). In further studies, LPS-treated vessels were co-incubated with both 
ODQ (5pM) and 1400W (lOpM; «=5) for 4hr, after which the response to 8-Br-cGMP 
was determined («=5). To assess the effects of prolonged exposure of vessels to an 
NO donor on cGMP-mediated dilatation, vessels were incubated with glyceryl 
trinitrate (GTN) alone (30pM; «=4) or GTN (30pM) and ODQ (5pM; n=4) for 4hr. 
Vessels were pre-contracted with U46619 to an approximate ECgo and concentration- 
response curves were constructed to 8-Br-cGMP (l-300p.M).
4.2.1.5 Effect of LPS on cAMP-mediated relaxation
Vessels were incubated with vehicle or LPS (0.3pg/ml) for 4hr and pre­
contracted with U46619 to an approximate ECgo- Concentration-response curves to 
forskolin (0.001-1 pM; n—1) or 8-Bromoadenosine-3’,5’-cyclic monophosphate 
(8-Br-cAMP; l-300pM; n=A) were constructed.
4.2.1.6 Reversibility of desensitisation of cGMP-mediated relaxation
To determine whether LPS-induced changes in cGMP-mediated relaxation 
were reversible, vessels were incubated with LPS (0.3pg/ml) for 4hr, after which 
ODQ (5pM; «=7), 1400W (lOpM; «=7) or both (n=5) were added to the LPS-treated 
rings. Tissues were pre-contracted with U46619 to an approximate ECgo and
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concentration-response curves to ANP (O.OlnM-O.lpM) or 8-Br-cGMP (l-300pM) 
were constructed.
4.2.2 Western blotting
Western blotting was used to detect iNOS protein following incubation of the 
tissues with LPS (0.3pg/ml; 4hr) in vitro. Aortic rings were removed from the organ 
bath, wrapped in aluminium foil, immediately snap frozen in liquid nitrogen and then 
stored at -80°C. Details of sample preparation, protein separation and identification 
by western blotting are described in section 2.6
4.2.3 Statistics
Organ bath studies are expressed as described in section 2.8. All curves were 
analysed by TW-ANOVA and where appropriate Bonferroni’s correction (BC) was 
applied.
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4.3 RESULTS
4.3.1 Effect of LPS on contraction
Incubation of rat aorta rings with LPS (0.01-1 pg/ml) for 4hr significantly 
reduced the response to PE (Figure 4.1 A). It was not possible to achieve stable pre­
contractions to PE after LPS treatment. Incubation of vessels with LPS (0.3pg/ml; 
4hr) also reduced the sensitivity to U46619 (pECso: 7.27±0.17 versus 6.63±0.17 in the 
absence and presence of LPS, respectively; n=10; P<0.05; Figure 4.IB). Co­
incubation with 1400W (lOpM) significantly reversed the LPS-induced 
hyporeactivity to U46619 (pECso: 7.44±0.17; n=10; P<0.05 versus LPS alone), 
whereas co-incubation with indomethacin (lOpM) had no effect (pECso: 6.34±0.27; 
«=10; P>0.05 versus LPS alone; Figure 4.IB). U46619 caused stable contractions in 
vessels incubated with LPS and was therefore used in all subsequent experiments to 
pre-contract tissues similarly (approximate EC80: -0.1 pM in control tissues and -0.3 
pM in LPS-treated tissues). Curves were compred by TW-ANOVA with BC.
4.3.2 Effect of LPS on relaxation
4.3.2.1 Effect of LPS on sGC-mediated relaxation
Incubation of rat aortic rings with LPS (0.3pg/ml, 4hr) significantly reduced 
the potency of ACh (pECso: 7.77±0.27 versus 6.99±0.39 in the absence and presence 
of LPS, respectively; n=6; P<0.05; Figure 4.2A), histamine (pECso: 6.22±0.33 versus 
5.96±0.25; n=5; P<0.05; Figure 4.2B), SPER-NO (pEC50: 7.08±0.35 versus 
6.34±0.63; n=12; P<0.05; Figure 4.3A), BAY 58-2667 (pECso: 8.13±0.26 versus 
6.31±0.39; n=7; P<0.05; Figure 4.3B) GSNO (pEC50: 7.14±0.37 versus 6.87±0.17; 
n=7; P<0.05; Figure 4.3C) and SNP (pECso: 8.96±0.28 versus 7.49±0.41; »=7; 
P<0.05; Figure 4.3D). Incubation of vessels with 1400W (lOpM) preserved relaxation 
to ACh after administration of LPS (pECso: 7.18±0.23 versus 7.80±0.357 in the 
absence and presence of 1400W, respectively; n=7; P<0.05; Figure 4.4A). Incubation 
with indomethacin (1M; lOpM) had no effect on responses to ACh (pEC5o: 7.35±0.39; 
n=5; P>0.05; Figure 4.4A). 1400W (lOpM) alone had no effect on responses to ACh 
(pECso: 7.77±0.27 versus 7.92±0.32 in the absence and presence of 1400W, 
respectively; n=3; Z^O.05; Figure 4.4A). Responses to SPER-NO were also restored
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by 1400W (pECso: 6.47±0.68 versus 6.94±0.17 in the absence and presence of 
1400W, respectively; n= 5; P<0.05) but not by indomethacin (pECso: 6.13±1.2; n=4; 
P>0.05; Figure 4.4B). All curves were compred by TW-ANOVA with BC.
4.1A
eoo
n©cN
120
00
80
60
40
20
0
-8 -7 -6 -5
Log [Phenylephrine] (M)
Phenylephrine 
LPS (0.01 pg/ml) 
LPS (0.1 pg/ml) 
LPS (1 pg/ml)
4.1B
■ U46619 
□ LPS
•  LPS+1400W 
O LPS+IM
Log [U46619] (M)
Figure 4.1 Concentration-response curves to (A) PE (InM-lOjuM) following 4hr 
incubation with vehicle or LPS (0.01-1 pg/ml; n=6) and (B) U46619 (InM-lpM) 
following 4hr incubation with vehicle, LPS (0.3pg/ml), LPS plus 1400W (lOpM) or 
LPS plus indomethacin (IM;10juM; n=10). Contraction is expressed as the 
percentage o f the contraction to KCl (48mM). Each point represents mean ± SEM.
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Figure 4.2 Concentration-response curves to (A) ACh (InM-lpM) and (B) histamine 
(InM-lOpiM) following 4hr incubation with vehicle or LPS (0.3pig/ml); n=5. 
Relaxation is expressed as the percentage reversal o f the U46619-induced tone. Each 
point represents mean ± SEM.
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Figure 4.3 Concentration-response curves to (A) SPER-NO (InM-lpM), (B) BAY58- 
2667 (InM-lpM), (C) GSNO (lnM-lpM) and (D) SNP (O.lnM-lpM) following 4hr 
incubation with vehicle or LPS (0.3jug/ml); n=5. Relaxation is expressed as the 
percentage reversal o f the U46619-induced tone. Each point represents mean ± SEM
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Figure 4.4 Concentration-response curves to (A) ACh (InM-lpM) and (B) SPER-NO
(InM-lpM) following 4hr incubation with vehicle, LPS (0.3pg/ml), 1400W (lOpM), 
LPS plus 1400W or LPS plus indomethacin (IM; lOpM); n>3. Relaxation is expressed 
as the percentage reversal o f the U46619-induced tone. Each point represents mean 
±SEM.
127
4.3.2.2 Effect of LPS on pGC-mediated relaxation
LPS (0.3pg/ml; 4hr) significantly reduced the potency of CNP (pECso: 
7.38±0.41 versus 6.54±0.44 in the absence and presence of LPS, respectively; w=4; 
P<0.05; Figure 4.5). Similarly, LPS (0.3pg/ml; 4hr) significantly reduced the potency 
of ANP (pECso: 8.95±0.17 versus 8.05±0.26 in the absence and presence of LPS, 
respectively; «=10; /><0.05; Figure 4.6). Co-incubation with 1400W (lOpM) with LPS 
preserved responses to ANP (pEC5o: 8.44± 0.29; n=6; P<0.05 versus LPS alone). 
Similarly, co-incubation with ODQ (5 pM), preserved relaxation to ANP (pECso: 
8.59±0.37; n=7; P<0.05 versus LPS alone). In the presence of both ODQ and 1400W, 
relaxation to ANP was fully restored (pEC5o: 8.89±0.38, n - 5; P<0.05 versus LPS 
alone; Figure 4.6). However, 1400W (lOpM) alone had no effect on responses to 
ANP in control tissues (pECso: 8.68±0.53 versus; n=3; ^>0.05 versus control; Figure 
4.6). Comparisons were done by TW-ANOVA with BC.
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Figure 4.5 Concentration-response curves to CNP (0. InM-lpM) following 4hr 
incubation with vehicle or LPS (O.Spg/ml); n=4. Relaxation is expressed as the 
percentage reversal o f the U46619-induced tone. Each point represents mean ± SEM.
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Figure 4.6 Concentration-response curves to ANP (0.0lnM-0. IpM) following 4hr 
incubation with vehicle, LPS (0.3pg/ml), LPS plus 1400W (lOpM), LPS plus ODQ 
(5pM) or LPS plus both ODQ and 1400W; n=5. Relaxation is expressed as the 
percentage reversal o f the U46619-induced tone. Each point represents mean ± SEM.
4.3.2.2.1 Reversibility of desensitisation of ANP-mediated relaxation
Incubation with LPS (0.3pg/ml) for 4 hrs significantly reduced the potency of 
ANP (pECso: 9.29±0.41 versus 7.91 ±.36 in the absence and presence of LPS, 
respectively; n=5; /><0.05). The responsiveness to ANP was restored immediately by 
addition of 1400W (lOpM; pECso 8.26±0.25; n=7; P<0.05 versus LPS alone), ODQ 
(5pM; pEC5o: 8.83±0.18; n=7; P<0.05 versus LPS alone) or both (pECso: 9.02±0.38; 
n=5; /><0.05 versus LPS alone; Figure 4.7). Curves were compared by TW-ANOVA 
with BC.
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Figure 4.7 Concentration-response curves to ANP (0.01nM-0. 1/j.M) following 4hr
incubation with vehicle or LPS (0.3pg/ml). At 4hr, 1400W (lOpM), ODQ (5pM) or 
both ODQ plus 1400W were added to LPS-treated vessels; n=5. Relaxation is 
expressed as the percentage reversal o f  the U46619-induced tone. Each point 
represents mean ± SEM.
4.3.2.3 Effect of LPS on the sensitivity of vessels to cGMP
LPS (0.3pg/ml; 4hr) significantly reduced the potency of 8-Br-cGMP (pECso: 
4.9±0.2 versus 3.91±0.22 in the absence and presence of LPS, respectively; n - 5; 
P<0.05; figure 4.8A). Co-incubation with both 1400W (10pM) and ODQ (5jjM) with 
LPS preserved the relaxations to 8-Br-cGMP (pEC5o: 4.64±0.34; n=5; P<0.05 versus 
LPS alone; Figure 4.8A). Similarly, ODQ and 1400W immediately restored 
responsiveness to 8-Br-cGMP following 4hr incubation with LPS (pECso: 3.91±0.22 
versus 4.95±0.36 in the absence and presence of ODQ and 1400W; n=5; P<0.05; 
Figure 4.8A). Incubation with GTN (30pM) for 4 hrs also reduced the potency of 8- 
Br-cGMP (pECso: 4.48±0.15 versus 4.98±0.26 in the presence and absence of GTN 
respectively; n= 4; P<0.05 Figure 4.8B). Co-incubation of ODQ (5pM) with GTN 
preserved the relaxations to 8-Br-cGMP (pECso: 4.74±0.15; n=4; P<0.05 versus GTN 
alone; Figure 4.8B). Cureves were compared by TW-ANOVA with BC.
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Figure 4.8 Concentration-response curves to (A) 8-Br-cGMP (1-SOOp.M) following 
4hr incubation with vehicle, LPS (0.3jug/ml), or LPS plus both 1400W (lOpM) and 
ODQ (5pM), or 4 hrs incubation with LPS (0.3jug/ml) and addition o f 1400Wplus 
ODQ at the 4hr timepoint (n=5) and (B) 8-Br-cGMP (l-300pM) following 4hr 
incubation with vehicle, GTN (30pM), or GTN plus ODQ (5pM); n=4. Relaxation is 
expressed as the percentage reversal o f the U46619-induced tone. Each point 
represents mean ± SEM.
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4.3.2A Effect of LPS on cAMP-mediated relaxation
LPS (0.3pg/ml; 4hr) had no effect on the potency of the adenylate cyclase 
activator, forskolin, (pECso: 6.15±0.74 versus 6.52±0.36 in the absence and presence 
of LPS, respectively; n=6; P>0.05; Figure 4.9A) or 8-Br-cAMP (pECso: 3.43±0.26 
versus 3.58±0.21 in the absence and presence of LPS, respectively; n=4; />>0.05; 
Figure 4.9B). Cureves were compared by TW-ANOVA.
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Figure 4.9 Concentration-response curves to (A) forskolin (InM-lpM; n=6) and (B) 
8-Br-cAMP (1-300/iM; n=4) following 4hr incubation with vehicle or LPS 
(0.3jug/ml). Relaxation is expressed as the percentage reversal o f the U46619- 
induced tone. Each point represents mean ± SEM.
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4.33  Detection of iNOS protein in LPS treated vessels
In the absence of LPS treatment, there was no detectable iNOS expression 
(Figure 4.10A). However, iNOS was detected in aortic rings treated with LPS 
(0.3pg/ml; 4hr) Figure 4.10B.
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Figure 4.10 Detection o f iNOS protein by western blotting following incubation o f  
vessels with (A) vehicle (B) LPS (0.3pg/ml; 4hr); n=5.
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4.4 DISCUSSION
This chapter demonstrates that exposure of rat aorta to LPS reduces the 
sensitivity of both sGC- and pGC-mediated relaxation. Desensitisation can be 
prevented by iNOS inhibition, consistent with iNOS-derived NO down-regulates both 
pathways. The effect is specific for cGMP signalling, since cAMP-mediated 
relaxation is unaffected. Desensitisation is mediated, at least in part, by cGMP 
generation, because inhibition of NO-mediated cGMP synthesis with ODQ partially 
restores sensitivity to ANP. Moreover, desensitisation of ANP-mediated dilatation is 
rapidly reversible, consistent with a mechanism dependent on altered activity of 
constitutive pathways rather than one requiring new protein synthesis. LPS also 
reduced the sensitivity to the cGMP analogue, 8 -Br-cGMP, implicating down- 
regulation of G-kinase (or an alternate distal step) in the mechanism of 
desensitisation.
Previous reports have shown that the NO-cGMP system is influenced by the 
prevailing concentration of NO and cGMP (Hussain at al., 1999). Exposure of the 
tissue to high concentrations of NO results in the reduction of the responses to 
subsequent application of NO or NO donors. Moreover, it has been identified that 
cross-talk between the NO-sGC-cGMP and the ANP-pGC-cGMP systems occurs, 
such that the changes in the sensitivity of one pathway are mirrored by the other 
cGMP-generating system (Hussain et al., 2001; Madhani et al., 2003). NO-donors 
reduce the sensitivity of murine aorta to ANP, an effect that is reduced by prevention 
of cGMP production with ODQ; conversely ANP reduces responsiveness to NO 
(Madhani et al., 2003). These observations directly implicate cGMP as a mediator of 
desensitisation of the cyclase pathways in response to GC activation.
It has been shown that iNOS-derived NO also desensitises blood vessels to 
NO donors, but the mechanism has not been described in detail (Chauhan at al., 
2003c; Bogle at al., 2000). In the present study, incubation with LPS was used to 
elicit iNOS induction (as confirmed by western blotting) and exposure of vessels to
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’high-output’ NO. LPS treatment reduced constrictor responses to PE and U46619, 
and hyporeactivity to U46619 was reversed by specific iNOS inhibition with 1400W, 
consistent with previous findings that hyporeactivity to vasoconstrictors in septic 
shock is in part a result of production of high output iNOS-derived NO (O’Brien et 
al., 2001 ;Miyamoto et al., 2004). Despite the reduction in response, contractions to 
U46619 (unlike PE) were sufficiently stable to investigate whether LPS-treatment 
induced vasodilator dysfunction. LPS-treatment reduced responses to the 
endothelium-dependent agonists (ACh and histamine) and SPER-NO, effects that 
were prevented by 1400W but not indomethacin. These data suggest that the principal 
cause of dilator dysfunction is iNOS-derived NO leading to reduced sensitivity of the 
vascular smooth muscle. The observed reduction in the sensitivity of sGC-cGMP 
pathway also extended to NO-independent activation of sGC, as responses to the 
direct sGC activator, BAY 58-2667, were also diminished in a similar fashion.
To investigate whether there was a generalised reduction in responses to GC 
activation, the response to CNP and ANP was used to determine the sensitivity of 
pGC in control and LPS-treated vessels. CNP and ANP-mediated relaxation was 
impaired, with restoration of the responses to ANP achieved by iNOS or sGC 
inhibition; indeed the combination of both 1400W and ODQ normalised responses to 
ANP. These data demonstrate that LPS causes an NO- and cGMP- dependent 
reduction in the responsiveness of vascular smooth muscle to activation of sGC and 
pGC. The reduction in sensitivity was specific to the sGC and pGC pathways because 
the direct adenylate cyclase activator forskolin and the cell permeable cAMP 
analogue, 8 -Br-cAMP, were equipotent in control and LPS-treated vessels. It is 
possible that different pre-contracting concentrations of U46619 in the presence and 
absence of LPS might affect the magnitude of relaxation. However, since the 
desensitisation is specific to the cGMP pathway (i.e. not cAMP), a potential 
confounding influence of different U46619 concentrations is unlikely.
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The mechanism of desensitisation of pGC is at least in part dependent on 
cGMP generation, evidenced by the effect of ODQ. Desensitisation to ANP was also 
rapidly reversible, because addition of ODQ and/or 1400W restored responsiveness 
within minutes, suggesting that desensitisation of pGC pathway is a consequence of 
biochemical rather than expressional changes in enzyme activity.
These observations are consistent with other previous findings using NO 
donors to induce GC desensitisation in murine aorta (Hussain at al., 1999). However, 
these studies indicated that the response to cGMP itself was unaffected by NO- 
induced desensitisation of the cyclase pathways. In the present study, I used 8 -Br- 
cGMP to determine the sensitivity of G-kinase and down-stream effector pathways in 
LPS-treated tissues. Responses to 8 -Br-cGMP were reduced in LPS-treated vessels 
suggesting that G-kinase activity might be reduced. Prolonged exposure of vessels to 
high concentrations of GTN also reduced the response to 8 -Br-cGMP, raising the 
possibility that with longer exposure of tissues to excess NO/cGMP, desensitisation 
occurs in distal parts of the cGMP signalling pathway. In both cases, inhibition of 
cGMP synthesis by ODQ partially restored the response to 8 -Br-cGMP, indicating 
that under these conditions, the response to cGMP is regulated by a classical negative 
feedback mechanism. Further studies will be necessary to delineate the components 
of this feedback loop.
These results extend the prior observations of the reciprocal regulation of 
ANP/NO signalling (Hussain et al., 2001; Madhani et al., 2003). This phenomenon 
has now been identified in murine, human and rat tissues, occurs in vivo (Sabrane et 
al., 2003), and largely accounts for vasodilator dysfunction in pathological states 
associated with iNOS induction (Chauhan et al., 2003c). It might also provide a 
mechanism to explain the link between the sustained increases in endogenous BNP 
and cardiovascular risk that has been reported recently in a variety of patient groups 
(Wang et al., 2004). Relaxation to GSNO was also desensitised by LPS implying that 
the responses to S-nitrosothiols are affected by similar desensitisation mechanisms as 
other NO-donors. There is no evidence that LPS induces a bioactivation mechanism 
of GSNO to modify the response to this NO-donor.
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Thus, altered vascular smooth muscle responsiveness to endogenous NO and 
ANP is a fundamental physiological mechanism within the blood vessel that is likely 
to play an important role in vascular tone and blood flow. It is possible that in 
vascular inflammation associated with bacterial sepsis, desensitisation of smooth 
muscle and platelet cGMP pathways contributes to microvascular constriction, 
thrombosis and tissue hypoxia (Vallet, 2003). Moreover, this mechanism has 
implications for the development of tolerance to NO or GC activators administered as 
therapy for angina and heart failure and the fluid retention in patients receiving 
nitrates. In particular, these data suggest that tolerance is a likely consequence of any 
vasodilator that is cGMP-mediated.
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CHAPTER FIVE
MECHANISMS OF DESENSITISATION 
BY LIPOPOLYSACCHARIDE
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5.1 INTRODUCTION
I have shown in chapter 4 that incubation of LPS with rat aorta resulted in the 
induction of iNOS. This in turn resulted in desensitisation of both the sGC and pGC 
signalling pathways. However, the mechanism(s) by which high output NO 
desensitises both sGC and pGC are unknown. The aim of this chapter was to explore 
mechanisms of the desensitisation using a pharmacological approach. A variety of 
mechanisms have been implicated in regulation of the sensitivity of GC signalling. 
These have been discussed in detail in Chapter 1 but are briefly discussed below.
Certain PDEs play an important role in the regulation of cGMP-signalling 
pathways (Rybalkin et al., 2003). In the rat, following induction of GTN tolerance in 
vivo, desensitisation of rat aortic rings in vitro to GTN was reversed by treatment with 
a selective cGMP phosphodiesterase (PDE5) inhibitor (De Garavilla et al., 1996). In 
addition, in this model of reduced responsiveness to sGC activation, there is also 
evidence of increased activity and expression of other PDE isoenzymes, specifically 
PDE1A1 (Kim et al, 2001). PDE3 may be involved in inflammatory vascular disease 
(Kondo et al., 1999). Protein kinase C (PKC) activation has also been shown to play a 
role in the regulation of guanylate cyclases, since it desensitises both sGC (Morrison 
et al., 1990; Murphy et al., 1994) and pGC (Potter & Garbers, 1994). However, the 
PKC-isozymes(s) causing this desensitisation is uncertain. Pathways that specifically 
regulate the sensitivity of sGC or pGC also appear to exist. For instance, 
desensitisation of pGC by protein phosphatase 2 A (PP2A) is well established (Potter 
& Garbers, 1992), possibly via activation by PKG (Zhou et al., 1996). In contrast, 
generation of oxygen free radicals (e.g. superoxide) is associated with impairment of 
NO-sGC signalling via scavenging of NO (Xia & Zweier, 1997; Stoclet et al, 1999) 
and by direct oxidation of sGC protein thiols (Mingone et al., 2006). Similarly, 
neutrophil-derived myeloperoxidase (MPO) modulates NO-mediated vasodilator 
responses during acute inflammation through its ability to generate free radicals 
(Eiserich et al., 2002).
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One approach to assess the roles of various signalling pathways in biological 
systems is to inhibit or activate certain components in the pathway of interest and 
observe the changes that occur. To investigate the mechanism(s) of NO-induced 
desensitisation of sGC and pGC, pharmacological tools (specific inhibitors or 
activators) were used to probe the putative roles of PDEs (types 1A1, 3 and 5), PKC, 
PP2A, SOD and MPO.
5.2 EXPERIMENTAL PROTOCOLS AND STATISTICS
5.2.1 Effect of LPS on the sensitivity of GC in the presence of sildenafil
Vessels were incubated with vehicle (DMSO; 0.03%), the PDE-5 inhibitor 
sildenafil (3pM), LPS (0.3pg/ml) or both LPS and sildenafil for 4 hrs. Vessels were 
pre-contracted with U46619 to an approximate ECgo and concentration-response 
curves to SPER-NO (InM-lOpM; n=4) and ANP (O.OlnM-O.lpM; n - 4) were 
constructed. Details of the IC50 of sildenafil and the other inhibitors used in this Chapter 
are described in Table 2.1.
5.2.2 Effect of LPS on the sensitivity of GC in the presence of vinpocetine
Vessels were incubated with vehicle (DMSO; 1%), the PDE-1A1 inhibitor 
vinpocetine (lOOpM; 30 mins pre-incubation), LPS (0.3pg/ml; 4hr) or both LPS and 
vinpocetine. Unlike other inhibitors, which inhibit PDE1 indirectly by binding to 
calmodulin, vinpocetine causes its effect by direct interaction with PDE1A1. The I C 5 0  
of vinpocetine was reported previously as 20pM (Hagiwara et al., 1984), but recent 
studies in rat aortic rings showed significant effects at 100pM when incubated for 30 
mins (Kim et al., 2001). Vinpocetine was added 30 mins before pre-contraction and 
at 4 hrs, vessels were pre-contracted with U46619 to an approximate ECso and 
concentration-response curves to SPER-NO (InM-lOpM; n=5) and ANP (0.0 lnM- 
0.1 pM; n=6 ) were constructed.
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5.2.3 Effect of LPS on the sensitivity of GC in the presence of milrinone
Vessels were incubated with vehicle (DMSO; 0.1%), the PDE-3 inhibitor 
milrinone (lOpM; 30 mins pre-incubation), LPS (0.3pg/ml; 4hr) or both LPS and 
milrinone. Milrinone was added 30 mins before pre-contraction and at 4 hrs vessels 
were pre-contracted with U46619 to an approximate ECgo and concentration-response 
curves to SPER-NO (InM-lOpM; n=4) and ANP (O.OlnM-O.lpM; n= 4) were 
constructed.
5.2.4 Effect of LPS on the sensitivity of sGC in the presence of SOD
Vessels were incubated with vehicle, SOD (2000units/ml; 4hr), LPS 
(0.3pg/ml; 4hr) or both LPS and SOD for 4hr. Vessels were pre-contracted with 
U46619 to an approximate ECgo and concentration-response curves were constructed 
to SPER-NO (InM-lpM; n= 4) and ACh (lnM-lpM; «=3).
5.2.5 Effect of LPS on the sensitivity of sGC in the presence of 4-aminobenzoic 
hydrazide
Vessels were incubated with vehicle (DMSO; 0.01%), the MPO inhibitor 4- 
aminobenzoic hydrazide (ABAH; lOpM; 30 mins), LPS (0.3pg/ml; 4hr) or both LPS 
and ABAH. ABAH is a suicide substrate that promotes inactivation of MPO through 
modulation of its haem group leading to the formation of the inactive ferrous enzyme 
(Kettle et al, 1995). ABAH was added 30 mins before pre-contraction and at 4 hrs 
vessels were pre-contracted with U46619 to an approximate ECgo and concentration- 
response curves to SPER-NO (InM-lOpM; «=4) were constructed.
5.2.6 Effect of the PKC activators on the sensitivity of GC and AC
Concentration-response curves to phorbol 12-myristate 13-acetate (PMA; 
lnM-10pM), and potassium chloride (KC1; 1-lOOmM) were constructed to determine 
their ECgo- PMA causes contraction via direct activation of PKC (it non-selectively 
activates both the conventional PKC isoforms a, p, and y and the novel PKC isoforms 
e, r\, 0, 8 and p; Tsao & Wang, 1997; Kim et al., 1997; Krotova et al., 2003) while 
KC1 causes contraction in a PKC-independent manner by opening dihydropyridine-
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sensitive voltage-gated Ca2+ channels (Ratz et al., 2005). Vessels were pre-contracted 
with PMA, U46619 and KC1 to an approximate ECso of their maximum contraction 
and concentration-response curves to ACh (InM-lOpM; n=4), SPER-NO (lnM- 
lOpM; n=4), ANP (O.OlnM-O.lpM; n=4), 8-Br-cGMP (l-300pM; n=4) and forskolin 
(InM-lpM; n=4) were constructed.
To determine roles for specific PKC isoforms in the desensitisation of GC and 
AC, vessels were equipotently pre-contracted with the selective PKC activator 
thymeleatoxin (a phorbol ester that selectively activates the conventional-PKC 
isoforms a, p and y; Ryves et al., 1991; Armstrong & Ganote, 1994; Llosas et al., 
1996; Krotova et al., 2003) and U46619 and concentration-response curves to ACh 
(InM-lOpM; n=4), SPER-NO (InM-lOpM; n=4), ANP (O.OlnM-O.lpM; n=4) and 
forskolin (lnM-lpM; n= 4) were constructed.
5.2.7 Effect of LPS on the sensitivity of GC and AC in the presence of protein 
phosphatase 2A inhibitors
Vessels were incubated with vehicle (DMSO; 0.03%), okadaic acid (300nM; 
30 mins) or cantharidic acid (500nM; 30 mins; both are PP2A inhibitors; Bialojan & 
Takai, 1988; Li & Casida, 1992), LPS (0.3pg/ml; 4hr) or both LPS plus okadaic acid 
or cantharidic acid. Okadaic acid or cantharidic acid was added 30 mins before pre­
contraction and at 4 hrs vessels were pre-contracted with U46619 to an approximate 
ECgo and concentration-response curves to ANP (0.01nM-0.1pM; n=5) were 
constructed. In some experiments, concentration-response curves were also 
constructed to SPER-NO (InM-lOpM; «=4) and forskolin (InM-lpM; n=A) in the 
presence of okadaic acid.
5.2.8 Statistics
Organ bath studies are expressed as described in section 2.8. All curves were 
analysed by TW-ANOVA and where appropriate Bonferroni’s correction (BC) was 
applied.
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5.3 RESULTS
5.3.1 Effect of LPS on sGC-mediated relaxation in the presence of sildenafil
Incubation of aortic rings with LPS (0.3pg/ml) for 4 hrs significantly reduced the 
potency of SPER-NO (pECso: 6.89±0.26 versus 6.15±0.38 in the absence and presence 
of LPS, respectively; n=4; P<0.05). The PDE5 inhibitor sildenafil (3pM) had no 
effect on the relaxations to SPER-NO in the presence of LPS (pEC5o: 5.89±0.43 in the 
presence of sildenafil; n=4; Z^O.05 versus LPS alone; Figure 5.1). Sildenafil 
significantly reduced responses to U46619 and enhanced the relaxation to SPER-NO 
(pEC50: 7.54±0.24 in the presence of sildenafil; n= 4; P<0.05 versus control; Figure 
5.1). Curves were compared by TW-ANOVA with BC.
Figure 5.1 Concentration-response curves to SPER-NO (InM-lOpM) following 4hr 
incubation with vehicle, LPS (0.3pg/ml), sildenafil (3pM) or LPS plus sildenafil; 
n=4. Relaxation is expressed as the percentage reversal o f the U46619-induced tone. 
Each point represents mean ± SEM.
5.3.2 Effect of LPS on pGC-mediated relaxation in the presence of sildenafil
Incubation of aortic rings with LPS (0.3pg/ml) for 4 hrs significantly reduced the 
potency of ANP (pECso: 8.97±0.26 versus 8.27±0.65 in the absence and presence of
00 ■ SPER-NO 
□ Sildenafil 
•  LPS
O LPS+Sildenafil
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LPS, respectively; n=4; / ,<0.05; BC). Sildenafil (3pM) had no effect on relaxations 
to ANP in the presence of LPS (pEC5o: 8.38±0.39 in the presence of sildenafil; n= 4; 
/ >>0.05 versus LPS alone; Figure 5.2). Sildenafil significantly reduced responses to 
U46619, but had no effect on the relaxation to ANP (pECso: 9.23±0.2 in the presence 
of sildenafil; n=4; P>0.05 versus control). Curves were compared by TW-ANOVA.
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Figure 5.2 Concentration-response curves to ANP (0.01nM-0. 1/j.M) following 4hr 
incubation with vehicle, LPS (0.3pg/ml), sildenafil (3pM) or LPS plus sildenafil; 
n=4. Relaxation is expressed as the percentage reversal o f the U46619-induced tone. 
Each point represents mean ± SEM.
5.3.3 Effect of LPS on sGC-mediated relaxation in the presence of vinpocetine
As expected, incubation of rat aortic rings with LPS (0.3pg/ml) for 4 hrs 
significantly reduced the potency of SPER-NO (pECso: 6.31±0.22 versus 5.72±0.28 in 
the absence and presence of LPS, respectively; n=5; P<0.05; BC). The PDE1A1 
inhibitor, vinpocetine (lOOpM), had no effect on the relaxations to SPER-NO in the 
presence of LPS (pEC50: 5.75±0.24 in the presence of vinpocetine; n=5; / >>0.05 
versus LPS alone; Figure 5.3). Vinpocetine significantly reduced responses to 
U46619, but had no effect on the relaxation to SPER-NO (pECso: 6.30±0.15 in the
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presence of vinpocetine; n—5; />>0.05; versus control). Curves were compared by 
TW-ANOVA.
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Figure 5.3 Concentration-response curves to SPER-NO (lnM-10pM) following 
incubation with vehicle, LPS (0.3jug/ml; 4 hrs), vinpocetine (100pM; 30 mins) or LPS 
plus vinpocetine; n=5. Relaxation is expressed as the percentage reversal o f the 
U46619-induced tone. Each point represents mean ± SEM.
5.3.4 Effect of LPS on pGC-mediated relaxation in the presence of vinpocetine
Similarly, incubation of rat aortic rings with LPS (0.3pg/ml) for 4 hrs 
significantly reduced the potency of ANP (pECso: 8.76±0.13 versus 7.92±0.24 in the 
absence and presence of LPS, respectively; n=6; P<0.05; BC). Co-incubation with 
vinpocetine (100pM) had no effect on the relaxations to ANP in the presence of LPS 
(pECso: 8.98±0.26 in the presence of vinpocetine; n=6; P>0.05; versus LPS alone; 
Figure 5.4). Vinpocetine significantly reduced responses to U46619, but had no effect 
on the relaxation to ANP (pECso: 8.98±0.16 in the presence of vinpocetine; n=6; 
P>0.05 versus control). Curves were compared by TW-ANOVA.
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Figure 5.4 Concentration-response curves to ANP (0.01nM-0. IjuM) following 
incubation with vehicle, LPS (0.3pg/ml; 4 hrs), vinpocetine (100juM; 30 mins) or LPS 
plus vinpocetine; n=6. Relaxation is expressed as the percentage reversal o f the 
U46619-induced tone. Each point represents mean ± SEM.
5.3.5 Effect of LPS on sGC-mediated relaxation in the presence of milrinone
Treatment of rat aortic rings with LPS (0.3pg/ml) for 4 hrs significantly reduced 
the potency of SPER-NO (pECso: 6.79±0.38 versus 5.63±0.29 in the absence and 
presence of LPS, respectively; n= 4; P<0.05; BC). The PDE 3 inhibitor, milrinone 
(lOpM) had no effect on the relaxations to SPER-NO in the presence of LPS (pECso: 
5.86±0.38 in the presence of milrinone; n= 4; P>0.05; versus LPS alone; Figure 5.5). 
Milrinone significantly reduced responses to U46619, but had no effect on the 
relaxation to SPER-NO (pEC5o: 6.55±0.18 in the presence of milrinone; n= 4; P>0.05 
versus control). Curves were compared by TW-ANOVA.
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Figure 5.5 Concentration-response curves to SPER-NO (InM-lOpM) following 
incubation with vehicle, LPS (0.3pg/ml; 4 hrs), milrinone (10pM; 30 mins) or LPS 
plus milrinone; n=4. Relaxation is expressed as the percentage reversal o f the 
U46619-induced tone. Each point represents mean ± SEM.
5.3.6 Effect of LPS on pGC-mediated relaxation in the presence of milrinone
Treatment of rat aortic rings with LPS (0.3fig/ml) for 4 hrs significantly reduced 
the potency of ANP (pECso: 8.74±0.32 versus 8.20±0.58 in the absence and presence 
of LPS, respectively; n=4; /><0.05; BC). Milrinone (lOpM) had no effect on the 
relaxations to ANP in the presence of LPS (pECso: 7.99±0.34 in the presence of 
milrinone; n=4; / >>0.05 versus LPS alone; Figure5.6). Milrinone significantly 
reduced responses to U46619, but had no effect on the relaxation to ANP (pECso: 
8.55±0.19 in the presence of milrinone; n=4; P>0.05 versus control). Curves were 
compared by TW-ANOVA.
147
ANP
Milrinone
LPS
LPS+Milrinone
Log [ANP] (M)
Figure 5.6 Concentration-response curves to ANP (0.01nM-0.lpM) following
incubation with vehicle, LPS (0.3pg/ml; 4 hrs), milrinone (lOpM; 30 mins) or LPS 
plus milrinone; n=4. Relaxation is expressed as the percentage reversal o f the 
U46619-induced tone. Each point represents mean ± SEM.
5.3.7 Effect of LPS on sGC-mediated relaxation in the presence of superoxide 
dismutase
Incubation of rat aortic rings with LPS (0.3pg/ml) for 4 hrs significantly reduced 
the potency of ACh (pECso: 8.04+0.43 versus 7.16+0.35 in the absence and presence 
of LPS, respectively; n=3; /><0.05; BC). SOD (2000U/ml) had no effect on the 
relaxations to ACh in the presence of LPS (pEC50: 7.15+0.77 in the presence of SOD; 
n=3; P>0.05 versus LPS alone; Figure 5.7A). SOD alone had no effect on the 
relaxation to ACh (pECso: 8.0+0.47 in the presence of SOD; n=3; P>0.05 versus 
control). Similarly, LPS significantly reduced the potency of SPER-NO (pECso: 
7.12+0.35 versus 6.51+0.73 in the absence and presence of LPS, respectively; n= 4; 
P<0.05; BC). SOD (2000U/ml) had no effect on the relaxations to SPER-NO in the 
presence of LPS (pECso: 6.13+0.38 in the presence of SOD; n=4; />>0.05 versus LPS 
alone; Figure 5.7B). SOD alone had no effect on the relaxation to SPER-NO (pECso: 
7.01+0.52 in the presence of SOD; n= 4; P>0.05 versus control). Curves were 
compared by TW-ANOVA.
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Figure 5.7 Concentration-response curves to (A) ACh (InM-lpM) and (B) SPER-NO 
(InM-lpM) following 4hr incubation with vehicle, LPS (0.3pg/ml), SOD (2000u/ml) 
or LPS plus SOD; n>3. Relaxation is expressed as the percentage reversal o f the 
U46619-induced tone. Each point represents mean ± SEM.
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5.3.8 Effect of LPS on sGC-mediated relaxation in the presence of aminobenzoic 
hydrazide
Rat aortic rings treated with LPS (0.3jig/ml) for 4 hrs showed significant 
reduction in the potency of SPER-NO (pECso: 6.36±0.22 versus 5.66±0.27 in the 
absence and presence of LPS, respectively; n=4; P<0.05; BC). Co-incubation with 
the MPO inhibitor, 4-aminobenzoic hydrazide (ABAH; lOpM) had no effect on the 
relaxations to SPER-NO in the presence of LPS (pECso: 5.58±0.27 in the presence of 
ABAH; w=4; P>0.05 versus LPS alone; Figure 5.8). ABAH alone had no effect on 
the relaxation to SPER-NO (pECso: 6.45±0.31 in the presence of ABAH; n=4; 
P>0.05 versus control). Curves were compared by TW-ANOVA.
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Figure 5.8 Concentration-response curves to SPER-NO (lnM-lOpM) following 
incubation with vehicle, LPS (0.3 jug/m I; 4 hrs), ABAH (lOpM; 30 mins) or LPS plus 
ABAH; n=4. Relaxation is expressed as the percentage reversal o f the U46619- 
induced tone. Each point represents mean ± SEM.
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5.3.9 Responses to sGC-mediated vasorelaxation in tissue precontracted with 
phorbol myristate acetate (PMA)
The effect of activation of protein kinase C on the sensitivity of sGC-cGMP 
pathway was studied by examining the response of rat aortic rings precontracted with 
the PKC activator, PMA, to ACh and SPER-NO and compared with aortic rings 
precontracted with U46619 and potassium chloride (KC1). The responsiveness of 
vessels precontracted with PMA, U46619 and KC1 to ACh was as follows: (pECso) 
7.26±0.13, 7.69±0.26 and 6.89±0.42, respectively. Relaxations to ACh were reduced 
in vessels precontracted with both PMA and KC1 versus U46619 («=4; PO.OS; 
Figure 5.9A). The pEC5o values for SPER-NO-induced relaxation in vessels 
precontracted with PMA, U46619 and KC1 were 6.17±0.14, 6.65±0.18 and 
6.55±0.33, respectively (/7=4). The pECso value for SPER-NO in vessels 
precontracted with PMA was significantly less than that of U46619 and KC1 (P<0.05; 
«=4; Figure 5.9B). Curves were compared by TW-ANOVA with BC.
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Figure 5.9 Concentration-response curves to (A) ACh (lnM-10pM) and (B) SPER- 
NO (InM-lOpM) in vessels precontracted to an EC go 'with PMA, U46619 and KCl; 
n>4. Relaxation is expressed as the percentage reversal o f the PMA, U46619 or KCl- 
induced tone. Each point represents mean ± SEM.
5.3.10 Responses to pGC-mediated vasorelaxation in tissue precontracted with
The effect of activation of PKC on the sensitivity of the pGC-cGMP pathway 
was also examined by stimulating pGC with ANP in aortic rings precontracted with 
PMA, U46619 and KCl. The responsiveness of vessels precontracted with PMA, 
U46619 and KCl to ANP was as follows: (pEC50) 8.26±0.26, 8.94±0.28 and
9.01 ±0.29, respectively {n=4). The pECso for ANP-induced relaxations in vessels 
precontracted with PMA was significantly less than that of U46619 and KCl (PO.OS; 
n=4; Figure 5.10). Curves were compared by TW-ANOVA with BC.
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Figure 5.10 Concentration-response curves to ANP (0.01nM-0. IpM) in vessels 
precontracted to an EC so with PMA, U46619 and KCl; n=4. Relaxation is expressed 
as the percentage reversal o f the PMA, U46619 and KCl-induced tone. Each point 
represents mean ± SEM.
5.3.11 Responses to cGMP-mediated vasorelaxation in tissue precontracted with
The effect of activation of PKC on the sensitivity of the downstream cGMP- 
pathway was examined by direct stimulation of protein kinase G with 8-Br-cGMP, in 
aortic rings precontracted with PMA or U46619. The potency of 8-Br-cGMP in 
vessels precontracted with PMA was significantly reduced (pECso: 3.68±0.22 and 
4.57±0.23 in tissues contracted with PMA or U46619, respectively; n>4; PO.05; 
Figure 5.11). Curves were compared by TW-ANOVA with BC.
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Figure 5.11 Concentration-response curves to 8-Br-cGMP (1-300/uM) in vessels 
precontracted to an EC so with PMA and U46619; n>4. Relaxation is expressed as the 
percentage reversal o f the PMA and U46619. Each point represents mean ± SEM.
5.3.12 Responses to AC-mediated vasorelaxation in tissue precontracted with 
PMA
The effect of activation of PKC on the sensitivity of adenylate cyclase (AC) 
was also studied by examining the vasorelaxant potency of forskolin in rat aortic 
rings precontracted with PMA, U46619 or KCl. The responsiveness of vessels 
precontracted with PMA, U46619 and KCl to forskolin was as follows: (pECso) 
6.11±0.36, 6.77±0.34 and 6.68±0.43, respectively (n=4). The pECso for forskolin in 
vessels precontracted with PMA was significantly less than that of U46619 and KCl 
(P<0.05; n=4; Figure 5.12). Curves were compared by TW-ANOVA with BC.
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Figure 5.12 Concentration-response curves to forskolin (InM-lpM) in vessels 
precontracted to an EC so with PMA, U46619 and KCl; n=4. Relaxation is expressed 
as the percentage reversal o f the PMA, U46619 and KCl-induced tone. Each point 
represents mean ± SEM.
5.3.13 Responses to sGC-mediated vasorelaxation in tissue precontracted with 
thymeleatoxin
The effect of activation of PKC on the sensitivity of sGC was confirmed by 
using a more selective PKC activator, thymeleatoxin (which only activates the 
conventional PKC isoforms a, p and y). The responsiveness of vessels precontracted 
with thymeleatoxin to ACh was significantly reduced compared to U46619 (pECso: 
8.04±0.39 and 6.87±0.42 in vessels contracted with U46619 or thymeleatoxin, 
respectively; n=3; P<0.05; Figure 5.13A). The responsiveness of vessels 
precontracted with thymeleatoxin to SPER-NO was also significantly reduced 
compared to U46619 (pECso: 6.84±0.33 and 5.58±0.26 in vessels contracted with 
U46619 or thymeleatoxin, respectively; n=3; PO.OS; Figure 5.13B). All curves were 
compared by TW-ANOVA with BC.
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Figure 5.13 Concentration-response curves to (A) ACh (InM-lO/uM) and (B) SPER- 
NO (InM-lOpM) in vessels equipotently precontracted with thymeleatoxin and 
U46619; n=3. Relaxation is expressed as the percentage reversal o f the 
thymeleatoxin or U46619-induced tone. Each point represents mean ± SEM.
5.3.14 Responses to pGC -mediated vasorelaxation in tissue precontracted with 
thymeleatoxin
The effect of activation of PKC on the sensitivity of pGC was also examined 
by pre-contracting vessels with thymeleatoxin or U46619. The responsiveness of 
vessels precontracted with thymeleatoxin to ANP was significantly reduced (pECso: 
8.59±0.38 and 7.65±0.36 in vessels contracted with U46619 or thymeleatoxin, 
respectively; /’O.OS; TW-ANOVA with BC; n=3; Figure 5.14).
Figure 5.14 Concentration-response curves to ANP (0.0lnM-0. lpM) in vessels 
equipotently precontracted with thymeleatoxin and U46619; n=3. Relaxation is 
expressed as the percentage reversal o f the thymeleatoxin or U46619-induced tone. 
Each point represents mean ± SEM.
5.3.15 Responses to AC-mediated vasorelaxation in tissue precontracted with 
thymeleatoxin
The response of rat aortic rings to forskolin was also studied in tissues 
precontracted with thymeleatoxin or U46619. The response of vessels precontracted 
with thymeleatoxin to forskolin was significantly reduced (pECso: 7.05±0.47 and
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5.64±0.36 in vessels contracted with U46619 or thymeleatoxin, respectively; n=3; 
/><0.05; TW-ANOVA with BC; Figure 5.15).
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Figure 5.15 Concentration-response curves to forskolin (InM-lpM) in vessels 
equipotently precontracted with thymeleatoxin and U46619; n=3. Relaxation is 
expressed as the percentage reversal o f the thymeleatoxin or U46619-induced tone. 
Each point represents mean ± SEM.
5.3.16 Effect of okadaic acid on the sensitivity of GC and AC-mediated 
relaxation
Rat aortic rings treated with LPS (0.3pg/ml) for 4 hrs showed significant 
reduction in the potency of ANP (pECso: 8.68±0.19 versus 7.96±0.51 in the absence 
and presence of LPS, respectively; n=A\ /><0.05; BC). Co-incubation with the PP2A 
inhibitor, okadaic acid (300nM; 30min) had no effect on the relaxations to ANP in the 
presence of LPS (pECso: 7.89±0.26 in the presence of okadaic acid; n=4; /*>0.05 
versus LPS alone; Figure 5.16A). Okadaic acid alone had a small but significant 
effect on the relaxation to ANP (pECso: 8.98±0.15 in the presence of okadaic acid; 
n=A\ P<0.05 versus control; BC), without affecting the sensitivity of SPER-NO 
(pEC50: 6.59±0.41 versus 6.51 ±0.29 in the absence and presence of okadaic acid,
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respectively; n=4; / >>0.05; Figure 5.16B) or forskolin (pECso: 6.69±0.57 versus 
6.77±0.34 in the absence and presence of okadaic acid, respectively; n=4; /}>0.05; 
Figure 5.16C). All curves were compared by TW-ANOVA.
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Figure 5.16 Concentration-response curves to (A) ANP (0.01nM-0. lpM) following 
incubation with vehicle, LPS (0.3pg/ml; 4hr), okadaic acid (300nM; 30 mins) or LPS 
plus okadaic acid (n=4); (B) SPER-NO (InM-lOpM; n=4) and (C) forskolin (lnM- 
lpM; n=4) following 30 mins incubation with vehicle or okadaic acid (300nM). 
Relaxation is expressed as the percentage reversal o f the U46619-induced tone. Each 
point represents mean ± SEM.
5.3.17 Effect of LPS on pGC-mediated relaxation in the presence of cantharidic 
acid
Rat aortic rings treated with LPS (0.3pg/ml) for 4 hrs showed significant 
reduction in the potency of ANP (pECso: 8.87±0.22 versus 8.01 ±0.41 in the absence 
and presence of LPS, respectively; n=5; P<0.05; BC). Co-incubation with the PP2A 
inhibitor, cantharidic acid (500nM; 30min) had no effect on the relaxations to ANP in 
the presence of LPS (pECso: 7.89±0.26 in the presence of cantharidic acid; n=4; 
P>0.05 versus LPS alone; Figure 5.17). Cantharidic acid alone had no effect on the
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relaxation to ANP (pECs0: 8.72±0.41 in the presence of cantharidic acid; n= 4; /*>0.05 
versus control). Curves were compared by TW-ANOVA.
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Figure 5.17 Concentration-response curves to ANP (O.OlnM-O.lpM) following 
incubation with vehicle, LPS (0.3pg/ml; 4 hrs), cantharidic acid (500nM; 30 mins) or 
LPS plus cantharidic acid; n=4. Relaxation is expressed as the percentage reversal o f 
the U46619-induced tone. Each point represents mean ± SEM.
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5.4 DISCUSSION
In this chapter, I have investigated mechanisms that might be involved in the 
desensitisation of the GC-cGMP pathway in LPS-treated vessels. The results obtained 
from this study demonstrate that the mechanism of iNOS-induced desensitisation of 
the GC-cGMP pathway does not involve activation of the phosphodiesterases PDE5, 
PDE1A1 and PDE3. It also suggests that the desensitisation is not explained solely by 
increased activity of PKC or PP2A. Moreover, it demonstrates that the reduced 
response to NO-donors is not mediated by the production of free radicals leading to a 
reduction in NO bioavailability.
5.4.1 Phosphodiesterases
Degradation of cGMP is tightly controlled by PDEs. These enzymes are 
abundant in various tissues including vascular smooth muscle. PDE5 is the most 
highly expressed cGMP-hydrolyzing isoform in VSMC with high specificity for 
cGMP (Rybalkin et al., 2003). The physiological importance of PDE5 in the 
regulation of vascular tone in human and animal has been demonstrated most clearly 
by the use of the selective inhibitor, sildenafil (Wallis et a l , 1999; Sharabi et al., 
2005). The finding that inhibition of PDE activities restored GTN-induced reduction 
in the response of rat model of tolerance to further treatment of GTN (Pagani et al., 
1993; De Garavilla et al, 1996) prompted me to investigate whether PDE5 is 
involved in the mechanism of desensitisation of sGC and pGC, as upregulation of 
PDE5 would lead to reduction in the activity of both GC signalling pathways. 
However, there does not seem to be a role for increased activity of PDE5 in the 
desensitisation, because sildenafil (at a concentration that reduced contraction to 
U46619 and shifted concentration-response curves for at least SPER-NO to the left 
suggesting efficient inhibition of PDE5) had no effect on the response to SPER-NO 
and ANP in LPS-treated tissues. Sildenafil enhanced relaxations to SPER-NO but not 
ANP; this raises the possibility of a specific subcellular localisation of PDE5 that 
enables the enzyme to metabolise sGC-, but not pGC-, generated cGMP.
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In the vasculature, PDE1A1 is present in VSMC (Sonnenburg et al., 1998). 
Moreover, it appeared that PDE1A1 activity is important for the regulation of 
vascular smooth muscle cGMP levels and reactivity because PDE1A1 activity, 
mRNA and protein levels are selectively upregulated following nitrate tolerance in the 
rat (Kim et al, 2001). These observations encouraged me to examine the possible 
involvement of PDE1A1 in the mechanism of desensitisation induced by LPS. 
However, vinpocetine (Hagiwara et al., 1984) did not restore LPS-induced 
desensitisation of SPER-NO and ANP suggesting that upregulation of PDE1A1 
activity is not involved in the mechanism of desensitisation of the sGC-cGMP and 
pGC-cGMP pathways.
PDE3 is one of the major PDEs that is present in VSMC. Although PDE3 is 
considered to hydrolyse cAMP preferentially, it is also able to breakdown cGMP 
(Beavo, 1995). In order to examine whether upregulation of PDE3 might underlie the 
mechanism of desensitisation of the sGC-cGMP and pGC-cGMP pathways, LPS- 
treated tissues were incubated with milrinone. However, PDE3 does not seem to play 
a role in the desensitisation mediated by LPS because milrinone (at a concentration 
that reduced contraction to U46619- suggesting efficient increased production of 
cGMP and/or cAMP and inhibition of PDE3) did not restore relaxation to SPER-NO 
and ANP. The inability of milrinone to enhance relaxation to SPER-NO and ANP 
may suggests that PDE3 is less effective in metabolizing cGMP compared to cAMP. 
In summary, these observations suggest that PDE5, PDE1A1 and PDE3 are unlikely 
responsible for the desensitisation of GC-cGMP induced by LPS.
5.4.2 Protein kinase C
Several PKC isoforms have been reported to exist in VSMC including the 
conventional-PKC isoforms (a and P), the novel-PKC isoforms (e, rj, 0, 5 and p) and 
the atypical (£ and X) (Yano et al., 1999; Itoh et al., 2001; Salamanca & Khalil, 
2005). Precontraction of rat aortic rings with the PKC activators, PMA (which 
activates both the conventional and the novel-PKC isoforms) or the more selective
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5.4 DISCUSSION
In this chapter, I have investigated mechanisms that might be involved in the 
desensitisation of the GC-cGMP pathway in LPS-treated vessels. The results obtained 
from this study demonstrate that the mechanism of iNOS-induced desensitisation of 
the GC-cGMP pathway does not involve activation of the phosphodiesterases PDE5, 
PDE1 Al and PDE3. It also suggests that the desensitisation is not explained solely by 
increased activity of PKC or PP2A. Moreover, it demonstrates that the reduced 
response to NO-donors is not mediated by the production of free radicals leading to a 
reduction in NO bioavailability.
5.4.1 Phosphodiesterases
Degradation of cGMP is tightly controlled by PDEs. These enzymes are 
abundant in various tissues including vascular smooth muscle. PDE5 is the most 
highly expressed cGMP-hydrolyzing isoform in VSMC with high specificity for 
cGMP (Rybalkin et a l, 2003). The physiological importance of PDE5 in the 
regulation of vascular tone in human and animal has been demonstrated most clearly 
by the use of the selective inhibitor, sildenafil (Wallis et al., 1999; Sharabi et al., 
2005). The finding that inhibition of PDE activities restored GTN-induced reduction 
in the response of rat model of tolerance to further treatment of GTN (Pagani et al., 
1993; De Garavilla et al., 1996) prompted me to investigate whether PDE5 is 
involved in the mechanism of desensitisation of sGC and pGC, as upregulation of 
PDE5 would lead to reduction in the activity of both GC signalling pathways. 
However, there does not seem to be a role for increased activity of PDE5 in the 
desensitisation, because sildenafil (at a concentration that reduced contraction to 
U46619 and shifted concentration-response curves for at least SPER-NO to the left 
suggesting efficient inhibition of PDE5) had no effect on the response to SPER-NO 
and ANP in LPS-treated tissues. Sildenafil enhanced relaxations to SPER-NO but not 
ANP; this raises the possibility of a specific subcellular localisation of PDE5 that 
enables the enzyme to metabolise sGC-, but not pGC-, generated cGMP.
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In the vasculature, PDE1A1 is present in VSMC (Sonnenburg et al, 1998). 
Moreover, it appeared that PDE1A1 activity is important for the regulation of 
vascular smooth muscle cGMP levels and reactivity because PDE1A1 activity, 
mRNA and protein levels are selectively upregulated following nitrate tolerance in the 
rat (Kim et al., 2001). These observations encouraged me to examine the possible 
involvement of PDE1A1 in the mechanism of desensitisation induced by LPS. 
However, vinpocetine (Hagiwara et al., 1984) did not restore LPS-induced 
desensitisation of SPER-NO and ANP suggesting that upregulation of PDE1A1 
activity is not involved in the mechanism of desensitisation of the sGC-cGMP and 
pGC-cGMP pathways.
PDE3 is one of the major PDEs that is present in VSMC. Although PDE3 is 
considered to hydrolyse cAMP preferentially, it is also able to breakdown cGMP 
(Beavo, 1995). In order to examine whether upregulation of PDE3 might underlie the 
mechanism of desensitisation of the sGC-cGMP and pGC-cGMP pathways, LPS- 
treated tissues were incubated with milrinone. However, PDE3 does not seem to play 
a role in the desensitisation mediated by LPS because milrinone (at a concentration 
that reduced contraction to U46619- suggesting efficient increased production of 
cGMP and/or cAMP and inhibition of PDE3) did not restore relaxation to SPER-NO 
and ANP. The inability of milrinone to enhance relaxation to SPER-NO and ANP 
may suggests that PDE3 is less effective in metabolizing cGMP compared to cAMP. 
In summary, these observations suggest that PDE5, PDE1A1 and PDE3 are unlikely 
responsible for the desensitisation of GC-cGMP induced by LPS.
5.4.2 Protein kinase C
Several PKC isoforms have been reported to exist in VSMC including the 
conventional-PKC isoforms (a and p), the novel-PKC isoforms (s, r\, 0, 6 and p.) and 
the atypical (C, and X) (Yano et al, 1999; Itoh et al, 2001; Salamanca & Khalil, 
2005). Precontraction of rat aortic rings with the PKC activators, PMA (which 
activates both the conventional and the novel-PKC isoforms) or the more selective
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PKC activator, thymeleatoxin (which activates only the conventional-PKC isoforms) 
reduced the responsiveness of rat aorta to sGC (ACh and SPER-NO), pGC (ANP) and 
AC (forskolin) activators, suggesting that PKC activity desensitises both GC and AC 
signalling pathways. Since the observation that iNOS-induced desensitisation is 
specific to the cGMP pathway, and that PKC activators desensitised both GC and 
AC-dependent signalling, it is unlikely that the mechanism of desensitisation is 
mediated solely by up-regulation of PKC in the LPS-treated vessels (as if it was 
mediated by PKC, then the responsiveness to forskolin in LPS-treated vessels would 
have been also reduced).
It is not clear which PKC isozymes cause desensitisation of GC and AC 
signalling pathways in the vasculature. The specific effect of thymeleatoxin suggests 
that one or both of the thymeleatoxin-activated PKC isozymes (a and p; both are 
expressed in VSMC) are more likely to underlie the desensitisation of GC and AC. 
The effect of PMA on sGC and AC is consistent with Kamata et al, who showed that 
in PMA-precontracted mesenteric vessels, responses to both SNP and forskolin were 
reduced (Kamata et al, 1995). The effect of PMA on the cell permeable cGMP 
analogue, 8-Br-cGMP, suggests that the cGMP down-stream pathway is also 
desensitised. This study also provides functional data on the role of PKC on responses 
to ANP, which is in accord with the observed role of PKC on the phosphorylation 
status of the ANP receptor in cultured VSMC (Yasunari et al., 1992). The mechanism 
by which PKC attenuates ANP responses is thought to occur as a result of 
dephosphorylation of ANP receptor (Potter & Garbers., 1994). Whether PKC causes 
phosphorylation-mediated inhibition of (so far unknown) a protein kinase that 
(normally) phosphorylates ANP receptor, or causes phosphorylation-mediated 
activation of a protein phosphatase (possibly PP2A) that ultimately dephosphorylates 
the receptor, is unknown.
Unlike PKC-mediated contraction, K+ at higher concentrations causes
2+
depolarisation of VSMC leading to influx of Ca through voltage-gated channels 
(Ratz et al., 2005). Thus, the reduced vasorelaxant potency of GC and
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5.4.4 Role of superoxide
It has been reported that endotoxin treatment may be associated with O2 
production in the vasculature (Javesghani et al., 2003). Moreover, tolerance and 
cross-tolerance to NO-donors may result from increased O2 production (Munzel et 
al., 1995) since O2 is known to inactivate NO (Gryglewski et al., 1986). SOD is an 
important determinant of NO bioavailability in blood vessels through its ability to 
dismutate O2 (Munzel et al, 1995; Fukai et al., 2002). To examine the role of O2 in 
the reduced responsiveness to ACh and SPER-NO in LPS-treated tissues, vessels 
were incubated with SOD. The results demonstrate that SOD does not restore the 
relaxation to ACh or SPER-NO, suggesting that the reduced responsiveness to these 
agents is not mediated by reduced bioactivity of NO as a result of increased 
production of O2 . However, although SOD was added in excess (2000U/ml), it is 
possible that SOD did not cause an effect due to difficulty in penetrating cell 
membranes.
5.4.5 Myeloperoxidase
Acute inflammation has been associated with an increase in the activity of 
MPO, which itself has been reported to modulate vascular signalling and vasodilatory 
functions of NO, either by direct consumption of NO or via MPO-derived substrate 
radicals (Eiserich et al., 2002) leading to a reduction in NO bioavailability. Moreover, 
the effect of MPO could result from its ability to up-regulate the catalytic activity of 
iNOS by preventing NO feedback inhibition (Galijasevic et al., 2003), thereby 
increasing iNOS-dependent desensitisation of GC. In order to examine whether MPO 
is involved in the reduced responsiveness of vascular tissue to SPER-NO, LPS-treated 
tissues were co-incubated with the MPO inhibitor, ABAH. ABAH did not restore 
relaxation to SPER-NO suggesting that reduced responses to the NO-donor are not 
mediated by consumption of NO by MPO or by MPO-generated free radicals. 
However, it is possible that MPO expression by vascular cells is not occurring and its 
availability is entirely dependent on expression by immune cells which are not 
present in this in vitro model.
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5.4.6 Summary
In summary, this chapter attempted to investigate mechanisms that might be 
involved in the iNOS-induced desensitisation of sGC and pGC, by using 
pharmacological tools to probe the roles of PDEs (type 1A 1, 3 and 5), PP2A, SOD 
and MPO, each of which has been shown to modulate cGMP activity. However, none 
of these pathways appears to be involved in desensitisation of the sGC and pGC- 
cGMP signalling pathways by iNOS-derived NO. PKC activation mimics to a degree 
the effect of LPS, but the vascular phenotype also include cAMP dilator dysfunction, 
which is not a component of that induced by LPS.
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6. Summary
This thesis describes studies to investigate the regulation of guanylate cyclases 
pathways in blood vessels. This thesis attempted to answer three main questions:
1. What is the relative contribution of enzymatic and non-enzymatic mechanisms 
in the biotransformation of S-nitrosothiols in blood vessels?
2. What is the effect of LPS on the sensitivity of sGC and pGC-cGMP pathway?
3. What is the mechanism(s) that mediate the desensitisation of sGC and pGC by 
LPS?
6.1 Enzymatic or non-enzymatic?
In this study, I investigated the responsiveness of isolated rat aorta to 
stereoisomers of the endogenous, GSNO and CYSNO, and the exogenous 
S-nitrosothiols, SNAP to determine whether the biotransformation of S'-nitrosothiols 
involves enzyme-dependent mechanism. I have also investigated the effect of free 
copper ions as a control for non-stereospecific effect, and the copper-containing 
enzyme, Cu/Zn SOD, on the stereoisomers of GSNO and SNAP. By using the 
colorimetric assay of Saville and the organ bath pharmacology, I demonstrated that in 
isolated rat aorta, there were no stereospecific vasorelaxant effects of .S’-nitrosothiols, 
consistent with non-enzymatic release of NO. Cu(I)-dependent mechanisms play an 
important role in the biotransformation of S'-nitrosothiols by blood vessels.
The use of a novel water soluble derivative of Cu(I) complex, Cu(I)- 
acetonitrile and the selective Cu(I) chelator, BCS, gave a direct insight into the role of 
Cu(I) in the decomposition of S-nitrosothiols. This supported previous findings, in 
which Cu(I) but not Cu(II) is the active catalyst that cause the decomposition. 
S-nitrosothiols decomposed differently to copper ions with a raking order of stability: 
G SN O  SNAP> CYSNO.
Data from individual enzyme, Cu/Zn SOD to whole tissue, rat aorta, suggest 
that S-nitrosothiols are metabolised non-stereospecifically. This non-stereospecificity
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to S-nitrosothiols may be important physiologically. It suggests that access to 
endogenously stored or exogenously applied NO is easy due to the availability of 
various intracellular and extracellular copper-containing enzymes and any 
abnormality in the availability or functionality of one enzyme may be substituted by 
the many other copper-containing enzymes or proteins.
As discussed earlier, NO is an important vasodilator, anti-atherogenic, 
anti-proliferative, and anti-apoptotic agent. Therefore disturbance in NO 
bioavailability would lead to cardiovascular abnormalities. Indeed, a strong 
relationship between copper-deficiency and ischemic heart disease has been reported 
(Klevay, 2000). Increased aortic lesion areas and elevated serum cholesterol were 
found in animals fed with a copper-deficient diet, compared with the copper-adequate 
group (Hamilton et al, 2000). Rats fed a copper-deficient diet developed a defect in 
NO-mediated dilatation an observation which supports the physiological relevance of 
this thesis (Schuschke et al., 1992). Inhibition of Cu/Zn-SOD as a result of copper 
deficiency may increases the concentration of vascular superoxide. High level of 
superoxide is associated with various cardiovascular disorders such as hypertension, 
atherosclerosis, and diabetic vascular disease due to its ability to reduce NO 
bioavailability (Nedeljkovic et al., 2003; Uriu-Adams et al.,2005). In contrast, 
increased copper bioavailability that occurs in Wilson’s disease, copper poisoning 
(Uriu-Adams et al.,2005), and cystic fibrosis (Percival et al., 1999) may leads to 
increased consumption of S-nitrosothiols and subsequently depletion of endogenous 
NO stores (Grasemann et al., 1999). Therefore, the effect of copper ions on the 
bioavailability of NO from its endogenous stores might provide a link between copper 
ion bioavailability and cardiovascular diseases.
This thesis also demonstrates a possible role of Cu(I) ions in the regulation of 
vascular tone through its ability to activate eNOS. The exact mechanism by which 
eNOS is activated by Cu(I) is unknown. Previous reports demonstrated that Cu(II) 
activates eNOS (Demura et al., 1998a), may by mediated by intracellular Ca2+ 
mobilisation (Demura et al., 1998b). It is possible that Cu(II) is reduced by
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endogenous thiols to Cu(I), which subsequently cause eNOS activation. However, 
further investigation is required to explore this mechanism. The role of Cu(I) on 
eNOS, further provides a strong link between copper ions and NO biology.
6.2 Feedback regulatory mechanism
The sensitivity of sGC to NO and pGC to ANP regulates vasodilatation in 
response to these mediators. To determine the role of endogenous NO as a feedback 
regulator of both sGC and pGC, rat aorta was incubated in vitro with LPS to stimulate 
production of high output NO as an in vitro model of sepsis. This thesis demonstrated 
that induction of iNOS by LPS (confirmed by western blotting) reduces the sensitivity 
of both sGC- and pGC-mediated relaxation. This desensitisation was blocked by 
specific iNOS inhibition, consistent with iNOS-derived NO down-regulating both 
pathways. The desensitisation is specific for cGMP signalling, and is mediated at 
least in part by cGMP generation, because inhibition of NO-mediated cGMP 
synthesis with ODQ partially restores sensitivity to ANP. Moreover, the observed 
desensitisation is rapidly reversible, consistent with a mechanism dependent on 
altered activity of constitutive pathways rather than expression of new protein. The 
reduced sensitivity to 8-Br-cGMP implicates down-regulation of one or more 
downstream pathways.
To conclude, alteration in the responsiveness to endogenous NO and ANP is 
an important negative feedback mechanism within the vasculature that is likely to 
play an important role in the regulation of vascular tone and blood flow. During 
inflammatory episodes such as in sepsis, this physiological mechanism might offset 
the systemic hypotension by causing vasoconstriction. Therapeutically, this 
desensitisation has implications for the development of tolerance to NO or GC 
activators administered as therapy for treatment for certain cardiovascular diseases 
emphasising that tolerance is a likely consequence of any vasodilator that is cGMP- 
mediated.
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Extending this work to study the relationship between the two guanylate 
cyclase pathways in vivo particularly in human is now required. This de novo work 
will provide insight as to whether this regulatory mechanism is important in human 
health and disease.
6.3 What is causing the desensitisation?
In chapter five, I investigated possible mechanism(s) that might be involved in 
the desensitisation of GC-cGMP pathway in LPS-treated vessels. Pharmacological 
tools were used to investigate the roles of phosphodiesterases (type 1A 1, 3 and 5), 
protein kinase C, protein phosphatase 2A, superoxide dismutase, and 
myeloperoxidase, each of which has been shown to modulate cGMP activity.
The results obtained from this study demonstrate that the mechanism of 
desensitisation of GC-cGMP pathway does not involve activation of the 
phosphodiesterases PDE5, since the selective inhibitor of PDE5, sildenafil did not 
restore the desensitisation to SPER-NO and ANP. Similarly, vinpocetine and 
milrinone, the inhibitors of PDE1A1 and PDE3 respectively, did not restore 
relaxation to SPER-NO and ANP in LPS treated tissues, ruling out the role of 
PDE1 Al and PDE3 in the mechanism of desensitisation.
The data obtained from this study reveal an important role for PKC in the 
desensitisation of both GC and AC signalling pathways. However, since the 
sensitivity of AC signalling pathway is intact in the LPS-treated tissue, but reduced 
under conditions of high PKC activity, this suggests that upregulation of PKC activity 
may not be responsible for the desensitisation of the GC-cGMP pathway following 
LPS treatment. Moreover, the data indicate that PKC-a and/or -(3 isoforms are likely 
responsible for the desensitisation. Since PKC normally phosphorylates enzymes 
while the mechanism of pGC desensitisation by PKC is thought to occur through 
dephosphorylation (Potter & Garbers, 1994), further work is required to explore the
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signalling cascade involved in the PKC-mediated desensitisation leading to 
dephosphorylation of pGC.
Given the important role of sGC- and pGC-cGMP signalling pathways (as 
described in sections 1.1.7 and 1.2.3) in the regulation of cardiovascular physiology, 
their desensitisation by PKC might have important implications in the 
pathophysiology of cardiovascular disease. Indeed, increased PKC expression/activity 
has been suggested to play an important role in the elevation of blood pressure. PKC- 
a enhances Ca2+-dependent VSMC contraction, and its overexpression has been 
implicated in the pathogenesis of hypertension (Salamanca & Khalil, 2005). 
Imbalance between NO-cGMP and PKC system has also been suggested to cause 
cerebral vasospasm (Laher & Zhang, 2001). Diabetes is commonly associated with 
abnormal vascular function. Increases in PKC specific activity in the membranous 
fraction induced by hyperglycemia have been reported in retina, aorta, heart, 
monocytes and glomeruli from animals and humans with diabetes (Way et al., 2001). 
Preferential activation of the PKC-P isoform by elevated glucose is reported to occur 
in a variety of vascular tissues (Way et al., 2001). In this thesis I demonstrated that 
PKC-a and/or -p cause desensitisation of GC and AC. If it was mediated by PKC-P, 
then this would be expected to cause abnormal GC and AC signalling in diabetic 
patients and causing further complications in this disease. Increased PKC activity is 
also associated with cardiac myocyte hypertrophy (Gu & Bishop, 1994) and heart 
failure (Bowling et al., 1999).
This study also demonstrates that desensitisation of pGC by LPS is not 
mediated by increased activity of PP2A because the selective PP2A inhibitors, 
okadaic acid and cantharidic acid did not restored the sensitivity of ANP-mediated 
relaxation in LPS treated tissue. The reduced responses to NO donors is not mediated 
by scavenging of NO by superoxide or by free radicals generated by myeloperoxidase 
since superoxide dismutase or ABAH respectively did not restore relaxation to ACh 
and SPER-NO.
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This thesis does not directly exclude the possibility of depletion of GC 
substrate (i.e GTP) that might occur through excessive utilisation as a result of 
continuous activation of GC by iNOS-induced NO in LPS treated tissues. However, 
since GTP is involved in so many cellular functions, one would expect that depletion 
of GTP would affect cellular function globally therefore making this potential 
mechanism unlikely.
To sum up, upregulation of PDE1A1, PDE3, PDE5, PKC and PP2A, or 
increased superoxide bioavailability or depletion of GTP are unlikely to be the 
mechanisms of desensitisation of sGC and pGC-cGMP by iNOS-derived NO. PKC 
desensitises both GC and AC signalling pathway, where PKC-a and/or -p isoforms 
are likely to mediate the desensitisation.
6.4 Future studies
In Chapter Three I showed that rat aorta decomposed S-nitrosothiols by a 
Cu(I)-dependent mechanism. However, whether the biotransformation of 
S-nitrosothiols occurred by the endothelial cells, VSMC or both remains uncertain. It 
is of interest to examine the relative contribution of endothelial versus VSMC in the 
Cu(I)-dependent decomposition of S-nitrosothiols. This study can be done by 
examining the decomposition of S-nitrosothiols by rat aorta in the presence and 
absence of endothelial cells. It is also of interest to examine the relative contribution 
of membranous versus cytosolic Cu(I) ions in the biotransformation of 
S-nitrosothiols. This study can be done by measuring the amount of NO release from 
S-nitrosothiols following exposure to membranes or cytosolic preparations.
In section 3.4.6 I showed that Cu(I) did not produce S-nitrosothiol-dependent 
relaxation. However, since S'-nitrosothiols are light sensitive substances (Megson et 
al., 2000a; Chauhan et al., 2003b), it is possible that exposure of rat aorta in the organ 
bath to the ambient light for several hours before performing the concentration-
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response curve to Cu(I) has depleted endogenously stored S'-nitrosothiols. Further 
work in light protected preparations is required to confirm this study.
Another potential mechanism possibly causing the desensitisation of sGC and 
pGC-cGMP by iNOS-derived NO worth studying is the role of PKG. This study can 
be done either by pharmacological inhibition of PKG by using selective PKG 
inhibitor such as Rp-8-Br-PET-cGMPS, or by examining this mechanism in PKG 
knockout mice. However, it is important to note that such studies are likely to be 
complicated by the fact that PKG is responsible for mediating the relaxation to sGC 
and/or pGC activators. However, it is possible that a residual relaxation will remain to 
enable potential study of the mechanism of desensitisation.
It remains possible that an increase in the production of carbon monoxide 
(CO), which can activate sGC, by the inducible haem-oxygenase-1 (HO-1) could 
contribute to desensitisation of the GC-cGMP pathway. However, despite its poor 
purified-sGC activating ability (Stone & Marietta, 1994; Friebe et al., 1996), one 
major problem of studying the effect of inhibition of HO-1, is that the most widely 
used inhibitors (zinc protoporphyrin IX, tin protoporphyrin IX and chromium 
mesoporphyrin) of this enzyme are known to produce HO-1-independent effects, by 
interfering with other pathways such as iNOS, sGC and ANP-mediated relaxation 
(Meffert et al., 1994; Serfass & Burstyn et al., 1998; Ny et al., 1995; Jozkowicz & 
Dulak, 2003). Thus, the use of these inhibitors is not suitable. Therefore, synthesis of 
selective inhibitors for HO-1 is required for future work to explore the capacity of CO 
in causing desensitisation of GC-cGMP in sepsis. Alternatively, this study can be 
examined by stimulating sGC by CO-releasing molecules such as CORM-A1 and 
CORM-3 and observing their effects on the sensitivity of GC-cGMP pathway.
In contrast to septic shock, the physiological relationship between sGC- and 
pGC-cGMP pathways need to be further explored in disease states associated with 
reduced NO bioavailability. Diabetes mellitus, for instance, is commonly associated 
with endothelial dysfunction (Pieper & Peltier, 1995; Xiong et al., 2003; Witte et al.,
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2002; McNeill et al., 2000). Further work is required to investigate the thesis that 
decreased production or activity of NO-sGC in diabetes might lead to an enhanced 
sensitivity of NPs-pGC to compensate for the reduced activity of the NO-cGMP 
pathway in this disease state. However, since PKC activity might be increased in 
diabetes mellitus (Way et al., 2001), it is also important to investigate whether an 
increase in the activity of PKC might lead to a down-regulation of both pathways. 
This work can be done on vessels from animal model of type 1 diabetes mellitus such 
as streptozotocin-induced diabetes or on animal model of type 2 diabetes mellitus 
such as Goto-Kakizaki rat.
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